

AUTHOR INDEX

Aakvaag, A., 89
 Aanderud, S., 89
 Aarons, J., 1140
 Abdel-Rahman, E., 788
 Abelmann, A., 1180
 Acerini, C.L., 1481
 Ackermans, M.T., 217
 Adams, M.R., 391
 Adler, R.A., 425
 Adlercreutz, H., 1440
 Agami, O., 1
 Agardh, C.-D., 269
 Agardh, E., 269
 Agha, N., 420
 Aglialoro, A., 1490
 Aida, K., 699
 Alagona, P., 1097
 Al-Ashwal, A., 900
 Al Banchaabouchi, M., 355
 Al-Bassam, A., 900
 Alberti, K.G.M., 250
 Aldaghlas, T.A., 1504
 Alex, S., 154
 Alford, F.P., 522
 Al-Rabeeah, A., 900
 Alsalmi, I., 1337
 Al-Sheikh, N., 420
 Anand, S.S., 182
 Anderson, J.H., 371
 Anderson, R.A., 396
 Ando, S., 1083
 Andreasen, F., 83
 Andrés, C., 637
 Anker, S.D., 1156
 Ansari, B.M., 541
 Apstein, M.D., 367
 Arai, S., 44
 Araújo-Vilar, D., 313
 Arii, K., 598
 Arikawa, E., 1037
 Arisaka, T., 257
 Arita, N., 804
 Armiendo, A., 993
 Arnesen, H., 292
 Arslanian, S., 309
 Asagami, T., 493
 Ascaso, J.F., 508
 Aso, Y., 362
 Aspelin, T., 292
 Asplund, K., 384
 Assmann, G., 336
 Astorri, E., 915
 Attalah, M., 503
 Attali, J.-R., 503, 934
 Aubo, C., 1040
 Audouin-Chevallier, I., 301
 Auer, C., 965
 Aussedat, B., 799
 Averbukh, E., 1331
 Azuma, N., 456
 Babazono, T., 1325
 Bahouth, S.W., 1455
 Bahr, R., 439
 Bakker, O., 1052
 Ballesta, A.M., 560
 Balogh, Z., 1070
 Balsano, F., 993
 Bänsch, D., 336
 Banyai, S., 1058
 Bao, W., 998
 Barakat, H., 1048, 1222
 Barazzoni, R., 669
 Baron, A.D., 573
 Barreca, A., 1490
 Barrett, P.H.R., 478, 484
 Barton, B.A., 514
 Basson, M.D., 133
 Batta, A.K., 878
 Battezzati, A., 713
 Baur, L.A., 106
 Bävenholm, P., 113
 Beck-Nielsen, H., 522
 Bedair, S.M.A., 1337
 Begay, C.K., 223
 Begum, N., 54
 Behar, A., 503
 Beisiegel, U., 1160
 Bell, B.M., 484
 Bell-Farrow, A.D., 401
 Bendahan, D., 769
 Beníký, J., 1269
 Bennett, F., 617
 Berenson, G.S., 757, 998
 Berger, V., 1499
 Berman, D.M., 467
 Berry, G.T., 1423
 Beucler, I., 965
 Bhatheña, S.J., 1199
 Biesalski, H., 1
 Birkenhäger, J.C., 675
 Biro, F.M., 514
 Bistrian, B.R., 345
 Björntorp, P., 1187
 Blachar, Y., 264
 Black, B.L., 1354
 Boddie, A.M., 207
 Bode, B.P., 608
 Bojanovski, D., 1160
 Bolognino, M., 1315
 Bønaa, K.H., 848
 Bonilla, S., 301
 Bories, D., 1413
 Børshesm, E., 439
 Bosch, M., 1040
 Botion, L.M., 1217
 Bozzola, M., 1490
 Bradfield, J., 1048
 Braverman, L.E., 154
 Bravi, M.C., 993
 Bremme, K.A., 840
 Brewer, H.B., Jr., 1160
 Brindley, D.N., 1383
 Brito, M.N., 1217

Brito, N.A., 1217
 Brito, S.R.C., 1217
 Brna, R., 309
 Brousse, N., 1366
 Brouwer, E.M.C., 1462
 Brown, J.A., 377
 Bugianesi, E., 792
 Buongiorno, A., 129
 Buzzetti, R., 1205
 Byun, Y., 955
 Cabana, V.G., 234
 Cabezas-Cerrato, J., 313
 Caccese, D., 97
 Caffari, G., 50, 814
 Cagen, L.M., 869
 Caiazza, A., 893
 Caiola, S., 129
 Caixàs, A., 371
 Calcutt, N.A., 650
 Calvo, C., 297
 Calzoni, F., 988
 Cameron-Smith, D., 149
 Camilleri, M., 7
 Campbell, J.D., 1199
 Capretti, L., 50, 814
 Caranton, M., 535, 831
 Carey, K.D., 731
 Carey, T.E., 955
 Carmena, r., 508
 Carreras, G., 371
 Caruso, A., 158
 Casals, E., 560
 Casimirri, F., 988
 Cassone-Faldetta, M., 993
 Caumo, A., 135, 1009
 Cavagnini, F., 143
 Cavallo, M.G., 1205
 Cazes, P., 934
 Cefalu, W.T., 401, 947
 Ceseña, R.M., 650
 Chalkley, S.M., 1121
 Chaudhuri, A., 788
 Cheetham, S.T., 31
 Chen, C.-F., 1211
 Chen, J.-J., 1211
 Chen, L.-D., 731
 Chen-Haudenschild, C., 336
 Cherrington, A.D., 135
 Chiao, Y.-C., 1211
 Chiodera, P., 50, 814, 893, 897
 Chisholm, D.J., 1121
 Choi, J.-H., 955
 Chou, C.-J., 1211
 Chow, J.C., 345
 Christiansen, J.S., 83, 1134
 Chrouzos, G.P., 1289, 1419
 Chua, T.-P., 1156
 Chung, J.W., 955
 Ciampelli, M., 158
 Cianci, J., 1315
 Ciaraldi, T.P., 940

Ciechanowicz, A., 844
 Clark, J.S.C., 844
 Clarke, J.T.R., 836
 Claus, R., 1105
 Clevenger, C.M., 1112
 Coast, A.J.S., 1156
 Coates, R.J., 207
 Cobanov, B., 1127
 Cobelli, C., 135, 484, 1009
 Cohen, A.M., 1274
 Cohen, W.R., 121
 Cohen-Boulakia, F., 503
 Coiro, V., 50, 814, 893, 897
 Colla, R., 50, 814
 Collier, G.R., 125, 1308
 Colomb, V., 1366
 Colvin, P.L., Jr., 391
 Colzani, R., 154
 Conley, M., 1140
 Cooney, G.J., 149, 409
 Corsetti, J.P., 1315
 Cortese, C., 97
 Coudray-Lucas, C., 1366
 Cowett, R.M., 1239
 Cozzani, P.J., 769
 Craveri, A., 915
 Croft, K., 1180
 Croom, J., 1354
 Crouse, J.R., III, 401
 Crouse, S.F., 377
 Crowne, E.C., 31
 Cruickshank, K., 617
 Cushman, S.W., 3
 Cynober, L., 1366
 Dacou-Voutetakis, C., 1408
 D'Adamo, M., 129
 Daimon, M., 1167
 Dalferes, E.R., Jr., 998
 Dall, R., 1134
 Dall'Aglio, P., 915
 Dal Ponte, D.B., 982
 Dandona, P., 788
 Daniels, M.C., 449
 Darmaun, D., 497, 549, 1429
 Davidson, M., 1097
 Davidson, N.O., 869
 Davis, S.N., 135
 Davoren, P.M., 250
 De Bandt, J.P., 1366
 Deckers, J.W., 675
 De Deyn, P.P., 355
 De Faire, U., 113
 Defensor, R., 1289
 De Ferri, A., 50
 Dekker, E., 217
 De la Bretonne, J.A., 1520
 De Leiva, A., 371
 Delitala, G., 143
 De Martin, M., 143
 De Mattia, G., 993
 Dembure, P.P., 207
 Dengel, D.R., 1075
 Dennis, K.E., 467
 Denver, A.E., 637
 Derfler, K., 1058
 De Riva, C., 4194
 Desjeux, F., 1429
 DeSouza, C.A., 1112
 Deutsch, J., 121
 Devlin, A.M., 20
 Dhillon, A.S., 1180
 D'Hooge, R., 355
 Diehl, E., 63
 Dines, K.C., 650
 Dinneen, S.F., 7
 Dirkes-Kersting, A., 336
 Dobbins, R.L., 135
 Doi, T., 1303
 Dolnikowski, G.G., 922
 Donckier, J., 592
 Donner, M.G., 273, 863
 Donohoue, P., 584
 Dörner, G., 855
 Dornhorst, A., 1245
 Douskas, G., 1379
 Dracopoulou, M., 1408
 Drake, K., 121
 Drash, A.L., 309
 Drukker, A., 264
 Dubuc, G.R., 429
 Dumas, F., 1366
 Dumon, H., 549
 Dunbar, J.C., 185
 Dunger, D.B., 31, 1481
 Dutra, S.L., 1429
 Ebbeling, C.B., 1434
 Edwards, C.L., 1354
 Efendic, S., 627
 Egloff, M., 965
 Eisen, E.J., 1354
 Elam, M.B., 869
 El Banna, N., 541
 Elkasabani, A., 998
 Elkasabany, A., 757
 Ellsworth, J.L., 325
 Elsas, L.J., II, 207
 ElZalabani, M.M., 541
 Enas, E.A., 182
 Endert, E., 217
 Endoh, A., 474
 Ericsson, C.-G., 113
 Ericsson, U.-B., 89
 Erkintalo, M., 769
 Evani, R., 425
 Even, P.C., 777
 Ezaki, O., 724
 Fabreguettes, C., 769
 Facchini, F.S., 831
 Fain, J.N., 1455
 Falkner, B.E., 70
 Fang, S.L., 154
 Fang, V.S., 1468
 Fantus, I.G., 630
 Fattah, M.A., 541
 Feinglos, M.N., 1089
 Fellin, R., 535
 Fendri, S., 1372
 Feng, J.Y., 751
 Fernandez, M.L., 883
 Ferri, C., 993
 Fink, L.M., 686
 Fiorina, P., 915
 Fisher, L., 836
 Fisker, S., 1514
 Fijiyawa, K., 1152
 Flamina, R., 792
 Flores, G., 1127
 Flyvbjerg, A., 817, 1331
 Fogt, D.L., 982
 Fonda, M.L., 168
 Fonseca, V.A., 686
 Fóris, G., 1070
 Forrester, T., 617
 Foster, D.M., 484
 Fouda, K., 900
 Foy, C.A., 622
 Frangos, M., 1423
 Frank, J.W., 7
 Frishberg, Y., 264
 Frost, G., 1245
 Fu, C.L., 1360
 Fujimura, T., 177
 Fujisawa, K., 333
 Fujita, T., 1005
 Fujitani, J., 874
 Fukuo, K., 195
 Fukushima, T., 1528
 Fukuzawa, M., 977
 Fulghesu, A.M., 158
 Funahashi, T., 929
 Furler, S.M., 409
 Furukawa, L.N., 493
 Fusegawa, T., 1348
 Gabriel, H., 1058
 Galal, D.O., 420
 Gambineri, A., 988
 Gandy, R.E., 1281
 Gangnerau, M.N., 799
 Gao, T.Q., 1528
 García-Estevez, D.A., 313
 Garcin, H., 301
 Garfinkel, M.R., 809
 Gateva, E., 121
 Gautier, V., 965
 Gelardi, N.L., 1239
 Genma, R., 1083
 George, B.C., 367
 Georgiou, E., 1379
 Gerich, J., 1227
 Getz, G.S., 234
 Giaccari, A., 129
 Gielkens, H.A.J., 321
 Giral, P., 965
 Giuliani, N., 814, 893
 Godslund, I.F., 113, 657
 Goff, D., 1174
 Goldberg, A.C., 1097
 Goldberg, A.P., 467, 1075
 Golde, H., 484
 Goldstein, M., 409
 Goto, N., 724

Gottsauner-Wolf, M., 1058
 Gottschalk, W.K., 449
 Goulet, O., 1366
 Graham, S.E., 1383
 Grandjean, P.W., 377
 Grant, P.J., 622
 Green, T., 1048
 Gregg, R.E., 1160
 Gries, F.A., 250
 Grøfte, T., 83
 Gronboek, H., 817
 Guido, M., 158
 Gylling, H., 744

Hafeez, R., 788
 Haffner, S., 182
 Haffner, S.M., 230, 1174
 Hagberg, J.M., 1075
 Hales, C.N., 1450
 Hallmans, G., 384
 Halpert, M., 1331
 Hamada, K., 1303
 Hamadeh, M.J., 1145
 Hamman, R.F., 1174
 Hamsten, A., 113
 Han, I.S., 955
 Hansen, C.T., 1199
 Hara, T., 149
 Harada, T., 1472
 Harder, T., 855
 Harris, A.G., 1419
 Harris, D.A., 1481
 Hartley, C.J., 1295
 Hashimoto, K., 598, 804
 Hassager, C., 212
 Hasslacher, C., 63
 Hata, I., 1344
 Hata, K., 333
 Hattori, J., 351, 783
 Hautanen, A., 1440
 Havel, P.J., 429
 Hawa, M., 1205
 Hayakawa, T., 804
 Hayashi, H., 1391
 Haynes, W., 584
 Hector, R., 663
 Heikkinen, S., 1397
 Heimberg, M., 869
 Heinemann, L., 1263
 Heise, T., 1263
 Hennig, B., 566
 Henriksen, E.J., 982
 Henriksen, J.E., 522
 Henry, R.R., 686
 Hettiarachchi, M., 1121
 Heuman, D.M., 285
 Hew, L.F., 522
 Hickey, M., 1222
 Hickman, M.G., 940
 Higaki, Y., 874
 Higashino, K., 695, 739, 1005
 Higashiyama, M., 1391
 Higueret, P., 301
 Hilton, F.K., 168
 Hilton, M.A., 168

Hiltunen, T.P., 1258
 Hinson, W.H., 401
 Hirano, K.-I., 869
 Hiraoka, M., 1403
 Hiroishi, K., 695, 739, 1005
 Ho, L.-T., 1468
 Hobensack, K., 663
 Hoffer, L.J., 1145
 Höfling, B., 863
 Holaday, N.J., 223
 Holeček, M., 681
 Holleran, A.L., 1504
 Holly, J.M.P., 31
 Holmes, L., 1140
 Honda, N., 257
 Hoogerbrugge, N., 675
 Hooi, S.C., 603
 Hori, C., 1403
 Hori, M., 908
 Horikawa, S., 1295
 Horiuchi, R., 1083
 Hörl, W.H., 1058
 Hosoda, K., 456
 Höstrmark, T., 439
 Howard, B.V., 1174
 Howell, S., 617
 Howell, T., 751
 Hsu, Y.-P., 1468
 Hu, Y., 799
 Huang, X.-H., 1258
 Hubel, C.A., 1281
 Hubinger, A., 250
 Hudig, F., 1052
 Hultberg, B., 269
 Humalaja, K., 644
 Hwu, C.-M., 1211

Ichihara, S., 177
 Ichikawa, Y., 94
 Ichino, I., 1494
 Idriss, S., 934
 Igaki, T., 456
 Igarashi, M., 1167
 Igawa, K., 1295
 Ikeda, M., 44
 Ikeda, T., 1152
 Ikeda, Y., 598
 Ikemoto, S., 724
 Innis, S.M., 20
 Inoue, M., 598
 Inukai, T., 362
 Invitti, C., 143
 Ishida, T., 1295
 Ishii, Y., 1403
 Ishikawa, K., 493
 Ishikawa, S.-e., 1391
 Ishimori, M., 351, 783
 Isobe, A., 1528
 Israel, R.G., 1222
 Ito, H., 598
 Itoh, H., 456
 Ivandić, A., 13
 Iwamoto, Y., 1325
 Iwase, E., 699

Jacob, S., 982
 Janosky, J.E., 309
 Jansen, H., 675
 Jeevanandam, M., 223
 Jenkins, S., 1097
 Jensen, M.D., 280
 Jenssen, T., 848
 Jeppesen, J., 831
 Ježová, D., 1269
 Jiang, Z.L., 1472
 Jones, P.J.H., 751
 Jones, P.P., 1112
 Jørgensen, J.O.L., 83, 1134, 1514
 Jovanovic, L., 1140
 Jovinge, S., 113
 Juan, C.-C., 1468
 Jurić, M., 13

Kafonek, S.D., 1097
 Kagawa, T., 874
 Kagen, P.A., 217
 Kalayoglu, M., 200
 Kalhan, S.C., 309
 Kang, K.W., 39
 Kannmatsuse, K., 493
 Kano, H., 1065
 Kaplan, L.M., 603
 Karam, G., 934
 Karjalainen, L., 1397
 Kasayama, S., 804
 Kashyah, M., 1097
 Katsumori, K., 27
 Kawahara, R., 27
 Kawakami, A., 1391
 Kawamori, R., 44, 257, 908
 Kawanishi, K., 1295
 Kelleher, J.K., 1504
 Kelly, W., 250
 Keltikangas-Järvinen, L., 1440
 Kemmer, H., 1105
 Kern, P.A., 686
 Ketelslegers, J.-M., 592
 Kettelhut, I.C., 1217
 Khan, A., 627
 Khurana, R., 1315
 Kielar, D., 844
 Kim, S.H., 955
 Kim, S.Y., 955
 Kinoshita, J., 257
 Kinsley, B.T., 1252
 Kishimoto, T., 804
 Kitahara, A., 1083
 Kitano, S., 195
 Kiyonaga, A., 874
 Kjeldsen, S., 292
 Klein, G.K., 273
 Klein, J.C., 799
 Klein, S., 706
 Knardahl, S., 439
 Knopp, R., 1140
 Knopp, R.H., 1097
 Knowler, W.C., 622
 Knuutila, M.L.E., 578
 Kodama, H., 1233
 Koenig, J.I., 603

Koga, M., 804
 Kohno, M., 1065
 Kohzuki, M., 1472
 Koike, T., 1348
 Koivula, T., 1258
 Kokkaku, K., 1391
 Kolanowski, J., 592
 Kotsuji, F., 1344
 Kovács, É., 1070
 Kovács, P., 1070
 Kraegen, E.W., 409, 1121
 Kraemer, F.B., 555
 Krauss, R.M., 1174
 Kreider, M., 1227
 Krempf, M., 497, 549
 Krieg, R.J., Jr., 425
 Kriketos, A.D., 106
 Kristensen, K., 1514
 Kubota, M., 44, 908
 Kumar, V., 461
 Kume, S., 699
 Kumon, Y., 598
 Kurahashi, Y., 257
 Kurzawski, G., 844
 Kusaka, I., 1391
 Kushiro, T., 493
 Kushner, H., 70
 Kushwaha, R.S., 731
 Kusunoki, M., 149
 Kuwajima, S., 1348
 Kuznetsov, N.K., 903
 Kwok, C.-F., 1468
 Kyriakidis, M., 1379
 Laakso, M., 1397
 Lagrost, L., 965
 Laher, I., 1037
 Lala, A., 97
 Lalau, J.-D., 1372
 Lam, W.F., 321
 Lamarche, B., 234
 Lambrinoudaki, I., 1379
 Lamers, C.B.H. W., 321
 Landau, B.R., 627
 Lanfredini, M., 915
 Lanzone, A., 158
 Lardner, A.L., 163
 Larue-Achagiotis, C., 777
 Lau, D.C.W., 461
 Laurenti, O., 993
 Lavige, S., 1366
 Laws, A., 1174
 Lazarus, D.D., 75
 Le Boucher, J., 1366
 Lee, H.R., 955
 Lee, K.-S., 955
 Lee, S., 125
 Lee, Y.-C., 1468
 Lee, Y.J., 1140
 Leeds, A., 1245
 Lehotay, D.C., 836
 Lehtimäki, T., 1258
 Leibel, R.L., 584
 Leiser, R., 1105
 Lemonnier, F., 799
 Lenders, J.W.M., 243
 Leslie, R.D.G., 1205
 Levi, S., 264
 Levillain, O., 355
 Levine, J., 280
 Levy, J., 185
 Levy, J.R., 285
 Lewis, G.F., 234
 Leyva, F., 657, 1156
 Li, G., 824
 Liang, J., 959
 Lichtenstein, A.H., 922
 Lien, E.A., 89
 Lin, H., 1211
 Lin, L.-C., 1211
 Lin, S.-H., 1468
 Lindahl, B., 384
 Lindenthal, B., 1504
 Ling, P.-R., 345
 Littman, E.D., 809
 Litwak, K.N., 947
 Liu, Y.-J., 474
 Livier, C., 1490
 Lohmann, R., 608
 Longui, C.A., 1419
 Lorente, R.I., 508
 Lormeau, B., 1372
 Lotan, D., 264
 Lotsikas, A.J., 1289
 Louheranta, A.M., 529
 Louisot, P., 1499
 Lovejoy, J.C., 1520
 Lu, B., 630
 Lu, C.-C., 1211
 Luo, J., 663
 Lutterman, J.A., 243
 Luzi, L., 713
 Lyall, F., 1281
 Ma, D., 1233
 McArthur, M.D., 1383
 McClain, C.J., 566
 McClain, D., 449
 McCormick, K., 1360
 MacDougall, D.E., 751
 McFarlane-Anderson, N., 617
 McGill, H.C., Jr., 731
 Macho, L., 1269
 MacLean, P., 1048, 1222
 McNamara, D.J., 883
 McNeill, J.H., 1037
 Macor, C., 988
 Magotti, M.G., 893
 Makita, Z., 1348
 Manaka, H., 1167
 Mancuso, S., 158
 Mandal, A.K., 1065
 Manglik, S., 1127
 Manns, M.P., 1160
 Mansouri, A., 425
 Marchesi, C., 50, 814
 Marchesini, G., 792
 Marchini, J.S., 497, 549
 Marcovina, S., 1097
 Marescau, B., 355
 Margara, R., 1245
 Marietti, G., 1205
 Marks, L.M., 497
 Marks, R.H., 1222
 Maroccia, E., 129
 Martin, A., 1499
 Martinez, A.J., 301
 Martinez-Valls, J., 508
 Maruyama, K., 724
 Masclee, A.A.M., 321
 Masuda, T., 977
 Masuzaki, H., 456
 Mathes, P.B., 273
 Matsuhisa, M., 44, 908
 Matsumoto, K., 1303
 Matsuo, Y., 94
 Matsuoka, N., 456
 Matsura, F., 929
 Matsuzawa, Y., 929
 Mattéi, J.-P., 769
 Matthews, D.E., 713
 Mattila, P.T., 578
 Matyka, K.A., 1481
 Maugère, P., 549
 Mayer-Davis, E.J., 1174
 Mayumi, M., 333, 1344, 1403
 Meeter, K., 675
 Mello, A., 915
 Menzinger, G., 97
 Merchant, A., 508
 Messaoudi, L., 592
 Messing, B., 1429
 Metz, S.A., 824
 Metzger, B., 1140
 Meyer, C., 1227
 Mezzetti, A., 535
 Michaelis, O.E., IV., 1199
 Mick, G., 1360
 Miettinen, T.A., 744
 Migliorini, R.H., 1217
 Mikami, T., 1083
 Millar, J.S., 922
 Mills, J.L., 1140
 Minami, M., 1065
 Minehira, K., 1303
 Miossec, P., 934
 Miura, M., 333, 1344
 Miyaguchi, S., 977
 Miyamoto, Y., 456
 Moan, A., 292
 Mochizuki, K., 257
 Mohamed-Ali, V., 622, 637
 Moldawer, L.L., 75
 Montano, C.E., 883
 Morales, A.J., 940
 Morgan, D., 584
 Morgan, T., 401
 Morimoto, S., 195
 Morishima, T., 908
 Morita, T., 598
 Moriwaki, Y., 695, 739, 1005
 Morrison, J.A., 514
 Morviducci, L., 129
 Moshe, R., 1331

Motomura, T., 804
 Motti, C., 97
 Mourad, M., 420
 Moussa, M.A.A., 420
 Mudaliar, S., 686
 Murgia, F., 158

Nadjafi, R., 1127
 Nagasaka, S., 1391
 Nagi, D.K., 622
 Naim, M., 1
 Nakagawa, Y., 474
 Nakahara, I., 908
 Nakai, Y., 874
 Nakajima, M., 195
 Nakamura, H., 1083
 Nakamura, M., 257
 Nakamura, T., 929, 1391
 Nakano, T., 695, 739, 1005
 Nakao, K., 456
 Nakashima, K., 351, 783
 Nakauchi, Y., 598
 Naliboff, B.D., 39
 Naruse, M., 27
 Naruszewicz, M., 844
 Nasuda, K., 474
 Natsume, H., 1083
 Natu, V., 555
 Naveas, R., 297
 Nawata, H., 1494
 Neal, D., 135
 Nedrebo, B.G., 89
 Nelson, A., 1274
 Nephesh, I., 1331
 Nestle, P.J., 1308
 Newsome, C., 617
 Nguyen, P., 549
 Nguyen, T.N., 934
 Nicklas, B.J., 467
 Nicolosi, R.J., 959
 Nicolson, M., 1525
 Niijima, A., 1167
 Niinobu, T., 195
 Nikkari, T., 1258
 Nikodémová, M., 1269
 Nilsson, J., 113
 Nilsson, T.K., 384
 Nishi, S., 456
 Nishida, M., 929
 Nishimura, H., 456
 Nishiyama, K., 1083
 Nishizawa, H., 44
 Nkansa-Dwamena, D., 420
 Noel-Suberville, C., 301
 Normand, S., 1499
 Nørrelund, H., 83, 1514
 Nowaczyk, M.J.M., 836
 Nowotny, P., 119, 974, 1376
 Nozaki, S., 929
 Nygård, O., 89

O'Brien, B.C., 377
 O'Brien, W.T., 878
 O'Connor, J., 106
 Odom-Ford, R., 940

O'Donovan, D.J., 163
 Ogihara, T., 195
 Ohara, M., 101
 Ohata, H., 695, 1005
 Ohnuma, H., 1167
 Ohsawa, N., 101
 Ohzeki, T., 474
 Ojuel, J., 560
 Okamura, K., 1303
 Okumura, S., 351, 783
 Olefsky, J.M., 940
 Omori, Y., 27, 1325
 Onaya, T., 699
 Onishi, T., 195
 Opara, E.C., 401, 809
 Ordóñez-Llanos, J., 371
 Ordovas, J.M., 922
 Ørskov, H., 817
 Otal, C., 371
 Otvos, J., 1222
 Ozaki, Y., 699
 Ozand, P.T., 900
 Ozanne, S.E., 1450

Pachiaudi, C., 1499
 Pacini, G., 792
 Paganini, C., 1490
 Pallet, V., 301
 Palmer, T.N., 1180
 Palmieri, E., 535
 Palmieri, M., 1423
 Pan, D.A., 106
 Panahloo, A., 637
 Pandak, W.M., 285
 Papanicolaou, D.A., 1289
 Paragh, G., 1070
 Parekh, P.I., 1089
 Parhofer, K.G., 478
 Paries, J., 503, 934
 Park, E., 1140
 Parsons, W., 751
 Parviaainen, M.T., 529
 Pasquali, M., 207
 Pasquali, R., 988
 Pasquon, B., 1490
 Pasternack, A., 1258
 Patel, B.K., 603
 Patterson, B.W., 706
 Payés, A., 371
 Pearson, T., 182
 Peca, M.G., 915
 Pecka, M., 681
 Pedersen, S.B., 1514
 Peppa-Patrikiou, M., 1408
 Pérez, A., 371
 Périer, S., 1499
 Perriello, G., 1227
 Peters, T.J., 1180
 Petersen, S.C., 223
 Peterson, R.G., 1042, 1315
 Petro, A.E., 1089, 1354
 Petry, C.J., 1450
 Phanumas, L., 39
 Phillips, H., 836
 Phinney, S.D., 429

Phung, T.L., 1315
 Piercy, V., 1477
 Pignon, J.-M., 1413
 Pihlajamäki, J., 1397
 Piloquet, H., 549
 Pirsch, J.D., 200
 Pitchumoni, S., 809
 Plagemann, A., 855
 Platt, B.-A., 836
 Pogue, J., 182
 Polansky, M.M., 396
 Pomeroy, S.E., 1308
 Poretsky, L., 690
 Portillo, M.P., 301
 Poulsen, P.L., 83
 Pouteau, E., 549
 Pozzilli, P., 1205
 Pratley, R.E., 1075
 Pritsker, A., 3
 Proudiere, A., 113
 Proukakis, C., 1379
 Prpić-Križevac, I., 13

Qi, R., 699
 Qian, Y., 269
 Qiang, X., 977
 Qu, Z., 345
 Quan, J., 663

Raab, S., 1105
 Radetti, G., 1490
 Raghow, R., 869
 Ragolia, L., 54
 Räikkönen, K., 1440
 Rajab, A., 1337
 Rajpal, S., 200
 Ramachandran, A., 230
 Rantalaaho, V., 1258
 Rantzau, C., 522
 Rapoza, R.E., 1239
 Raslich, M., 200
 Ravaja, N., 1440
 Ravussin, E., 1525
 Raz, I., 1331
 Reach, G., 799
 Real, J.T., 508
 Reaven, G.M., 663, 831
 Refsum, H., 89
 Reifen, R., 1, 264
 Reviriego, J., 371
 Reynolds, R., 1423
 Rice, K.S., 731
 Richelsen, B., 1514
 Richter, W.O., 273, 863
 Ricour, C., 1366
 Rieth, N., 777
 Rios, M., 297
 Rioux, M.F., 20
 Rissanen, J., 1397
 Rizza, R.A., 7
 Robbins, D.C., 1174
 Roberts, J.M., 1281
 Rodriguez, N.R., 1434
 Rodriguez-Villar, C., 560
 Rogus, E.M., 467, 1075

Rohac, M., 1058
 Rohack, J.J., 377
 Rohde, W., 855
 Roine, R.P., 644
 Romano, C., 959
 Romijn, J.A., 217
 Ronchi, M., 792
 Rood, J.C., 1520
 Ros, E., 560
 Roseau, S., 777
 Rosenfalck, A.M., 1514
 Rosenthal, M.J., 39
 Rosmond, R., 1187
 Roth, M.D., 1042
 Roussel, B., 1372
 Rubio, S.I., 690
 Russell, J.C., 1383
 Russell-Jones, D.L., 1481

Saad, M.F., 1174
 Saegusa, H., 474
 Sagara, M., 977
 Saïdi, Y., 965
 Saito, T., 1391
 Sakamoto, M., 874
 Salaspuro, M., 644
 Salen, G., 878
 Samra, J.S., 31
 Sanllehy, C., 560
 Saris, W.H.M., 1462
 Sarkkinen, E.S., 744
 Sasahara, T., 1308
 Sasaki, A., 783
 Sasaki, H., 1167
 Sato, T., 1472
 Satoh, J., 977
 Satoh, K., 699
 Satoh, N., 456
 Satyavani, K., 230
 Sauerwein, H.P., 217
 Sbraccia, P., 129
 Scalbert, E., 1199
 Schaefer, E.J., 922
 Schalch, D.S., 200
 Schiffelers, S.L.H., 1462
 Schmidt, B., 686
 Schmidt, H.J.-H., 1160
 Schulte, H., 336
 Schumitzky, A., 484
 Schwab, U.S., 529
 Schwandt, P., 273, 863
 Scoppola, A., 97
 Seals, D.R., 1112
 Segal, S., 1423
 Segu, V.B.G., 824
 Sekine, K., 1344
 Selby, J., 1174
 Seljeffot, I., 292
 Sentí, M., 1040
 Sepúlveda, J., 297
 Sepúlveda, S., 297
 Servatius, R.J., 878
 Sgambati, S.A., 133
 Shaltout, A.A., 420
 Shankar, R.R., 573
 Shefer, S., 878

Shen, H.-Q., 1042
 Sherif, K., 70
 Shi, Z.Q., 1274
 Shiba, Y., 908
 Shigemoto, M., 456
 Shillabeer, G., 461
 Shimizu, S., 1303
 Shimoike, T., 1494
 Shindo, M., 874
 Shiroshita, K., 1348
 Shiwaku, K., 1528
 Shukin, R., 20
 Shukla, N., 1048
 Shuldiñer, A.R., 1525
 Sich, D., 965
 Silver, K., 1525
 Simonson, D.C., 713, 1252
 Simpson, J.L., 1140
 Sivitz, W.I., 584
 Skjærboe, C., 817
 Smith, J.M., 1450
 Smith, R.J., 345
 Smits, P., 243
 Smolyar, D., 690
 Snelhalatha, C., 230
 Snitker, S., 1525
 Soliman, A.T., 541, 1337
 Song, M.K., 39
 Sorci-Thomas, M.G., 391
 Souba, W.W., 608
 Sowden, M.P., 1315
 Sparks, C.E., 1315
 Sparks, J.D., 1315
 Sprecher, D., 514, 1097
 Šrongo, L., 681
 Srinivasan, S.R., 757, 998
 Starke, A.A.R., 1263
 Starr, J.R., 325
 Steen, M.T., 207
 Stern, J.S., 429
 Stevens, W., 285
 Stevenson, J.C., 435, 657
 Stock, S.M., 840
 Stoffel, M., 592
 Stolarczyk, R., 690
 Storlien, L.H., 106, 149
 Štrbák, V., 1269
 Streicher, J., 1058
 Striffler, J.S., 396, 1199
 Strobl, W., 1058
 Stumvoll, M., 1227
 Sučić, M., 13
 Suehiro, T., 598
 Suga, J., 456
 Sugahara, K., 1233
 Sugimoto, M., 351, 783
 Sugiyama, K., 1167
 Sulikowski, T., 844
 Sullivan, C., 663
 Sullivan, K.M., 207
 Superko, H.R., 1097
 Suprasongsin, C., 309
 Surwit, R.S., 1089, 1354
 Suzuki, M., 190
 Svanberg, M.J., 578
 Svenedesen, O.L., 212

Szabó, J., 1070
 Szabolcs, M., 1070
 Sztalryd, C., 555

Tack, C.J.J., 243
 Takahara, J., 1295
 Takahashi, A., 493
 Takahashi, K., 977
 Takahashi, M., 724
 Takahashi, S., 695, 739, 1005
 Takami, K., 351, 783
 Takami, R., 351, 783
 Takayanagi, R., 1494
 Takeda, D., 555
 Takeda, N., 351, 783
 Takemura, Y., 362
 Takeuchi, M., 333, 1348
 Tamatani, M., 195
 Tamburrano, G., 129
 Tan, R., 836
 Tanaka, H., 874, 1112
 Tanaka, T., 456
 Tang, S., 630
 Taniguchi, A., 874
 Taveroff, A., 1145
 Tawata, M., 699
 Tayek, J.A., 1127
 Teraoka, S., 1325
 Terry, J.G., 401
 Tessari, P., 669
 Thibault, N., 1199
 Thien, H.V., 217
 Thien, T., 243
 Thomaseth, K., 792
 Thomé-Duret, V., 799
 Thomforde, G.M., 7
 Thorngate, F.E., 869
 Thuillier, F., 1429
 Thusu, K., 788
 Thuy, L.T.D., 217
 Tibbo, E., 461
 Tichý, M., 681
 Tietge, U.J.F., 1160
 Tiller, J.M., 1089
 Tint, G.S., 878
 Toborek, M., 566
 Toft, I., 848
 Tohjima, T., 257
 Tokuyama, K., 190, 874
 Tominaga, M., 1167
 Tomita, T., 908
 Tomonaga, O., 1325
 Tonetti, C., 1413
 Tong, W.-M., 415
 Tønnessen, T., 292
 Tornvall, P., 113
 Torpy, D.J., 1289
 Toseland, C.D.N., 1477
 Toyka, K., 474
 Toyota, T., 977
 Trew, G., 1245
 Tribout, B., 1372
 Trimble, L.A., 75
 Tsai, J., 663
 Tsai, S.-C., 1211
 Tsekes, G., 1379

Tsigos, C., 1289
 Tsukahara, H., 333, 1344, 1403
 Tsuneoka, Y., 94
 Tsunoda, N., 724
 Tsutsumi, K., 101, 149
 Tsutsumi, Z., 695, 739, 1005
 Tulliez, M., 1413
 Turner, N.C., 1477
 Turpeinen, A.K., 529
 Turpin, G., 965

Ueda, T., 1348
 Ueland, P.M., 89
 Uffelman, K.D., 234
 Ulloa, N., 297
 Umeda, F., 1494
 Umpleby, A.M., 1481
 Uusitupa, M.I.J., 529, 744

Vaag, A., 522
 Vadlamudi, S., 1048, 1222
 Vague, P., 769
 Vahl, N., 1134
 Valasquez, M.T., 1199
 Valensi, P., 503, 934
 Valve, R., 1397
 Van Baak, M.A., 1462
 Van Daele, A., 355
 Vanderbloomer, T., 1360
 Van Druten, J., 243
 Van Marck, E., 355
 Veldhuis, J.D., 143
 Verdugo, C., 297
 Verentsov, G.E., 903
 Vergnani, L., 535
 Verkijk, M., 321
 Verma, S., 1037
 Veronelli, A., 915
 Vettor, R., 988
 Vettore, M., 669
 Vicennati, V., 988
 Vicini, P., 484
 Vidgren, H.M., 529
 Vierhapper, H., 119, 974, 1376
 Vijay, V., 230
 Vircici, F., 1194
 Virkamäki, A., 449
 Visalli, N., 1205
 Volpato, S., 535
 Volpi, R., 50, 814, 893, 897
 Von Eckardstein, A., 336
 Von Wronski, M.A., 869
 Vore, S., 1048

Vottero, A., 1419
 Wagner, J.D., 391, 947
 Walder, K., 125
 Waldhäusl, W., 119, 974, 1376
 Walsh, S., 584
 Walton, C., 435
 Wang, C.L., 1450
 Wang, F., 415
 Wang, G.-J., 1211
 Wang, J., 1274
 Wang, P.S., 1211
 Wang, S.-W., 1211
 Wang, Z.Q., 401
 Ward, G.M., 522
 Wasada, T., 27
 Watanabe, H., 724
 Watanabe, K., 257
 Watanabe, Y., 94
 Watts, A.P., 31, 1481
 Weidinger, F., 1058
 Weinstein, S.P., 3
 Weiser, H., 1
 Weiss, O., 1331
 Weissfeld, L., 1281
 Welt, C.K., 1252
 Werbel, S., 401
 Werle, E., 63
 Whately-Smith, C., 250
 Wherli, S., 1423
 Whitcomb, L., 1274
 Wiersinga, W.M., 1052
 Wilcox, H.G., 869
 Wilks, R., 617
 Willemse, J.J., 243
 Williamson, J.R., 1423
 Wilson, C.M., 3
 Wilson, G.S., 799
 Wilson, T.A., 959
 Windhauer, M.M., 1520
 Wingrove, C.S., 435, 657
 Wirta, O., 1258
 Wolthers, T., 83

Xu, D., 1180
 Xu, G., 878

Yamada, M.A., 177
 Yamakita, J.-i., 695, 739, 1005
 Yamamoto, K., 333, 1403
 Yamamoto, S., 257
 Yamamoto, T., 695, 739, 1005
 Yamamoto, Y., 456
 Yamane, Y., 1528

Yamasaki, Y., 44, 908
 Yamashita, S., 929
 Yamashita, T., 1308
 Yamatani, K., 1167
 Yanagisawa, K., 1348
 Yanase, T., 1494
 Yang, F., 566
 Yang, H., 200
 Yanko, L., 1331
 Yanko, R., 1331
 Yao, L., 1037
 Yaroshenko, Y.Y., 903
 Yasuda, K., 351, 783
 Yasunari, K., 1065
 Yen, S.S.C., 940
 Yki-Järvinen, H., 449
 Yokokawa, K., 1065
 Yokokawa, M., 1472
 Yokota, M., 177
 Yoshikawa, J., 1065
 Yoshimasa, T., 456
 Yoshimasa, Y., 456
 Yoshimi, T., 1083
 Yoshimoto, T., 257
 Yoshino, K., 351, 783
 Young, I.S., 690
 Young, V.M., 566
 Young, V.R., 497
 Yu, H.K., 955
 Yudkin, J.S., 622, 637
 Yusuf, S., 182

Zaccaro, D.J., 1174
 Zadik, Z., 264
 Zakrzewski, K., 608
 Zambón, D., 560
 Zanetti, M., 669
 Zech, L.A., 1160
 Zhang, J., 1233
 Zhang, M., 1233
 Zhang, Y., 799
 Zhao, G., 706
 Zhu, J.-S., 573
 Zhu, Z., 185
 Zillikens, M.C., 675
 Zimmet, P., 125
 Zittoun, J., 1413
 Zong-Chao, L., 627
 Zorbas, Y.G., 903
 Zorretta, D., 129
 Zulet, M.O., 301
 Zuliani, G., 535

SUBJECT INDEX

A, *see* Androstenedione
 A-3826G promoter variant of UCP-1 gene, Trp 64 Arg polymorphism of β_3 -adrenoreceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402
 AA(s), *see* Amino acids
 AAAs (aromatic amino acids), plasma, relationship between Phe hydroxylation and concentrations of, 669-674

Abdominal adipose tissue (AT)
 body composition, insulin resistance, and IAT, 402, 404, 406
 exercise effects, 191
 related to anxiety and depression, endocrine and metabolic aberrations in men with, 1187-1193

Absorptiometry, *see* Dual-energy x-ray absorptiometry, assessment of body composition with

ACAT (acyl coenzyme A:cholesterol acyltransferase), effects of inhibition of, on C uptake in Caco-2 cells, 325-332

ACE, *see entries beginning with terms: Angiotensin-converting enzyme [1-13C]Acetate, role of glucose and glutamine in differential recovery of ¹³CO₂ from infused [2-¹³C]acetate versus, 549-554*

Acetoacetate

- blood, in offspring of protein-malnourished subjects, 1451-1452
- IGF-I effects on, in young IDDM adults, 34
- α (alpha)-N-Acetylarginine, nephrectomy effects on, 358-359
- N*-Acetyl-glucosamine, *O*-linked, insulin and GLcN effects on level of, in muscle proteins, 449-455

N-Acetyl- β -glucosaminidase (NAG)

- in NIDDM, 363
- urinary excretion of, in newborns, 1345

Acetylhydrolase gene, PAF, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181

Acidosis, HCl, 163-167

Aciduria, methylsuccinic and ethylmalonic, in ethylmalonic encephalopathy, due to abnormal Ile, 836-839

Acipimox

- effects of, on dyslipidemia and glucose metabolism in NIDDM, 250-256
- lipolysis inhibition with, effects of, on β_1 -adrenoceptor-mediated thermogenesis in men, 1462-1467

Acquired immunodeficiency syndrome (AIDS), urinary free cortisol in, 690-694

ACTH, *see Corticotropin*

Actinomycin D, RA catabolism inhibited by, 956

Active celiac disease, leucine and glutamine kinetics in, in assessment of whole-body protein metabolism, 1429-1433

Acute hyperinsulinemia

- ET-1 in, with ANG II type 1 receptor antagonist-treated essential hypertension, 292-296
- plasma HCY regulated by, in nondiabetics but not in NIDDM, 686-689

Acute insulin resistance due to alcohol-related diols, 1180-1186

Acute single-dose interleukin-6 (IL-6), effects of, on thyroid function in healthy subjects, 1289-1293

Acute spinal cord injury (SCI), serum lipids following, 367-370

Acyl coenzyme A, long-chain, effects of FFA elevation on, 1122-1123

Acyl coenzyme A:cholesterol acyltransferase (ACAT), effects of inhibition of, on C uptake in Caco-2 cells, 325-332

Acyltransferase, *see Acyl coenzyme A:cholesterol acyltransferase; Leathin:cholesterol acyltransferase*

Adaptation, intestinal, after small bowel resection, enteral OKG effects on, 1366-1371

Adenoma, pituitary, inhibition of signal transduction by splice variant of GHRH receptor expressed in, 804-808

Adenosine-5'-diphosphate (ADP)

- NIDDM complications and platelet aggregation induced by, 702
- skeletal muscle, in hyperthyroidism, 771

Adenosine monophosphate, *see cAMP*

Adenosine triphosphatase, *see ATPase*

Adenosine triphosphate (ATP), skeletal muscle, in hyperthyroidism, 771, 774-775

Adhesion molecule-1, vascular cell, and LDLs in hyperlipidemia of preeclampsia, 1281-1288

Adipocytes

- adrenoceptor binding and lipolysis of, in obese postmenopausal women, AT distribution and, 467-473
- ET-1 inhibition of insulin-stimulated glucose uptake in, through ETA receptors, 1468-1471
- leptin and, *see Adipocytes, leptin and* in NIDDM, insulin signaling in, 54-62

Adipocytes (Continued)

- [¹²⁵I]transferrin binding and ⁵⁹Fe uptake in, stimulated by vanadate, 630-636
- in women with risk factors for CHD, 1248
- see also Lipoprotein lipase activity in adipocytes*

Adipocytes, leptin and

- leptin effects on glucose metabolism in, 1360-1365
- leptin release in hypothyroidism, 1455-1461

Adipose tissue (AT; body fat)

- body composition, insulin resistance and, 402, 404, 406
- distribution of, *see Adipose tissue distribution*
- and family history of NIDDM, 523
- and HRT effects on plasma lipids and Lps, 1224
- NO-1886 effects on, 104, 150
- in OC users, 281
- restricted caloric intake effects on, 429-434
- and RMR in normal subjects, 1135, 1136
- SHBG and, in insulin-resistant women, race and, 71
- see also Adipocytes; Adipose tissue, exercise and; Adipose tissue, leptin and; Adipose tissue distribution in postmenopausal women; Fat mass; Obesity*

Adipose tissue (AT; body fat), exercise and

- AT as risk factor for CHD in postmenopausal exercising women, 1112-1120
- exercise effects on abdominal AT, 191
- glucose effectiveness in endurance exercise and, 875
- menopausal status and exercise effect on serum lipids and, 378, 379

Adipose tissue (AT; body fat), leptin and

- insulin secretion and therapy mode association with serum leptin and, in IDDM and NIDDM, 1391-1396
- leptin receptor isoforms expressed in AT, 844-847
- and plasma leptin in children, 310
- serum leptin in obese PCOS women correlated with BW and AT but not with androgen and insulin levels, 988-992

Adipose tissue (AT; body fat) distribution

- low- and high-fat diet effects on, 1091-1092
- in premenopausal IDDM and NIDDM women, DXA measuring, 212-216
- serum leptin in obese PCOS women correlated with BW and, but not with androgen and insulin levels, 988-992

see also Abdominal adipose tissue; Adipose tissue distribution in postmenopausal women; Intraabdominal adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue

Adipose tissue (AT) distribution in postmenopausal women

- IDDM or NIDDM women, DXA measuring, 212-216
- in obese women, adrenoceptor binding and adipocyte lipolysis in, 467-473

Adipose tissue lipoprotein lipase (ATLPL), activity of, in adipocytes, AT distribution and, 469

Adolescents

- hepatic 11 β -HSD1 activity and mRNA in hypothyroidic, T₄ and T effects on, 474-478
- IDDM, urinary ET-1 excretion in, 1408-1412
- racial difference in HDL-C and TG levels in, 514-521
- see also Puberty*

ADP, *see Adenosine-5'-diphosphate*

Adrenal catecholamines, *see Epinephrine; Norepinephrine*

Adrenal function

- long-term alcohol intake effects on, at puberty, 1270-1271
- see also specific aspects of adrenal functions*

Adrenal sterol 27-hydroxylase, protein level and activity of, 734

Adrenaline, *see Epinephrine*

Adrenoceptor(s)

- adipocyte lipolysis and binding of, in obese postmenopausal women, AT distribution and, 467-473

Adrenoceptor(s) (Continued)

- see also* β -Adrenoceptor blockade; Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- β (beta)-Adrenoceptor, effects of blockade of, on EPOC and TG/FA cycling, 439-448
- β_1 (beta₁)-Adrenoceptor, effects of lipolysis inhibition on thermogenesis mediated by, in men, 1462-1467
- β_3 -Adrenoceptor gene, *see* Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
- Adrenocorticotropic hormone, *see* Corticotropin
- Adrenomedullary system, insulin effects on, 247-248
- Advanced glycation end (AGE) products in DM
 - aminoguanidine effects on role of, in NIDDM progression, 1477-1480
 - fluorescence assay of blood and urine, 1348-1353
- Adverse effects
 - of acipimox, 254
 - of IL-6 injection, 1291
 - of LDL apheresis, 866
 - of pyridostigmine, 815
- Aerobic exercise, effects of weight loss and, on BP, glucose metabolism, and Lps in obese hypertensive middle-aged men, 1075-1082
- African American subjects, *see* Race and ethnicity
- AGE products, *see* Advanced glycation end products in DM
- Age
 - of AIDS patients, urinary free cortisol and, 691
 - CAD and, *see* Age, CAD and
 - of celiac disease patients, 1430
 - and CHD, *see* Age, CHD and
 - of CHF patients, 1157
 - of cirrhotic subjects, 793
 - and cortisol response to ACTH, 1253
 - of DM subjects, blood and urine AGE products and, 1349; *see also* Age of IDDM subjects; Age of NIDDM subjects
 - of endogenous depression subjects, 51
 - of exercising subjects, *see* Age of exercising subjects
 - of falciparum malaria subjects, 219
 - of familial HBLP subjects, 1162
 - of FCHL, *see* Age of FCHL subjects
 - GH and, 340, 1517
 - of gout subjects, 337
 - of HALP subjects, 968, 1162
 - and HRT effects on plasma lipids and Lps, 1224
 - of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects
 - of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 - of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects
 - of hyperthyroidic and hypothyroidic subjects, 90, 91
 - of hypertriglyceridemic subjects, 236
 - and insulin resistance, *see* Age, insulin resistance and
 - leptin and, *see* Age, leptin and
 - and Lp(a) levels, 183
 - maternal, and FPG reduction in pregnancy, 1141
 - of nondiabetic subjects, *see* Age of nondiabetic subjects
 - of non-obese IGT subjects, insulin kinetics, muscle morphology and, 850
 - of obese subjects, *see* Age of obese subjects
 - of OC users, 281
 - of osteopenic men, 196
 - of PCOS subjects, 941, 989
 - of postmenopausal women, *see* Age of postmenopausal women
 - of premenopausal women, *see* Age of premenopausal women
 - race and, *see* Age, race and

Age (Continued)

- and RMR, 1135, 1136
- of Robinow syndrome patients, 1341
- of subjects with family history of NIDDM, 523, 525
- of syndrome X subjects, 536, 537
- see also* Adolescents; Aging; Children; Older subjects and entries beginning with terms: Middle-aged, Young
- Age, CAD and
 - age as risk factor, 179
 - of nondiabetics with metabolic syndrome and electrocardiographic CAD, 624
- Age, CHD and
 - age as risk factor, 114
 - with NIDDM, 1246
 - total plasma HcY and, 274
- Age, insulin resistance and
 - and body composition, 402, 404, 406
 - Hct, Hb and, 832, 834
 - SHBG, race and, in insulin-resistant women, 71
- Age, leptin and
 - and effects of HF versus LF diets on S, and serum leptin in women, race and, 1521
 - and insulin secretion and mode of therapy association with leptin and AT in IDDM, 1394, 1395
 - see also* Age, plasma leptin and
- Age, plasma leptin and
 - in obese women, and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, 1309, 1312
 - in pregnant nondiabetics, 841
 - and Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, 1526
- Age, race and
 - of adolescent males, HDL-C and TG levels and, 516
 - and distribution of serum LpA-I and LpA-I:A-II, 758, 759
 - and effects of HF versus LF diets on S, and serum leptin in women, 1521
 - of nondiabetics, relationship between Lps and insulin resistance in, 1176, 1177
 - SHBG and, in insulin-resistant women, 71
- Age of exercising subjects
 - β -adrenoceptor blockade effects on EPOC, 440
 - of exercising postmenopausal women, AT as risk factor for CDH and, 1113
 - glucose effectiveness in endurance exercise and, 875
 - menopausal status and exercise effects on serum lipids, 378, 379
 - with NIDDM, hemodynamic response to handgrip test and, 935, 936
- Age of FCHL subjects
 - and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398, 1400
 - of nondiabetic FCHL subjects, insulin resistance and, 509, 510
- Age of hypercholesterolemic subjects
 - and efficacy of plain niacin versus Niaspan, 1099
 - and fat-modified diet effects on concentrations of serum C precursors and phytosterols, 745
 - LDL apheresis and, 1059
 - with polygenic hypercholesterolemia, 98
 - with primary hypercholesterolemia, 561
 - with severe heterozygous FH, 864, 866
- Age of hyperinsulinemic subjects
 - with acute hyperinsulinemia, 687
 - healthy non-obese, 832, 834
 - premenopausal, 16, 17
- Age of IDDM subjects
 - CFA and, 504

Age of IDDM subjects (*Continued*)
 at IDDM onset, immune parameters and, 1208
 and insulin secretion and mode of therapy association with leptin and AT, 1394, 1395
 of postmenopausal and premenopausal subjects, DXA measuring body composition and AT in, 213
 of pregnant IDDM subjects, plasma leptin and, 841
 and proinsulin levels following whole pancreas-kidney transplantation, 1326
 and urinary ET-1 excretion, 1409, 1410

Age of NIDDM subjects
 acipimox effects and, 251
 CFA and, 504
 CHD and, 1259, 1260
 dietary protein restriction effects and, 1147
 and glucose and GLP-1 stimulation effects on insulin release, 1043
 and GSH effects on glucose metabolism, 994
 hemodynamic response to handgrip test and, 935, 936
 IR isoform mRNA and, 130
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 obese, *see* Age of obese subjects with NIDDM
 platelet 12-LOX activity and, 258-260
 postmenopausal and premenopausal, DXA measuring body composition and AT in, 213
 serum PON activity and, 599
 and SPA relationship to NIDDM complications, 701-703
 tHcy and microalbuminuria and, 916
 Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457
 urinary and serum TM and, 363, 364

Age of nondiabetic subjects
 with FCHL, insulin resistance and, 509, 510
 with metabolic syndrome, and electrocardiographic CAD, 624
 pregnant, plasma leptin and, 841
 relationship between Lps, insulin resistance and, race and, 1176, 1177

Age of obese subjects
 with IGT, insulin kinetics, muscle morphology and, 850
 with NIDDM, *see* Age of obese subjects with NIDDM
 of obese men, VAT accumulation effects on uric acid metabolism in, 930
see also Age of obese women

Age of obese subjects with NIDDM
 LDL receptors and lipid metabolism and, 1071
 S_i, insulin action, fibrinolysis and, 1372-1375

Age of obese women
 and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, compared, 1309, 1312
 of hyperinsulinemic premenopausal women, 14, 16
 with PCOS, serum leptin in, 989
 postmenopausal, adrenoceptor binding, adipocyte lipolysis and, 469

Age of postmenopausal women
 exercising, AT as risk factor for CHD and, 1113
 with IDDM or IDDM, DXA measuring body composition and AT in, 213
 non-obese, serum uric levels and, 437
 obese, adrenoceptor binding, adipocyte lipolysis and, 469

Age of premenopausal women
 hyperinsulinemic, 14, 16
 with IDDM or IDDM, DXA measuring body composition and AT in, 213
 non-obese, serum uric levels and, 437

Aging
 insulin resistance and body composition related to, CV disease risk factors and, 401-408
see also Older subjects

AIDS (acquired immunodeficiency syndrome), urinary free cortisol in patients with, 690-694

Alanine (Ala)
 endotoxin effects on, 683, 684
 in exercise, glucose and AA infusion effects on, 1306
 in familial HALP and HBLP, 1164
 plasma, *see* Plasma alanine
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227

Alanine aminotransferase (ALT)
 in elderly NIDDM subjects, Pro-Z effects on, 42
 endotoxin effects on, 682
 in LT recipients, 201
 in prepubertal children with β -thalassemia and/or CSS, 543
 serum, *see* Serum alanine aminotransferase

Albumin
 in celiac disease, 1430
 in cirrhosis, 793
 in IDDM, *see* Albumin in IDDM
 in LT recipients, 201
 in NIDDM, *see* Albumin in NIDDM
 NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
 in osteopenic elderly men, 196
 in prepubertal children with β -thalassemia and/or CSS, 543
 urinary excretion of, *see* Urinary excretion, albumin

Albumin in IDDM
 with normoalbuminuria, serum laminin levels and, 64-65
 relationship of capillary filtration of, to gender, hypertension, microangiopathy, and neuropathy, 503-507

Albumin in NIDDM
 CV risk factors, fibrinolysis, and urinary excretion of, 639
 in elderly subjects, Pro-Z effects on, 42
 microalbuminuria and vascular damage in NIDDM, tHcy levels and, 915-921
 relationship of capillary filtration of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
 TM and, 363

Alcohol intake
 in fat-modified diet for hypercholesterolemia, 745
 in gout, 337
 long-term, effects of, on food intake, BW, plasma leptin, corticosterone, and insulin levels at puberty, 1269-1273
 maternal, and FPG reduction in pregnancy, 1141
 by non-obese premenopausal and postmenopausal women, serum uric acid levels and, 437

Alcohol-related diols, acute insulin resistance due to, 1180-1186

Alkaline phosphatase (ALP)
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in LT recipients, 201
 in prepubertal children with β -thalassemia and/or CSS, 543
 serum, in CRF children, 265

Allele frequency
 for ACE genotype, metabolic syndrome and, 622, 623
 for Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457, 458, 618, 619

All-trans-retinoic acid (RA), cytochrome P450-mediated oxidation of, by retinoids in HNSCC cell lines, 955-958

All-trans-retinoic acid (RA) receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308

ALP, *see* Alkaline phosphatase

Alpha (α)-N-acetylarginine, nephrectomy effects on, 358-359

Alpha (α)-ketoglutarate, enteral ornithine, effects of, on intestinal adaptation after small bowel resection, 1366-1371

Alpha (α)-keto- δ -guanidinovaleric acid (α -keto- δ -GVA), nephrectomy effects on, 358-359

Alpha-lipoprotein, *see* High-density lipoprotein

Alpha tocopherol, *see* Vitamin E

ALT, *see* Alanine aminotransferase

Amino acids (AAs)

- effects of glucose and, on ureagenesis before and during exercise, 1303-1307
- endotoxin effects on, 683, 684
- incorporation of, into LDL apo B, 488-490
- in post-small bowel resection enteral diet, 1367
- in trauma, 226, 227, 608-616
- see also* Hepatic amino acids; Plasma amino acids and specific amino acids

Aminoguanidine, effects of, on role of AGE products in NIDDM progression, 1477-1480

Aminotransferases

- branched-chain, effects of tyrosine-deficient TPN on, 168-176
- see also* Acyl coenzyme A:cholesterol acyltransferase; Alanine aminotransferase; Aspartate aminotransferase; Galactose-1-phosphate uridylyltransferase deficiency; Galactosyltransferase; γ Glutamyl transferase; Lecithin:cholesterol acyltransferase; Tyrosine aminotransferase

Amiodarone, effects of, on LDL receptor mRNA and protein, 1052-1057

AMP (adenosine monophosphate), cyclic, glucagon effects on concentrations of, 696, 697

Anaerobic threshold, uric acid in CHF and, 1156-1159

Androgens

- serum leptin in obese PCOS women correlated with BW and AT distribution but not with levels of insulin, 988-992
- see also* specific androgens

Androstenedione (A; Δ_4 -DIONE)

- in hyperinsulinemic obese premenopausal women, 13-19
- in PCOS, 159, 990

ANF (atrial natriuretic factor), very-low-calorie diet effects on, in obesity, 592-597

Angiotensin-converting enzyme (ACE) gene polymorphism with CHD in NIDDM, 1258-1262

- plasma ACE levels and, associated with metabolic syndrome and electrocardiographic CAD in Pima Indians, 622-626

Angiotensin-converting enzyme (ACE) inhibitors, verapamil and captopril as, effects of, on glucose tolerance and insulin action in insulin resistance, 982-987

Angiotensin II (ANG II) type 1 receptor antagonist

- AVP and OT responses to, in men, 893-896
- ET-1 in acute hyperinsulinemia and essential hypertension treated with, 292-296

1,5-Anhydroglucitol in NIDDM

- platelet 12-LOX activity and, 258
- urine and serum TM and, 363

Anthropometrics

- relationship between fasting plasma insulin, metabolic parameters and, in very old subjects, 535-540
- see also* specific anthropometric data; for example: Waist-to-hip ratio

Antiatherogenic effects of Cholazol H, 959-964

Antibodies

- against oxidized LDLs, effects of ERT on, in hypercholesterolemic postmenopausal women with CHD, 675-680
- TNF, effects of, on hepatic AA transport in burn injury, 612

Anxiety, endocrine and metabolic aberrations in men with abdominal obesity related to depression and, 1187-1193

Apheresis (immunoapheresis), LDL, in FH

- LDL apo B metabolism following, simulation studies of tracer kinetics of, 478-483

Apheresis (immunoapheresis), LDL, in FH (Continued)

- long-term effects of, on plasma Lps and CHD in native vessels and coronary bypass in severe heterozygous FH, 863-868
- Lp(a) reduction by, 1058-1064

Apo(s), *see* Apolipoprotein(s)

ApoBec-1 mRNA (messenger ribonucleic acid), insulin effects on abundance of, in hepatocytes, 869-873

Apolipoprotein(s) (apo)

- serum, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- see also* specific apolipoproteins

Apolipoprotein A (apo A), insulin resistance and, SHBG, race and, 72

Apolipoprotein A-I (apo A-I)

- BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
- effects of stearic and oleic acid diets on, 532
- gemfibrozil effects on, 236, 562
- lovastatin effects on, in primary hypercholesterolemia, 562
- in NIDDM, *see* Apolipoprotein A-I in NIDDM
- plasma, *see* Plasma apolipoprotein A-I
- race, sex, and LpA-I and LpA-I:A-II relation to, in children, 760
- relationship of GH to HDL-C and, independently of IGF-1 and insulin, in women, 339-344
- serum, menopausal status and exercise effect on, 378, 379
- synthesis of, in familial HALP and HBLP, 1160-1166
- in very old syndrome X subjects, 536

Apolipoprotein A-I (apo A-I) in NIDDM

- acipimox effects on, 252
- insulin versus sulfonylurea therapy effects on, 641
- serum PON activity effects on, 599

Apolipoprotein A-I/B (apo A-I/B), plasma, HRT effects on, 1224

Apolipoprotein A-II (apo A-II)

- GH levels in women correlated with, 340-342
- in NIDDM, *see* Apolipoprotein A-II in NIDDM
- plasma, in HALP, 968, 969

Apolipoprotein A-II (apo A-II) in NIDDM

- insulin versus sulfonylurea therapy effects on, 641
- serum PON activity effects on, 599

Apolipoprotein B (apo B)

- in adolescent males, race and, 516, 517
- BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
- in familial HALP and HBLP, 1160-1166
- GH levels in women correlated with, 340-342
- lovastatin and gemfibrozil effects on, in primary hypercholesterolemia, 562
- plasma, *see* Plasma apolipoprotein B
- regulation of Lp-containing, by vitamin C level and dietary fat saturation, 883-891
- serum, *see* Serum apolipoprotein B
- stearic and oleic acid diet effects on, 532
- in very old syndrome X subjects, 536, 537
- see also* Apolipoprotein B, LDL; Apolipoprotein B in FCH; Apolipoprotein B in insulin resistance; Apolipoprotein B mRNA editing complex; Apolipoprotein B in NIDDM

Apolipoprotein B (apo B), LDL, 487-490

- AA incorporation into, 488-490
- metabolism of, following apheresis, 478-483
- multicompartmental model of kinetics of, 487-488

Apolipoprotein B (apo B) in FCH

- and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-382G promoter variant of UCP-1 gene, 1398, 1399
- in nondiabetic FCH, insulin resistance and, 509, 510

Apolipoprotein B (apo B) in insulin resistance
in insulin resistant women, SHBG, race and, 72
and nondiabetic FCH, 509, 510

Apolipoprotein B (apo B) mRNA (messenger ribonucleic acid) editing complex, insulin effects on expression of catalytic subunit of, 869-873

Apolipoprotein B (apo B) in NIDDM
acipimox effects on, 252
insulin versus sulfonylurea therapy effects on, 641
serum PON activity effects on, 599

Apolipoprotein B48 (apo B48) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1320

Apolipoprotein B100 (apo B100) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1320

Apolipoprotein E (apo E)
multicompartmental model in study of metabolism of, 922-928
in NIDDM, LDL receptor-induced secretion of, 1072
see also Apolipoprotein E genotype; Apolipoprotein E phenotype in hypercholesterolemia

Apolipoprotein E (apo E) genotype, cholesterologenesis in polygenic hypercholesterolemia and, 97-100

Apolipoprotein E (apo E) phenotype in hypercholesterolemia
and Lp response to lovastatin or gemfibrozil for primary hypercholesterolemia, 560-565
noncholesterol sterol and plant sterol relationship to, 746, 747

Apoptosis, small intestinal cell, effects of energy intake and purines on, 1105-1111

A posteriori identifiability in compartmental modeling, 1016-1018

A priori identifiability in compartmental modeling, 1015-1016

Aquaporin-2 (AQP-2), renal water channel expression and urinary excretion of, in newborns, 1344-1347

Arachidonic acid metabolites, LOX and COX pathways of, in preadipocyte differentiation regulation, 461-466

Arginine (Arg)
in familial HALP and HBLP, 1164
nephrectomy effects on, 358-359
in NIDDM *see* Arginine in NIDDM
plasma, *see* Plasma arginine
in post-small bowel resection enteral diet, 1368
reduced energy intake effects on, in obese children, 1438
and RMR in healthy adults, 1135, 1136
in trauma, 226, 227
see also Trp 64 Arg polymorphism of β_3 -adrenoceptor gene

Arginine (Arg) in NIDDM
insulin secretion stimulating by, 575
and Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese NIDDM subjects, 456-460

Arginine vasopressin (AVP)
responses of OT and, to angiotensin II type 1 receptor antagonist, in men, 893-896
urinary excretion of, in newborns, 1344-1347

Argininosuccinic acid, nephrectomy effects on, 358-359

Aromatic amino acids (AAAs), plasma, relationship between Phe hydroxylation and concentrations of, 669-674

Arterial compliance, systemic, effects of weight loss with meat-based or plant-based diet on BP, plasma leptin, and plasma lipids in women, compared, 1308-1314

Arterial insulin
G effects, 1228
plasma, in exercise, glucose and AA infusion effects on, 1305, 1306

Arterial low-density lipoprotein (LDLs) in STZ-DM, chronic hyperglycemia effects on atherosclerosis and metabolism of, 947-954

Arterial pressure, *see* Blood pressure

Ascorbic acid, *see* Vitamin C

Asian Indians
insulin and proinsulin levels in nondiabetic, 230-233
Lp(a) levels in, CHD and, 182-184

Asn, *see* Asparagine

Asp (aspartic acid), reduced energy intake effects on, in obese children, 1438

Asparagine (Asn)
in familial HALP and HBLP, 1164
plasma, *see* Plasma asparagine
reduced energy intake effects on, in obese children, 1438
in trauma, 226, 227

Aspartate, endotoxin effects on, 683, 684

Aspartate aminotransferase (AST)
endotoxin effects on, 682
in falciparum malaria, 219
in Keshan disease, 416, 417
in LT recipients, 201
serum, *see* Serum aspartate aminotransferase

Aspartic acid (Asp), reduced energy intake effects on, in obese children, 1438

AST, *see* Aspartate aminotransferase

AT, *see* Adipose tissue

Atherosclerosis
antiatherogenic effects of Cholazol H, 959-964
in STZ-DM, chronic hyperglycemia effects on arterial LDL metabolism and, 947-954

Athletes, *see* Exercise

ATLPL (adipose tissue lipoprotein lipase), activity of, in adipocytes, AT distribution and, 469

ATP (adenosine triphosphate), skeletal muscle, in hyperthyroidism, 771, 774-775

ATPase (adenosine triphosphatase)
 Na^+,K^+ , activity of, in RBCs of women on levothyroxine therapy following total thyroidectomy for Graves' disease, 1194-1198
pancreatic islet Ca^{2+} -, in NIDDM, glucose and Ca effects on, 185-189

At-rest subjects, heart rate of NIDDM, in response to handgrip test, 935, 936

Atrial natriuretic factor (ANF), very-low-calorie diet effects on, in obesity, 592-597

Autonomic nervous system, GH and prednisolone effects on, 84-85

AVP, *see* Arginine vasopressin

B cells, PKW mitogen stimulating, 79

BA:CA (bone age-to-chronological age) ratio in CRF children, 265

BCAAs (branched-chain amino acids), *see* Amino acids

BCAT (branched-chain aminotransferase), effects of tyrosine-deficient TPN on, 168-176

Beta (β)-adrenoceptor, effects of blockade of, on EPOC and TG/FA cycling, 439-448

Beta₁ (β_1)-adrenoceptor, effects of lipolysis inhibition on thermogenesis mediated by, in men, 1462-1467

Beta₃-adrenoceptor gene, *see* Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene

Beta (β) cells
MTS and metabolic activation of, 824-830
selenium and vitamin E effects on Keshan disease-induced alterations in, 415-419
sensitivity of, and insulin signaling, 1031-1033
in young children of NIDDM parents, 1000

zinc supplementation effects on secretion of, 795
see also Non-insulin-dependent diabetes mellitus, beta-cell function

Beta (β)-guanidinopropionic acid, nephrectomy effects on, 358, 359

Beta-hydroxybutyrate, *see* β -Hydroxybutyrate

11Beta (β)-hydroxysteroid dehydrogenase 1 (11β-HSD1) mRNA (messenger ribonucleic acid), hepatic, in pubertal hypothyroid male subjects, T₄ and T effects on activity of, 474-478

Beta lipoprotein, *see* Low-density lipoprotein

Beta₂-microglobulin, *see* β₂-Microglobulin

Beta (β)-thalassemia, BMD in prepubertal children with, 541-548

BH₄ (tetrahydrobiopterin), insulin-induced vasodilation dependent on synthesis of, 1037-1039

Bile, endotoxin effects on production of, 683

Bile acid(s)

- breast milk and/or formula effects on, during development, 23
- effects of enterohepatic circulation manipulation and composition of, on *Lep* gene regulation, 285-291

Bile acid sequestrant, Cholazol H as, 959-964

Biliary dolichols, effects of Triton WR 1339 and orotic acid on, 644-649

Bilirubin

- in cirrhosis, 793
- in falciparum malaria, 219
- in prepubertal children with β-thalassemia and/or CSS, 543
- total, *see* Total bilirubin

Binding protein, *see* Growth hormone-binding protein; Insulin-like growth factor-binding protein(s)

Black Americans, *see* Race and ethnicity

Blood acetacetate in offspring of protein-malnourished subjects, 1451-1452

Blood advanced glycation end (AGE) products in DM, fluorescence assay for, 1348-1353

Blood flow

- regional, in exercise, glucose and AA infusion effects on, 1305, 1306
- renal, glucagon effects on, 1228

Blood glucose

- hyperglucagonemia effects on, 499, 500
- IDDM and PP, CFA and, 504
- in NIDDM, *see* Blood glucose in NIDDM
- in offspring of protein-malnourished subjects, 1451
- in PAM, 1265
- in STZ-DM, *see* Blood glucose in STZ-DM

Blood glucose in NIDDM

- platelet 12-LOX activity and, 258
- PP, CFA and, 504
- see also* Fasting blood glucose in NIDDM

Blood glucose in STZ-DM

- levels of, gliclazide inhibiting diabetic neuropathy in, irrespective of, 977-981
- plasma leptin and, 604

Blood β (beta)-hydroxybutyrate (BOHB), acipimox effects on, in NIDDM, 253

Blood inorganic phosphate, xylitol effects on, 741

Blood lactic acid, xylitol effects on, 741, 742

Blood pH, HCl effects on, 164

Blood pressure (BP)

- in adolescent males, race and, 516, 517
- in CHF, 1157
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- epinephrine effects on, 246, 247
- and ETA receptor antagonist-induced osteopenia, 1404
- in FCH, *see* Blood pressure in FCH
- in Graves' disease, 1195
- and HRT effects on plasma lipids and Lp, 1224
- in hyperinsulinemia, 687, 832, 834, 835
- insulin resistance and, *see* Blood pressure, and insulin resistance
- lipolysis inhibition effects on, 1465
- in NIDDM, *see* Blood pressure in NIDDM

Blood pressure (BP) (*Continued*)

- in non-obese Kuwaiti children, serum lipids and, associated with fasting insulin levels in, 420-424
- in obesity, *see* Blood pressure in obesity
- relationship between ET-1 excretion and, in IDDM adolescents and young adults, 1408-1412
- and serum uric acid levels in non-obese premenopausal and postmenopausal women, 437, 438
- and Trp 64 Arg mutation of β₃-adrenoceptor gene, 457-458
- in young children of NIDDM parents, 999
- see also* Hypertension

Blood pressure (BP), and insulin resistance

- body composition, 402, 404, 406
- Hb, Hct and, 832, 834, 835
- SHBG, race and, in insulin-resistant women, 72

Blood pressure (BP) in FCH

- FFA and glucose regulation by Trp 64 Arg polymorphism of β₃-adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
- in nondiabetics with insulin resistance, 509, 510

Blood pressure (BP) in NIDDM

- CHD and, 1259, 1260
- CV risk factors, fibrinolysis and, 639
- GSH effects on, 994
- tHcy and microalbuminuria and, 916
- urinary and serum TM and, 363

Blood pressure (BP) in obese men

- middle-aged hypertensive, effects of aerobic exercise and weight loss on glucose metabolism, Lps and, 1075-1082
- and VAT accumulation effects, 930

Blood pressure (BP) in obesity

- changes in vasoactive regulatory hormones, volume regulatory hormones and, with very-low-calorie diet, 592-597
- SAC, plasma leptin, plasma lipids and, in women, effects of weight loss with meat-based or plant-based diet on, compared, 1308-1314
- serum lipids and, associated with fasting insulin levels in obese Kuwaiti children, 420-424
- see also* Blood pressure in obese men

Blood pyruvic acid, xylitol effects on, 741

Blood urea nitrogen (BUN) in elderly NIDDM subjects, Pro-Z effects on, 42

BM 15.766 [4-(2-[1-(4-chlorocinnamyl)piperazin-4-yl]ethyl)-benzoic acid], effects of, on cholesterol synthesis, 878-882

BMC (bone mineral content), and ETA receptor antagonist-induced osteopenia, 1404, 1405

BMD, *see* Bone mineral density

BMI, *see* Body mass and body mass index

BNP (brain natriuretic peptide), plasma, very-low-calorie diet effects on, in obesity, 592-597

Body composition

- effects of high-sucrose and HF diets on, 1354-1359
- insulin resistance and, related to aging, CV disease risk factors and, 401-408
- plasma leptin level in children related to sex, puberty, S_v, EE and, 309-312
- see also* Dual-energy x-ray absorptiometry, assessment of body composition with; Fat-free mass; Fat mass

Body fat, *see* Adipose tissue

Body mass and body mass index (BMI)

- CHD and, 114, 115, 1246
- of cirrhotic subjects, 793
- and cortisol response to ACTH, 1253
- of CRF children, 265

Body mass and body mass index (BMI) (*Continued*)
 and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 exercise and, 386-387, 875
 of falciparum malaria subjects, 219
 and family history of NIDDM, 523, 525
 of FCH, *see* Body mass and body mass index of FCH subjects
 GH and, 340, 1516
 of gout subjects, 337
 HRT effects on, 1224
 of hypercholesterolemic subjects, *see* Body mass and body mass index of hypercholesterolemic subjects
 hyperglycemia and, associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 617-621
 of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects
 of hypertriglyceridemic subjects, gemfibrozil effects on, 236
 of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
 of IGT subjects, insulin kinetics, muscle morphology and, 850
 insulin resistance and, *see* Body mass and body mass index, insulin resistance and
 maternal, and FPG reduction in pregnancy, 1141
 of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
 of osteopenic elderly men, 196
 of PCOS subjects, 159, 941
 plasma leptin and, *see* Body mass and body mass index, plasma leptin and
 of postmenopausal women, *see* Body mass and body mass index of postmenopausal women
 of premenopausal women, 213, 437
 race and, *see* Body mass and body mass index, race and
 serum lipids and BP associated with fasting insulin levels and, 421
 of very old syndrome X subjects, 536, 537
 of young children of NIDDM parents, 999
see also Fat-free mass; Fat mass; Obesity
 Body mass and body mass index (BMI), insulin resistance and
 body composition and, 402, 404, 406
 Hct, Hb and, 832, 834, 835
see also Body mass and body mass index, insulin resistance, race and
 Body mass and body mass index (BMI), insulin resistance, race and
 and effects of HF versus LF diets on S_i and serum leptin in women, 1521
 of nondiabetics, 1176, 1177
 SHBG, race and, in insulin-resistant women, 71, 72
 Body mass and body mass index (BMI), plasma leptin and
 in children, 310
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, 1526
 Body mass and body mass index (BMI), race and
 of adolescent males, HDL-C and TG levels and, 516, 517
see also Body mass and body mass index, insulin resistance, race and
 Body mass and body mass index (BMI) of FCH subjects
 FFA and glucose regulation by Trp 64 Arg polymorphism of
 β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1
 gene, 1398, 1399
 in nondiabetics with insulin resistance, 509, 510
 Body mass and body mass index (BMI) of hypercholesterolemic subjects
 fat-modified diet effects on, 745
 plain niacin versus Niaspan effects on, 1099
 with polygenic hypercholesterolemia, 98
 with primary hypercholesterolemia, 561
 Body mass and body mass index (BMI) of hyperinsulinemic subjects
 with acute hyperinsulinemia, 687
 healthy non-obese, 832, 834
 Body mass and body mass index (BMI) of IDDM subjects
 CFA and, 504
 effects of insulin Lispro versus regular insulin on lipid metabolism and, 372
 and insulin secretion and mode of therapy associated with leptin and AT in, 1394, 1395
 postmenopausal and premenopausal, DEXA measuring body composition and AT in, 213
 Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457-459
 and urinary ET-1 excretion, 1409, 1410
 Body mass and body mass index (BMI) of NIDDM subjects
 acipimox effects and, 251
 CFA and, 504
 CHD and, 1259, 1260
 CV risk factors, fibrinolysis and, 639
 dietary protein restriction effects on, 1147
 hemodynamic response to handgrip test and, 935, 936
 and insulin secretion and mode of therapy associated with leptin and AT, 1394, 1395
 LDL receptors, lipid metabolism and, 1071
 of nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 platelet 12-LOX activity and, 258, 259
 in prediabetic stage of NIDDM, 910
 premenopausal, DEXA measuring body composition and AT in, 213
 serum PON activity and, 599
 urinary and serum TM and, 363
 Body mass and body mass index (BMI) of postmenopausal women
 exercising, and AT as risk factor for CHD, 1113
 with IDDM and NIDDM, DEXA measuring body composition and AT in, 213
 of non-obese healthy women, serum uric acid and, 437
 Body temperature, IL-6 effects on, in healthy subjects, 1291
 Body weight (BW)
 bile acid and cholestyramine effects on, 286
 of celiac disease patients, 1430
 DEXA measurement of, in prone and supine position, 1379-1382
 dexamethasone effects on, 4
 and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 and ETA receptor antagonist-induced osteopenia, 1404
 exercise effects on, *see* Body weight, exercise and
 of familial HALP and HBLP subjects, 1162
 of GH-deficient subjects, 1516, 1517
 HCl effects on, 164
 and HRT effects on plasma lipids and Lp, 1224
 of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 of hypokinetic subjects, 904
 of IDDM subjects, 213
 of injured subjects, spermidine effects on, 224
 insulin resistance and, *see* Body weight, insulin resistance and
 long-term alcohol intake effects on, at puberty, 1269-1273
 loss in, *see* Weight loss
 neonatal insulin treatment effects on, 857
 and nephrectomy for renal failure, 356
 nicotine effects on, 155, 156
 of NIDDM subjects, *see* Body weight of NIDDM subjects
 NO-1886 effects on, 102-103, 150
 of OC users, 281
 of osteopenic elderly men, 196
 PKW mitogen effects on, 77
 race and, of adolescent males, HDL-C and TG levels and, 516
 of STZ-DM subjects, *see* Body weight of STZ-DM subjects

Body weight (BW) (Continued)

- Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526
- vitamin C and dietary fat saturation effects in regulation of apo B-containing Lps on, 885-886
- of young children, *see* Body weight of young children
- see also* Non-obese subjects; Obesity
- Body weight (BW), exercise and
- and β -adrenoceptor blockade effects on EPOC, 440
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- endurance exercise and, 191
- menopausal status and exercise effects on, 378, 379
- substrate oxidation, diet selection and, 779, 780
- Body weight (BW), insulin resistance and
- body composition and, 402, 404, 406
- in insulin-resistant women, SHBG, race and, 71, 72
- troglitazone effects on dexamethasone-induced resistance, 352
- Body weight (BW) of NIDDM subjects
- and effects of stimulation with glucose and GLP-1 on insulin release, 1043
- IR isoform mRNA and, 130
- metabolic rate and, 1146-1147
- postmenopausal and premenopausal, DXA measuring, 213
- in prediabetic stage of NIDDM, 910
- Body weight (BW) of STZ-DM subjects
- with diabetic neuropathy, 978
- food intake and insulin-dependent plasma *Lep* mRNA and, 604
- in insulin-treated STZ-DM subjects, 591
- Body weight (BW) of young children
- breast-feeding and, 108
- of NIDDM parents, 999
- BOHB, *see* β -Hydroxybutyrate
- Bone age-to-chronological age (BA:CA) ratio in CRF children, 265
- Bone age of Robinow syndrome patients, 1341
- Bone loss due to hyperprolactinemia and estrogen deficiency, 425-428
- Bone mineral content (BMC), and ETA receptor antagonist-induced osteopenia, 1404, 1405
- Bone mineral density (BMD)
- and ETA receptor antagonist-induced osteopenia, 1404, 1405
- in prepubertal children with β -thalassemia, 541-548
- Borderline hypertension, stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men, 1440-1449
- BP, *see* Blood pressure
- Brain guanidino compounds, nephrectomy effects on, 359
- Brain HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase, BM 15.766 effects on, 880, 881
- Brain natriuretic peptide (BNP), plasma, very-low-calorie diet effects on, in obesity, 592-597
- Bran, oat and wheat, in diet regulating small intestinal cell turnover, 1106
- Branched-chain amino acids, *see* Amino acids
- Branched-chain aminotransferase (BCAT), effects of tyrosine-deficient TPN on, 168-176
- Breast development, Tanner stage of, with recessive Robinow syndrome, 1341, 1342
- Breast milk
- influence of formula and, on hepatic HMG-CoA reductase and C7H mRNA but not on LDL receptor mRNA during development, 20-26
- see also* Phospholipids, breast milk effects on
- Brewer's yeast in diet regulating small intestinal cell turnover, 1106
- Brush-border enzymes, rectosigmoid mucosal colonocyte, SCFA effects on, 133-134
- Bucladesine sodium, effects of, on plasma concentrations and urinary excretion of purine bases, 1005-1008
- BUN (blood urea nitrogen)
- in elderly NIDDM subjects, Pro-Z effects on, 42
- in IDDM, urinary ET-1 and, 1409
- Burn injury, transport of hepatic AAs in, 608-616
- $1-[^{14}\text{C}]$ Butyrate in ethylmalonic encephalopathy, 837
- BW, *see* Body weight
- Bypass, coronary, long-term effects of LDL apheresis on plasma Lps and CHD in native vessels and, in severe heterozygous FH, 863-868
- C, *see* Cholesterol
- Ca (calcium)
- in osteopenic elderly men, 196
- in post-small bowel resection enteral diet, 1367
- in prepubertal children with β -thalassemia and/or CSS, 543, 545
- serum, *see* Serum Ca
- see also* Ca in NIDDM; Ca^{2+} -ATPase
- Ca (calcium) in NIDDM
- effects of glucose and, on pancreatic islet Ca^{2+} -ATPase, 185-189
- in elderly subjects, Pro-Z effects on, 41
- Ca^{2+} -ATPase (calcium-adenosine triphosphatase), pancreatic islet, in NIDDM, glucose and Ca effects on, 185-189
- Cachexia with Leydig cell tumors, NO-1886 effects on, 101-105
- Caco-2 cells, effects of ACAT inhibition on C uptake by, 325-332
- CAD, *see* Coronary artery disease
- Calcitriol, *see* 1,25-Dihydroxyvitamin D₃
- Calcium, *see* Ca
- Caloric intake
- with high-sucrose and/or HF diets, 1354-1355
- restricted, *see* Calorie restriction
- suboptimal, effects of excessive dietary protein and, on growth of CRF children before and during GH therapy, 264-268
- Calorie restriction
- effects of, on serum leptin, insulin, cortisol, glucose, ketones, and NEFAs, 429-434
- very-low-calorie diet effects on BP, vasoactive regulatory hormones, and volume regulatory hormones in obesity, 592-597
- cAMP (cyclic adenosine monophosphate)
- Chanzu effects on production of, 1213-1214
- glucagon effects on concentrations of, 696, 697
- Campesterol, relationship of, to apo E phenotype in hypercholesterolemia, 747
- Capillary filtration of albumin (CFA) in IDDM and NIDDM, relationship of, to gender, hypertension, microangiopathy, and neuropathy, 503-507
- Captopril, effects of verapamil and, on glucose tolerance and insulin action in insulin resistance, 982-987
- Carbohydrates (CHO)
- in diet regulating apo B-containing Lps, 884
- effects of exercise and, on PAI-1 activity, 385
- effects of glucose contribution on FA and glyceride-glycerol synthesis with high-protein, carbohydrate-free diet, 1217-1221
- in fat-modified diet for hypercholesterolemia, 745
- in high-sucrose and/or HF diets, 1354-1355
- in low glycemic diet, 1247
- in NIDDM diet, 664
- in obesity- and DM-inducing diet, 1090
- PP, G effects on metabolism of, in nondiabetics, 7-12
- in protein-restricted diet, 1147
- in reduced energy intake, effects of, on protein utilization, in obese children, 1436
- in stearic and oleic acid diets, 531
- see also* specific carbohydrates

Carbon dioxide, *see* CO_2 ; $^{13}\text{CO}_2$

Carboxylase, pyruvate, in ethylmalonic encephalopathy, 837

Cardioprotective profile in HALP associated with increased levels of HDL_2 and decreased HL activity, 965-973

Cardiovascular disease, *see* Chronic heart failure; Coronary artery disease; Coronary heart disease; Risk factors for CV disease

Carnitine in ethylmalonic encephalopathy, 837

Casein

- in diet regulating small intestinal cell turnover, 1106
- in high-monounsaturated fat diet, 725
- in obesity- and DM-inducing diet, 1090

Catecholamines, *see* Dopamine; Epinephrine; Norepinephrine

Celiac disease, active, whole-body protein metabolism assessed by leucine and glutamine kinetics in, 1429-1433

Cell differentiation

- preadipocyte, arachidonic acid metabolites of COX and LOX pathways regulating, 461-466
- small intestinal, effects of energy intake and purines on, 1105-1111

Cell proliferation, small intestinal, effects of energy intake and purines on, 1105-1111

Cell surface, skeletal muscle, insulin-stimulated GLUT4 recruitment to, dexamethasone effects on, 3-6

Cellulose in high-monounsaturated fat diet, 725

Central venous access devices, implantable, in children with metabolic diseases, 900-902

Cerebrospinal fluid (CSF), AAs in, in trauma, 227

CETP, *see* Cholesteryl ester transfer protein

CFA (capillary filtration of albumin) in IDDM and NIDDM, relationship of, to gender, hypertension, microangiopathy, and neuropathy, 503-507

C7H, *see* Cholesterol 7 α -hydroxylase mRNA

Chansu, effects of methanol extract of, on hypothalamic-pituitary-testicular function, 1211-1216

CHD, *see* Coronary heart disease

CHF (chronic heart failure), anaerobic threshold and uric acid in, 1156-1159

Children

- with metabolic diseases, implantable central venous access devices in, 900-902
- non-obese Kuwai, serum lipids and BP associated with fasting insulin levels in, 420-424
- obese, *see* Children, obese
- race and distribution of serum LpA-I and LpA-I:A-II in, 757-763
- see also* Newborns; Young children

Children, obese

- prepubertal, *see* Prepubertal children, obese
- reduced energy intake effects on whole-body protein utilization in, 1434-1439

Chloride, *see* Cl

4-(2-[1-(4-Chlorocinnamyl)piperazin-4-yl]ethyl)-benzoic acid (BM 15,766), effects of, on cholesterol synthesis, 878-882

CHO(s), *see* Carbohydrates

Cholazol H, bile acid sequestrant properties of, and its hypocholesterolemic and antiatherogenic effects, 959-964

Cholestanol, relationship of, to apo E phenotype in hypercholesterolemia, 747

Cholesterogenesis in polygenic hypercholesterolemia, apo E genotype and, 97-100

Cholesterol (C)

- abdominal obesity and, 1189, 1190
- abnormal synthesis of, and retarded learning, 878-882
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- extrahepatic sterol 27-hydroxylase activity and high-cholesterol, high-fat diet, 731-738

Cholesterol (C) (*Continued*)

- and family history of NIDDM, 523
- GH levels in women correlated with, 340
- in hypertriglyceridemia, gemfibrozil effects on, 236
- NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
- in obese postmenopausal women, adrenoceptor binding and adipocyte lipolysis and, 470
- OC effects on, 281
- in skeletal muscle membrane PLs of young children, 108
- tamoxifen effects on synthesis of, in HepG2 cells and hepatocytes, 1504-1513
- see also* Acyl coenzyme A:cholesterol acyltransferase; Cholesterogenesis; Cholesterol in CHD; Cholesterol 7 α -hydroxylase mRNA; Cholesterol in hyperinsulinemia; Cholesterol in IDDM; Cholesterol in NIDDM; Dietary cholesterol; Hepatic cholesterol; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Lecithin:cholesterol acyltransferase; Low-density lipoprotein-cholesterol; Plasma cholesterol; Serum cholesterol; Total cholesterol

Cholesterol (C) in CHD

- Lp(a) level and, 183, 276
- and total plasma Hcy as risk factor, 1246

Cholesterol 7 α -hydroxylase (C7H) mRNA (messenger ribonucleic acid)

- breast milk and formula influence on hepatic HMG-CoA mRNA and, but not on LDL receptor mRNA during development, 20-26
- sex hormone effects on 391-395

Cholesterol (C) in hyperinsulinemia

- in acute hyperinsulinemia, 687
- in hyperinsulinemic NIDDM with obesity, 1317

Cholesterol (C) in IDDM

- CFA and, 504
- urinary ET-1 and, 1409, 1410

Cholesterol (C) in NIDDM

- CFA and, 504
- in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
- see also* Total cholesterol in NIDDM

Cholesteryl ester transfer protein (CETP)

- in female transgenic subjects, sex steroids regulating, 1048-1051
- GH levels in women correlated with, 340, 342
- in HALP, 969
- HRT effects on, 1224
- in IDDM, effects of insulin Lispro versus regular insulin on activity of, 373-374
- plasma, effects of vitamin C and dietary fat saturation in regulation of apo B-containing Lps on, 888

Cholestyramine (CSTY)

- effects of, on BW and *Lep* gene, 286
- hypcholesterolemic effects of, 959-964

Choline in obesity- and DM-inducing diet, 1090

Chorionic gonadotropin, human, T response to, in recessive Robinow syndrome, 1337-1343

Chromatography, mass spectrometry with gas, of metabolic tracers, 706-712

Chromium, dietary, effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400

Chromium (Cr), dietary, effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400

Chronic heart failure (CHF), anaerobic threshold and uric acid in, 1156-1159

Chronic hyperglycemia, effects of, on arterial LDL metabolism and atherosclerosis in STZ-DM, 947-954

Chronic renal failure (CRF), excessive dietary protein and suboptimal caloric intake effects on growth of children with, before and during GH therapy, 264-268

Cigarette smoking, *see* Smoking

Circulation, enterohepatic, effects of bile acid composition and manipulation of, on *Lep* gene regulation, 285-291

Cirrhosis, effects of zinc supplementation on glucose disposal in, 792-798

Citrate synthase in ethylmalonic encephalopathy, 837

Citrulline in post-small bowel resection enteral diet, 1368

CK (creatine kinase), serum, in hypoglycemia, 1471-1476

Cl (chloride)

- bucladesine sodium effects on, 1006-1007
- in elderly NIDDM subjects, Pro-Z effects on, 42
- in hypoglycemia, 1472
- NaCl in obesity- and DM-inducing diet, 1090

Cl 316,243, effects of, on dexamethasone regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes of hypothyroidic subjects, 1455-1461

Classic glucose minimal model, 490

Clonidine, GH response to serum IGF-I and, in recessive Robinow syndrome, 1337-1343

CO₂ (carbon dioxide) in elderly NIDDM subjects, Pro-Z effects on, 42

¹³CO₂ (carbon dioxide), role of glucose and glutamine in differential recovery of, from infused [2-¹³C] versus [1-¹³C]acetate, 549-554

CoA (coenzyme A), *see* Acyl coenzyme A:cholesterol acyltransferase; HMG-CoA reductase

Coagulation factors, 529-540

- effects of stearic and oleic acid diets on, 529-534
- in very old syndrome X subjects, 535-540

Cobalamin, serum, in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91

Coconut oil in obesity- and DM-inducing diet, 1090

Coenzyme A, *see* Acyl coenzyme A; Acyl coenzyme A:cholesterol acyltransferase; HMG-CoA reductase

Collagen pyridinium cross-links in osteopenic preterm infants, urinary excretion of, 333-335

Colon of protein-depleted subjects, effects of dietary protein and TNF on IGF-I pathway components of, 345-350

Colonocyte brush-border enzymes, rectosigmoid mucosal, SCFA effects on, 133-134

Combined hormone replacement therapy (HRT), effects of, on plasma lipids and Lps, 1222-1226

Compartmental modeling, 1011-1018

- a priori identifiability in, 1015-1016
- estimation of parameters used and a posteriori identifiability in, 1016-1018
- fundamentals of, 1011-1012
- measurement equations in, 1015
- optimal experimental design in, 1018, 1028
- tracee model, 1012-1013
- tracer model, 1013-1014
- tracer-tracee model, 1014-1015
- *see also* Multicompartmental model

Compensatory hyperinsulinemia, insulin resistance and, in healthy non-obese subjects, Hb and Hct related to, 831-835

Computational algorithms of SAAM II, 486-487

Computer models, *see* Simulation studies; Systems model

Connecting peptide, *see* C-peptide

Conscious subjects, glucose in

- effects of portal venous and hepatic glucose positive and negative gradients on hepatic glucose uptake following glucose infusion in splanchnic bed of, 1295-1302

G activation and deactivation of HGP in, 135-142

ICV leptin effects on utilization of systemic glucose in, 1274-1280

Constitutional short stature (CSS), BMD in prepubertal children with, 541-548

Contraceptives, oral, effects of, on FFA metabolism, 280-284

Corn in diet regulating small intestinal cell turnover, 1106

Corn starch in obesity- and DM-inducing diet, 1090

Coronary artery disease (CAD)

- with FH, LDL apheresis and, 1059
- in Japanese men, G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene as risk factor for, 177-181
- metabolic syndrome and electrocardiographic, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626
- and primary hypercholesterolemia, 1099

Coronary artery smooth muscle cells (SMCs), heparin effects on migration of, 1065-1069

Coronary bypass, long-term effects of LDL apheresis on plasma Lps and CHD in native vessels and, in severe heterozygous FH, 863-868

Coronary heart disease (CHD)

- ACE gene polymorphism with, in NIDDM, 1258-1262
- glycolysis and, 657-662
- hypercholesterolemic postmenopausal women with, effects of ERT on level of antibodies against oxidized LDLs in, 675-680
- long-term effects of LDL apheresis on plasma Lps and, in native vessels and coronary bypass in severe heterozygous FH, 863-868
- Lp(a) level and, 182-184, 276
- risk factors for, *see* Risk factors for CHD
- total plasma HcY in, 273-280

Corticosterone

- long-term alcohol intake effects on, at puberty, 1269-1273
- *see also* Corticosterone in obesity

Corticosterone in obesity

- with hyperinsulinemic and insulinopenic NIDDM, 1317
- stress effects on, 1385, 1387

Corticotropin (ACTH; adrenocorticotrophic hormone)

- GH therapy effects on, 1377
- *see also* Corticotropin, cortisol and

Corticotropin (ACTH; adrenocorticotrophic hormone), cortisol and in PCOS, nighttime and morning release of pulsatile cortisol and, 143-148

plasma cortisol response to IM ACTH 1-24 in healthy men, 1419-1422

recurrent hypoglycemia effects on cortisol response to ACTH in normal subjects, 1252-1259

stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men, 1440-1449

Cortisol (hydrocortisone)

- ACTH and, *see* Corticotropin, cortisol and
- effects of, on free radical generation by MNCs, 788-791
- and G effects on glutamine uptake and release, 716
- GH and, *see* Growth hormone, cortisol and
- in PAM, 1264, 1265
- in PCOS, 143-148, 159
- plasma, *see* Plasma cortisol
- in prepubertal children with β-thalassemia and/or CSS, 543, 545-546
- restricted caloric intake effects on, 429-434
- sex differences in production of, 974-976
- urinary free, in AIDS patients, 690-694

COX (cyclooxygenase) pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466

C-peptide

- fasting, *see* Fasting C-peptide
- GH levels in women correlated with, 340
- in hyperinsulinemic obese premenopausal women, 14, 15
- in IDDM, 1208, 1328
- in IGT, insulin kinetics, muscle morphology and, 851
- in NIDDM, *see* C-peptide in NIDDM

C-peptide (*Continued*)
 plasma, *see* Plasma C-peptide
 and TNF α in CHD, 116
 in young children of NIDDM parents, 1001

C-peptide in NIDDM
 acipimox effects and, 253
 insulin versus sulfonylurea therapy effects and, 640
see also Serum C-peptide in NIDDM

CPK (creatine phosphokinase) in Keshan disease, vitamin E and selenium effects on, 416, 417

Creatine kinase (CK), serum, in hypoglycemia, 1471-1476

Creatine phosphokinase (CPK) in Keshan disease, vitamin E and selenium effects on, 416, 417

Creatinine
 bucladesine sodium effects on, 1006
 in CHF, 1157
 in CRF children, 265
 in falciparum malaria, 219
 in IDDM, 213; *see also* Serum creatinine in IDDM
 in LT recipients, 201
 nephrectomy effects on, 356
 in NIDDM, *see* Creatinine in NIDDM
 in obesity, 593, 930
 in osteopenic elderly men, 196
 plasma, *see* Plasma creatinine
 serum, *see* Serum creatinine
 in trauma, spermidine effects on, 224
 urinary ET-1 and, 1409, 1410

Creatinine in NIDDM
 serum TM and, 363, 364
 tHcy, microalbuminuria and, 916

Creatinine in obesity
 in semistarved subjects, 593
 urinary, effects of reduced energy intake on, in obese children, 1437
 in visceral fat obesity, 930

Creatininemia in IDDM and NIDDM, CFA and, 504

Creatinuria
 in NIDDM, 363, 364
 in polygenic hypercholesterolemia, 98

CRF (chronic renal failure) children, excessive dietary protein and suboptimal caloric intake effects on growth of, before and during GH therapy, 264-268

CBS (cystathione- β -synthase), deficiency of, in homocystinuria, 207-211

CS-O45, *see* Troglitazone effects on insulin resistance

CsA (cyclosporine), effects of prednisolone and, on renal and serum IGF-I, IGF-BPs, and renal growth following unilateral nephrectomy, 817-823

CSF (cerebrospinal fluid), AAs in, in trauma, 227

CSS (constitutional short stature), BMD in prepubertal children with, 541-548

CSTY, *see* Cholestyramine

Cushing' syndrome, sex and cortisol production in, 974-976

CV (cardiovascular) disease, *see* Chronic heart failure; Coronary artery disease; Coronary heart disease; Risk factors for CV disease

Cyclic adenosine monophosphate, *see* cAMP

Cycloheximide, RA catabolism inhibited by, 956

Cyclooxygenase (COX) pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466

Cyclosporine (CsA), effects of prednisolone and, on renal and serum IGF-I, IGF-BPs, and renal growth following unilateral nephrectomy, 817-823

CYP2D6 gene in Parkinson's disease, 94-96

Cystathione, liver and kidney, in D,L-propargylglycine-treated subjects, 1233-1238

Cystathionine ketimine, liver and kidney, in D,L-propargylglycine-treated subjects, 1233-1238

Cystathione- β -synthase (CBS), deficiency of, in homocystinuria, 207-211

Cysteine
 in CHD, 276
 in trauma, 226, 227

Cytochrome C reductase, NADH-, in ethylmalonic encephalopathy, 837

Cytochrome oxidase in ethylmalonic encephalopathy, 837

Cytochrome P450-mediated oxidation of RA by retinoids in HNSCC cell lines, 955-958

Cytokines
 in falciparum malaria, 219
 in prepubertal children with β -thalassemia and/or CSS, 545
 serum, in burn injury, 612
see also specific cytokines

Daily Mg (magnesium) supplementation, effects of, on Mg deficiency during prolonged restriction of motor activity, 903-907

DBP (diastolic blood pressure), *see* Blood pressure

Deconvolution problem in input-output modeling, 1019

Dehydroepiandrosterone sulfate (DHEAS; β -hydroxy-5-androsten-17-one)
 in hyperinsulinemic obese premenopausal women, 13-19
 in PCOS, 159, 990

Dehydrogenase
 pyruvate, in ethylmalonic encephalopathy, 837

T and T₄ effects on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroid males, 474-478
see also Glyceraldehyde-3-phosphate dehydrogenase; Lactate dehydrogenase

Delayed single-dose interleukin-6 (IL-6), effects of, on thyroid function in healthy subjects, 1289-1293

Delta₄-DIONE, *see* Androstenedione

[³H]Deoxyglucose (DG), PKW mitogen effects on uptake of, 79

2-[³H]Deoxyglucose (DG), dexamethasone effects on, 4

3-Deoxy-D-glucose (DG), 3-fluoro-, exercise effects muscle and liver uptake of, 44-49

Depression
 endocrine and metabolic aberrations in men with abdominal obesity related to anxiety and, 1187-1193

endogenous, pyridostigmine effects on TSH response to TRH in, 50-53

relationship of ACTH and cortisol to insulin and glucose in middle-aged men with depressive behavior, 1440-1449

Des-31,32 proinsulin
 in NIDDM, insulin versus sulfonylurea therapy and, 640

and TNF α in CHD, 116

Des-32,33 proinsulin in NIDDM and nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624

Desmosterol, relationship of, to apo E phenotype in hypercholesterolemia, 747

Development, *see* Growth and development

DEXA, *see* Dual-energy x-ray absorptiometry, assessment of body composition with

Dexamethasone (DXM)
 effects of, on insulin-stimulated GLUT4 recruitment to skeletal muscle cell surface, 3-6

effects of, on regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes of hypothyroidic subjects, 1455-1461

troglitazone effects on insulin resistance induced by, 351-354

DG, *see* [³H]Deoxyglucose; 2-[³H]Deoxyglucose; 3-Deoxy-D-glucose

DHEAS, *see* Dehydroepiandrosterone sulfate

Diabetes mellitus (DM)
 CHD, Lp(a) level and, 183

Diabetes mellitus (DM) (*Continued*)
 fluorescence assay of blood and urine AGE products in, 1348-1353
 HF diet-induced, *see* High-fat diet-induced diabetes mellitus and obesity
 and primary hypercholesterolemia, 1099
see also Advanced glycation end products in DM; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and *entries beginning with term*: Diabetic

Diabetic nephropathy, SPA and, 702

Diabetic neuropathy
 CFA relationship to gender, hypertension, microangiopathy and, 503-507
 HP228 effects on, 650-656
 SPA relationship to, 702, 703
 in STZ-DM inhibited by gliclazide irrespective of blood glucose levels, 977-981

Diabetic retinopathy
 in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 plasma IR-VEGF in, 28
 retinal GSH levels in STZ-DM and, effects of retinal ischemia followed by recirculation on, 269-272
 SPA relationship to, 701, 702

Diastolic blood pressure, *see* Blood pressure

Diet
 choice of, and substrate oxidation during exercise, 777-782
 effects of plasma glucose level and type of, on skeletal muscle membrane LCPUFAs in young children, 106-112
 hypercholesterolemia-inducing, effects of, on expression of T₃, RA, and glucocorticoid receptors, 301-308
see also Caloric intake; Fasting; Food intake; Refeeding; Starvation; Supplementation; Total parenteral nutrition *entries beginning with terms*: Dietary, Postprandial specific food groups and substances

Dietary Ca (calcium) in post-small bowel resection diet, 1367

Dietary cholesterol (C)
 in diet regulating apo B-containing Lps, 884
 effects of exercise and, on PAI-1 activity, 385
 in stearic and oleic acid diets, 531

Dietary chromium (Cr), effects of, on insulin resistance due to high-fat, mineral-imbalanced diet, 396-400

Dietary fat
 effects of exercise and, on PAI-1 activity, 385
 fat-modified diet effects on serum C precursors and phytosterol in hypercholesterolemia, 744-750
 in low glycemic diet, 1247
 in NIDDM diet, 664, 665
 in protein-restricted diet, 1147
 in reduced energy intake, effects of, on protein utilization, in obese children, 1436
 vitamin C level and saturation with, in regulation of apo B-containing Lps, 883-891
see also Fatty acids and *entries beginning with terms*: High-fat, Low-fat

Dietary K (potassium)
 in obesity- and DM-inducing diet, 1090
 in post-small bowel resection enteral diet, 1367

Dietary leucine (Leu), hyperglucagonemia and kinetics of, 497-502

Dietary Mg (magnesium) in post-small bowel resection enteral diet, 1367

Dietary protein
 with celiac disease, 1430
 contents of, in fasting and refeeding, PDI activity during, 1083-1088
 in diet regulating apo B-containing Lps, 884

Dietary protein (*Continued*)
 effects of TNF and, on colon and small intestine IGF-I pathway components in protein-depleted subjects, 345-350
 excessive, effects of suboptimal caloric intake and, on growth of CRF children before and during GH therapy, 264-268
 in fat-modified diet for hypercholesterolemia, 745
 in high-sucrose and/or HF diets, 1354-1355
 27-hydroxylase effects on, 733-734
 ketosis resistance in offspring of protein-malnourished subjects, 1450-1454
 in obesity- and DM-inducing diet, 1090
 in reduced energy intake, effects of, on protein utilization, in obese children, 1436
 spermidine effects on utilization of, in trauma and injury, 223-229
 in stearic and oleic acid diets, 531
see also Dietary protein, exercise and; Dietary protein in NIDDM: High-protein, carbohydrate-free diet

Dietary protein, exercise and
 effects of, on PAI-1 activity, 385
 protein intake and, 779, 780

Dietary protein in NIDDM
 in hyperinsulinemic insulinopenic obese subjects, 664
 restriction of, altering glucose but not protein metabolism, 1145-1151

Dietary specific sugars for serum protein enzymatic glycosylation, 1499-1503

Dihydroxyphenylalanine (DOPA), synthesis of, in neural tissue, effects of tyrosine-deficient TPN on, 168-176

1,25-Dihydroxyvitamin D₃ [1,25(OH)₂D₃; calcitriol; 1,25-dihydroxy-
 calciferol D₃]
 in osteopenic elderly men, 196
 serum, in gout, 336-338

3-[4,5-Dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfo-
 phenyl]-2H-tetrazolium, inner salt (tetrazolium salt; MTS), metabolic activation of beta cells and, 824-830

Diols, alcohol-related, acute insulin resistance due to, 1180-1186

Δ₄-DIONE, *see* Androstenedione

Diphosphate
 adenosine-5'-, *see* Adenosine-5'-diphosphate
 UDP-linked hexosamine and hexose, GlcN effects on, 451

Disulfide isomerase, activity of protein, during fasting and refeeding, protein contents and, 1083-1088

DM, *see* Diabetes mellitus

Dolichols, serum and biliary, effects of Triton WR 1339 and orotic acid on, 644-649

DOPA (dihydroxyphenylalanine), synthesis of, in neural tissue, effects of tyrosine-deficient TPN on, 168-176

Dopamine, very-low-calorie diet effects on urinary excretion of, in obesity, 594

Dual-energy x-ray absorptiometry (DEXA; DXA), assessment of body composition with
 and AT distribution in premenopausal and postmenopausal IDDM and NIDDM women, 212-216
 in prone and supine position, 1379-1382

Duration of obesity in hyperinsulinemic premenopausal women, sex hormones and, 13-19

DXA, *see* Dual-energy x-ray absorptiometry, assessment of body composition with

DXM, *see* Dexamethasone

Dynamis data in systems models, 1009

Dyslipidemia
 acipimox effects on glucose metabolism and, in NIDDM, 250-256
see also Hyperlipidemia

E, *see* Epinephrine

E₂, *see* Estradiol

ECU (electronic control unit), continuous glucose monitoring with, in STZ-DM, 799-803

EE, *see* Energy expenditure

EGF (epidermal growth factor), effects of, on leptin release in adipocytes, 1457-1458

Elderly subjects, *see* Older subjects

Electrocardiographic coronary artery disease (CAD), metabolic syndrome and, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626

Electrolytes

- very-low-calorie diet effects on, in obesity, 593
- see also* specific electrolytes

Electronic control unit (ECU), continuous glucose monitoring with, in STZ-DM, 799-803

EMA (ethylmalonic acid), abnormal isoleucine metabolism and elevated MSA and, in ethylmalonic encephalopathy, 836-839

Encephalopathy, ethylmalonic, abnormal isoleucine metabolism and elevated EMA and MSA in, 836-839

Endocrine disorders

- in men with abdominal obesity related to depression and anxiety, 1187-1193
- see also* specific conditions

Endocrine functions

- with recessive Robinow syndrome, 1337-1343
- see also* specific endocrine functions

Endogenous depression, pyridostigmine effects on TSH response to TRH in, 50-53

Endothelial cells, linoleic acid effects on inflammatory mediators of, 566-572

Endothelial growth factor (GF), plasma immunoreactive vascular, smoking relation to concentration of, 27-30

Endothelial injury, urinary and serum TM in NIDDM as marker for, 362-365

EndothelinA (ETA) receptors

- ET-1 inhibition of insulin-stimulated glucose uptake in adipocytes through, 1468-1471
- osteopenia induced by antagonists to, 1403-1407

Endothelin-1 (ET-1)

- in acute hyperinsulinemia with ANG II type 1 receptor antagonist-treated essential hypertension, 292-296
- plasma, very-low-calorie diet effects on, in obesity, 592-597
- urinary, in IDDM adolescents and young adults, 1408-1412
- see also* EndothelinA receptors

Endotoxin, leucine metabolism in liver and, 681-685

Endurance (strenuous) exercise, glucose effectiveness and, IVGTT measuring, 190-194, 874-877

Energy expenditure (EE)

- exercise effects on, 443
- GH and prednisolone effects on leptin levels and, 83-88
- lipolysis inhibition effects on, 1463
- relationship of plasma leptin in children to sex, puberty, body composition, S, and, 309-312

Energy intake

- effects of purines and, on small intestinal cell proliferation, differentiation, and apoptosis, 1105-1111
- reduced, effects of, on whole-body protein utilization in obese children, 1434-1439
- see also* Caloric intake; Diet

Enteral ornithine α -ketoglutarate (OKG), effects of, on intestinal adaptation after small bowel resection, 1366-1371

Enterohepatic circulation, effects of bile acid composition and manipulation of, on *Lep* gene regulation, 285-291

Epidermal growth factor (EGF), effects of, on leptin release in adipocytes, 1457-1458

Epinephrine (E; adrenaline)

- in acute hyperinsulinemia with losartan-treated hypertension, 293
- and cortisol response to ACTH, 1254
- and G effects on glutamine uptake and release, 716
- insulin-induced release of, 243-249
- in obesity, *see* Epinephrine in obesity
- in PAM, 1264, 1265
- plasma, *see* Plasma epinephrine
- sex and response of, to hypoglycemia, 121-124

Epinephrine (E; adrenaline) in obesity

- stress effects on, 1387
- very-low-calorie diet effects on urinary excretion of, 594

EPOC (excess postexercise O_2 consumption), β -adrenoceptor blockade effects on TG/FA cycling and, 439-448

Equations, measurement, in compartmental modeling, 1015

ERT, *see* Estrogen replacement therapy in postmenopausal women

Erythrocytes, *see* Red blood cell(s)

Estradiol (E₂)

- and HRT effects on plasma lipids and Lps, 1224
- in hyperinsulinemic obese premenopausal women, 13-19
- menopausal status and exercise effects on, 378, 379
- in PCOS, opioid tone and, 159
- and plasma leptin in children, 310

Estradiol

- bone loss due to hyperprolactinemia and deficiency in, 425-428
- and CETP regulation in female transgenic subjects, 1048-1051
- see also* Estrogen replacement therapy in postmenopausal women

Estrogen replacement therapy (ERT) in postmenopausal women

- hypercholesterolemic with CHD, effects of, on level of antibodies against oxidized LDLs, 675-680
- LCAT during short-term estrogen-progestin replacement therapy, 297-300

ETA, *see* Endothelin A receptors

ET-1, *see* Endothelin-1

Ethanol, *see* Alcohol intake

Ethnicity, *see* Race and ethnicity

Ethylmalonic acid (EMA), abnormal isoleucine metabolism and elevated MSA and, in ethylmalonic encephalopathy, 836-839

Ethylmalonic encephalopathy, elevated EMA and MSA in, due to abnormal isoleucine metabolism, 836-839

Excess postexercise O_2 consumption (EPOC), β -adrenoceptor blockade effects on TG/FA cycling and, 439-448

Exercise, 377-390

- diet selection and substrate oxidation during, 777-782
- effects of low-fat, high-fiber diet and, in subjects with multiple CV disease risk factors, 384-390
- effects of menopausal status and, on intravascular enzymes related to serum lipid transport, 377-383
- glucose and, *see* Glucose in exercise
- isometric, effects of parasympathetic dysfunction and hyperinsulinemia on hemodynamic response to, in NIDDM, 934-939
- liver 3-FDG uptake enhanced by, 44-49
- metabolic efficiency of skeletal muscle during, measured with ³¹P MRS in hyperthyroidic subjects, 771-774
- O_2 consumption and, *see* O_2 consumption, exercise and
- see also* Men, exercising; Women, exercising

Exon 9 of PAF acetylhydrolase gene, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181

Extrahepatic sterol 27-hydroxylase, high-cholesterol, high-fat diet and activity of, 731-738

FA(s), *see* Fatty acids

Factor VII in very old syndrome X subjects, 535-540

Falciparum malaria, indomethacin effects on glucose production in, 217-222

Familial combined hyperlipidemia (FCH; FCHL)
 FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene in, 1397-1402
 minimal model in study of insulin resistance in nondiabetics with, 509-513

Familial hyperalphalipoproteinemia (HALP) and hyperbetaalipoproteinemia (HBLP), apo A-I and apo B synthesis in, 1160-1166

Familial hypercholesterolemia, *see* Apheresis, LDL, in FH

Family history of NIDDM
 beta cell function and, 522-528
 race and characteristics of young children of NIDDM parents, 998-1004

Fasting
 effects of sex, GH therapy and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519
 by obese insulin-resistant subjects, leptin response to, 125-128
 and refeeding, protein contents and activity of PDI during, 1083-1088
see also entries beginning with term: Fasting

Fasting blood glucose in NIDDM
 and CHD, 1259, 1260
 and family history of NIDDM, 523
 GSH effects on, 994

Fasting cholesterol (C), and CHD, 1246

Fasting C-peptide
 in cirrhosis, effects of zinc supplementation on, 794
 and family history of NIDDM, 523-524
 in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 in NIDDM, *see* Fasting C-peptide in NIDDM
 serum, in IDDM, and insulin secretion and therapy mode associated with leptin and AT in, 1394
 in young children of NIDDM subjects, 1000

Fasting C-peptide in NIDDM
 acipimox effects on, 253
 serum, and insulin secretion and mode of therapy associated with leptin and AT in, 1394

Fasting free fatty acids (FFAs; nonesterified fatty acids)
 in IGT, insulin kinetics, muscle morphology and, 851
 plasma, in prediabetic stage of NIDDM, 910
 in young children of NIDDM parents, 1000

Fasting glucagon (G)
 in prediabetic stage of NIDDM, 910
 in young children of NIDDM parents, 1000

Fasting glucose
 CHD and, 1119, 1246
 in cirrhosis, effects of zinc supplementation on, 794
 and effects of HF versus LF diets on, 1521
 in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
 in Graves' disease, 1195
 in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 in IGT, insulin kinetics, muscle morphology and, 850, 851
 in men with abdominal obesity, 1189, 1190
 in NIDDM, 640, 1202; *see also* Fasting blood glucose in NIDDM; Fasting plasma glucose in NIDDM
 in PCOS, 941, 990
 plasma, *see* Fasting plasma glucose
 in postmenopausal women, 437, 438, 470
 race and, in nondiabetics, relationship between insulin resistance and, 1176

Fasting glucose (*Continued*)
 and serum uric acid levels in non-obese premenopausal women, 437, 438
 stress effects on, in middle-aged men, 1442, 1445
 in very old syndrome X subjects, 536, 537
 in young children of NIDDM parents, 1000

Fasting glycated hemoglobin (Hb) in young children of NIDDM parents, 1000

Fasting homocyst(e)ine (tHcy), correlation between microalbuminuria, vascular damage and, in NIDDM, 915-921

Fasting β (beta)-hydroxybutyrate (BOHB), acipimox effects on, in NIDDM, 253

Fasting insulin
 β_3 -adrenoceptor gene and, *see* Fasting insulin, β_3 -adrenoceptor gene and
 in cirrhosis, effects of zinc supplementation on, 794
 and effects of HF versus LF diets on S, and serum leptin in women, 1521
 in exercising postmenopausal women, CHD and, 1119
 and family history of NIDDM, 523-525
 in IGT, insulin kinetics, muscle morphology and, 850, 851
 in men with abdominal obesity, 1189, 1190
 in NIDDM, *see* Fasting insulin in NIDDM
 in non-obese subjects, *see* Fasting insulin in non-obese subjects
 in obese women, 470, 990
 in PCOS, 941, 990
 plasma, *see* Fasting plasma insulin
 race and, of nondiabetics, relationship between insulin resistance and, 1176
 serum lipids, BP and, in Kuwaiti children, 420-424
 stress effects on, in middle-aged men, 1442, 1443, 1445
 in subjects with multiple CV disease risk factors, effects of low-fat, high-fiber diet and exercise on, 384-390
 in very old syndrome X subjects, 536
 in young children of NIDDM parents, 1000

Fasting insulin, β_3 -adrenoceptor gene and
 in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
 in hyperglycemia associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620

Fasting insulin in NIDDM
 effects of, on hemodynamic response to isometric exercise, 935, 936
 with hypertension, perindopril effects on, 1202
see also Fasting plasma insulin in NIDDM

Fasting insulin in non-obese subjects
 menopause effects on, 437, 438
 serum lipids, BP and, in children, 420-424

Fasting intermediate-density lipoprotein (IDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fasting lipids
 gemfibrozil effects on, 236
see also specific lipids

Fasting low-density lipoprotein (LDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fasting plasma free fatty acids (FFAs) in prediabetic stage of NIDDM, 910

Fasting plasma glucagon (G) in prediabetic stage of NIDDM, 910

Fasting plasma glucose (FPG)
 diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
 dietary Cr effects on, 397, 398
 in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398

Fasting plasma glucose (FPG) (*Continued*)
 in hyperinsulinemia, plasma HcY concentrations and, 687
 in IDDM, and mode of therapy associated with leptin and AT, 1394
 low- and high-fat diet effects on, 1093
 in NIDDM, *see* Fasting plasma glucose in NIDDM
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 physiological reduction of, in first trimester of normal pregnancy, 1140-1144
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526
 VAT accumulation effects on, in obese men, 930, 931

Fasting plasma glucose (FPG) in NIDDM
 and insulin secretion and therapy mode associated with leptin and AT, 1394
 IR isoform mRNA and, 130
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 in prediabetic stage of NIDDM, 910
 urinary and serum TM and, 363

Fasting plasma insulin (FPI)
 dietary Cr effects on, 397, 398
 in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398
 in hyperinsulinemia, plasma HcY concentrations and, 687
 low- and high-fat diet effects on, 1093-1094
 in NIDDM, *see* Fasting plasma insulin in NIDDM
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 relationship between anthropometrics, metabolic parameters and, in very old syndrome X subjects, 535-540
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526

Fasting plasma insulin (FPI) in NIDDM
 GSH effects on, 994
 IR isoform mRNA and, 130
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 in prediabetic stage, 910

Fasting plasma lactate in prediabetic stage of NIDDM, 910

Fasting plasma leptin, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, 1526

Fasting plasma pyruvate in prediabetic stage of NIDDM, 910

Fasting plasma triglycerides (TGs)
 dietary Cr effects on, 397, 398
 in prediabetic stage of NIDDM, 910

Fasting proinsulin
 in IGT, insulin kinetics, muscle morphology and, 850, 851
 in young children of NIDDM parents, 1000

Fasting serum C-peptide in IDDM and NIDDM, and insulin secretion and therapy mode associated with leptin and AT, 1394

Fasting serum glucose, perindopril effects on, in NIDDM with hypertension, 1202

Fasting serum insulin, perindopril effects on, in NIDDM with hypertension, 1202

Fasting triglycerides (TGs)
 in IGT, insulin kinetics, muscle morphology and, 850, 851
 in nondiabetic South Indians, 232
 plasma, *see* Fasting plasma triglycerides
 as risk factors for CHD, 1246

Fasting very-low-density lipoprotein (VLDL) in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373

Fat, *see* Dietary fat entries beginning with terms: Fat, Fatty elements: Adip-, Lip- and specific fats

Fat-free mass (FFM)
 DEXA measurement of, in prone and supine position, 1379-1382
 exercise effects on, *see* Fat-free mass, exercise effects on

Fat-free mass (FFM) (*Continued*)
 in GH-deficient subjects, 1516, 1517
 and HRT effects on plasma lipids and Lps, 1224
 of NIDDM subjects, effects of dietary protein restriction on, 1147
 in obese prepubertal subjects, GH bioactivity and, 1491
 OC effects on, 281
 and plasma leptin in children, 310
 and RMR in normal subjects, 1135, 1136

Fat-free mass (FFM), exercise effects on of endurance exercise, 875
 in postmenopausal women, 1141

Fat mass (FM)
 DEXA measurement of, in prone and supine position, 1379-1382
 of exercising postmenopausal women, CHD and, 1141
 in GH-deficient subjects, 1516, 1517
 and HRT effects on plasma lipids and Lps, 1224
 leptin and, *see* Fat mass, leptin and
 in obese prepubertal subjects, GH bioactivity and, 1491
see also Adipose tissue; Obesity

Fat mass (FM), leptin and
 in IDDM and NIDDM subjects, insulin secretion and therapy mode associated with leptin and AT in, 1394
 and plasma leptin in children, 310

Fatty acids (FAs)
 β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448
 composition of, in skeletal muscle membrane PLs, in young children, 106-112
 glucose contribution to synthesis of, in subjects on high-protein, carbohydrate-free diet, 1217-1221
 in hypercholesterolemia-inducing diet, 302
 reoxygenation injury effects on response of pancreatic islets to, 809-813
 short-chain, effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134
see also Free fatty acids; Monounsaturated fatty acids; Polyunsaturated fatty acids; Saturated fatty acids

FCH (FCHL), *see* Familial combined hyperlipidemia

3-FDG (3-fluoro-3-deoxy-D-glucose), exercise enhancing muscle and liver uptake of, 44-49

^{59}Fe ($^{59}\text{iron}$), vanadate and uptake of, in adipocytes, 630-636

Female subjects
 adolescent, *see* Adolescents
 transgenic, sex steroids regulating CETP in, 1048-1051
see also Sex; Women

Ferritin in prepubertal children with β -thalassemia and/or CSS, 543

FFAs, *see* Free fatty acids

FFM, *see* Fat-free mass

FH (familial hypercholesterolemia), *see* Apheresis, LDL, in FH

Fiber
 in dietary regulation of apo B-containing Lps, 884
 effects of high-fiber, low-fat diet and exercise in subjects with multiple CV disease risk factors, 384-390
 in fat-modified diet for hypercholesterolemia, 745
 in NIDDM diet, 664
 in protein-restricted diet, 1147
 in stearic and oleic acid diets, 531

Fibrin in exercising postmenopausal women, CHD and, 1119

Fibrinogen
 in exercising postmenopausal women, CHD and, 1119
 in NIDDM, 641, 703
 in very old syndrome X subjects, 536

Fibrinolysis in NIDDM
 effects of insulin versus sulfonylurea therapy on, 637-643
 with obesity, S, insulin action and, 1372-1375

Fibroblasts in PCOS, insulin resistance in, 940-946

First trimester of normal pregnancy, physiological reduction of FPG in, 1140-1144

Fitness, *see* Exercise

Fluorescence assay for blood and urine AGE products in DM, 1348-1353

3-Fluoro-3-deoxy-D-glucose (3-FDG), exercise enhancing muscle and liver uptake of, 44-49

FM, *see* Fat mass

Folate

- in homocystinuria, 208, 209
- in NIDDM, tHcy, microalbuminuria and, 916
- see also* Folate, plasma Hcy and

Folate, plasma Hcy and

- plasma Hcy levels related to folate status and MTHFR gene mutation in healthy subjects, 1413-1418
- total plasma Hcy and serum folate in hyperthyroidism and hypothyroidism, 90, 91

Follicle-stimulating hormone (FSH)

- in PCOS, 159, 941
- in recessive Robinow syndrome, 1337-1343

Food intake

- by hypokinetic subjects, 904, 905
- and insulin-dependent increase in *Lep* mRNA and plasma leptin in STZ-DM, 603-607
- long-term alcohol intake effects on, at puberty, 1269-1273
- PKW mitogen effects on, 77
- see also* Diet

Forcing function describing AA incorporation into LDL apo B, 488-490

Formula, influence of breast milk and, on hepatic HMG-CoA reductase and C7H mRNA but not LDL receptor mRNA during development, 20-26

FPG, *see* Fasting plasma glucose

FPI, *see* Fasting plasma insulin

Free cortisol, urinary, in AIDS patients, 690-694

Free fatty acids (FFAs; nonesterified fatty acids)

- body composition, insulin resistance and, 404, 406
- breast milk and/or formula effects on, during development, 22
- effects of elevated, on muscle lipids and muscle glycogen synthesis, 1121-1126

in FCH, *see* Free fatty acids in FCH

in GH-deficient subjects, 1516

high-monounsaturated fat diet effects on, 726

in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

in hypertriglyceridemia, gemfibrozil effects on, 236

IGF-I effects on, in young IDDM adults, 34

in IGT, insulin kinetics, muscle morphology and, 851

in insulin resistance, 983

OC effects on metabolism of, 280-284

in PAM, 1265

plasma, *see* Plasma free fatty acids

restricted caloric intake effects on, 429-434

serum, *see* Serum free fatty acids

stress-induced release of, in obesity, 1383-1390

in young children of NIDDM parents, 1001

Free fatty acids (FFAs) in FCH

- nondiabetic, insulin resistance in, 509-511
- regulation of glucose oxidation and levels of, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-382G of UCP-1 gene in, 1397-1402

Free radicals, cortisol effects on generation of, by MNCs, 788-791

Fructosamine

- in IDDM, CFA and, 504
- see also* Fructosamine in NIDDM

Fructosamine in NIDDM

- acipimox effects on, 252
- CFA and, 504

Fructosamine in NIDDM (*Continued*)

- hemodynamic response to handgrip test and, 935, 936
- insulin versus sulfonylurea therapy of NIDDM and, 640
- platelet 12-LOX activity and, 258

Fructose

- in NIDDM, 259, 664, 665
- NO-1886 effects on hypertriglyceridemia induced by, 149-153
- pioglitazone effects on glucose metabolism and muscle and liver insulin uptake with high-fructose diet, 1152-1155

FSH, *see* Follicle-stimulating hormone

G, *see* Glucagon

G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene, as risk factor for CAD in Japanese men, 177-181

Galactitol, elevated RBC redox potential and synthesis of, 1424-1425

Galactonate, elevated RBC redox potential and synthesis of, Tolrestat effects on, 1423-1428

Galactose

- in cirrhosis, zinc supplementation effects on, 793
- effects of elevated RBC redox potential on, 1425-1426

Galactose-1-phosphate, RBC redox potential and synthesis of, 1425

Galactose-1-phosphate uridylyltransferase (GALT) deficiency, hereditary galactosemia due to, 1423-1428

Galactosemia, hereditary, due to GALT deficiency, 1423-1428

Galactosyltransferase, GLcN effects on, 452

GALT (galactose-1-phosphate uridylyltransferase) deficiency, hereditary galactosemia due to, 1423-1428

Gamma glutamyl transferase, *see* γ Glutamyl transferase

Gamma (γ) guanidinobutyric acid (GBA), nephrectomy effects on, 358, 359

GA3PDH, *see* Glyceraldehyde-3-phosphate dehydrogenase

Gas chromatography/mass spectrometry (GC/MS) of metabolic tracers, 706-712

Gastric emptying, G effects on, in nondiabetics, 7-12

Gastrointestinal (GI) hormones

- G effects on, in nondiabetics, 9
- see also* specific hormones

GBA (gamma guanidinobutyric acid), nephrectomy effects on, 358-359

GC/MS (gas chromatography/mass spectrometry) of metabolic tracers, 706-712

Gemfibrozil

- for hypertriglyceridemia, 234-242
- for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565

Gene

- CYP2D6, in Parkinson's disease, 94-96
- expression of, *see* mRNA
- GPIIIa, smoking and, and TG-rich Lps, 1040-1041
- Lep*, *see*: *Lep* gene
- see also* Allele frequency; Apolipoprotein E phenotype in hypercholesterolemia; Genotype; Mutation; Polymorphism

Genetics

- of S_i, 493-496
- see also* Gene entries beginning with term: Familial, Hereditary, Heterozygous, Recessive and specific hereditary conditions

Genotype

- ACE, metabolic syndrome and electrocardiographic CAD and, 622-626
- apo E, cholesterogenesis in polygenic hypercholesterolemia and, 97-100
- genotype frequency of Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457, 618, 619
- PON, PON activity in NIDDM and, 599-600

GF, *see* Growth factor

GFR (glomerular filtration rate) following whole pancreas-kidney transplantation in IDDM, 1326, 1328

GGT, *see* γ Glutamyl transferase
 GH, *see* Growth hormone
 GHBP (growth hormone-binding protein) in CRF children, 265
 GH/IGF-I/IGFBP3 (growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3) axis in prepubertal children with β -thalassemia and/or CSS, 541-548
 GHRH, *see* Growth hormone-releasing hormone; Growth hormone-releasing hormone receptor
 GI hormones, *see* Gastrointestinal hormones
 GLcN, *see* Glucosamine
 Gliclazide, diabetic neuropathy in STZ-DM inhibited by, irrespective of blood glucose levels, 977-981
 Gln, *see* Glutamine
 Globulin, *see* Sex hormone-binding globulin in women
 Glomerular filtration rate (GFR) following whole pancreas-kidney transplantation in IDDM, 1326, 1328
 GLP-1 (glucagon-like peptide-1), effects of stimulation with glucose and, on insulin release in NIDDM, 1042-1047
 Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)
 breast milk and/or formula effects on, during development, 22
 bucladesine sodium effects on, 1006-1007
 and cortisol response to ACTH, 1254
 effects of, on plasma uridine concentrations, 695-698
 effects of, on PP CHO metabolism in nondiabetics, 7-12
 in NIDDM, effects of dietary protein restriction on, 1147
 in PAM, 1264, 1265
 in young children of NIDDM parents, 1000, 1001
 in young IDDM adults, IGF-I effects on, 34, 1481-1489
 see also Fasting glucagon; Glucose, G effects on; Glutamine, G effects on; Hyperglucagonemia; Plasma glucagon
 Glucagon-like peptide-1 (GLP-1), effects of stimulation with glucose and, on insulin release in NIDDM, 1042-1047
 Glucocorticoid receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308
 Gluconeogenesis of hepatic and renal glutamine, glucagon effects on, in normal subjects, 1227-1232
 Glucosamine (GLcN)
 and beta-cell dysfunction in NIDDM, 573-577
 effects of insulin and, on O-GlcNAc levels in muscle proteins, 449-455
 Glucosaminidase, *N*-acetyl- β -, in NIDDM, 363
 Glucose
 in adipocytes, ET-1 inhibition of insulin-stimulated uptake of, in adipocytes, 1468-1471
 blood, *see* Blood glucose
 body composition, insulin resistance and, 402, 404, 406
 BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 breast milk and/or formula effects on, during development, 22
 bucladesine sodium effects on, 1006-1007
 in cirrhosis, effects of zinc supplementation on disposal of, 792-798
 in conscious subjects, *see* Conscious subjects, glucose in
 contribution of, to glyceride-glycerol and FA synthesis with high-protein, carbohydrate-free diet, 1217-1221
 cortisol, ACTH and, *see* Glucose, cortisol, ACTH and
 and differential recovery of $^{13}\text{CO}_2$ from infused [2- ^{13}C] versus [1- ^{13}C] acetate, 549-554
 exercise and, *see* Glucose in exercise
 fasting, *see* Fasting glucose
 following whole pancreas-kidney transplantation in IDDM, 1328
 G and, *see* Glucose, G effects on
 and GH deficiency, 1516
 hepatic, *see* Hepatic glucose
 homeostasis of neonatal, 1239-1244
 Glucose (Continued)
 and HRT effects on plasma lipids and Lps, 1224
 in hyperinsulinemia, *see* Glucose in hyperinsulinemia
 indomethacin effects on production of, in falciparum malaria, 217-222
 leptin and, *see* Glucose, leptin and
 metabolic disturbances TGs and, predisposing to CHD, TNF α and, 113-118
 peptin and, *see* glucose, peptin and
 in NIDDM, *see* Glucose in NIDDM
 NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
 in nondiabetic Asian Indians, 231
 in obesity, *see* Glucose in obesity
 in PCOS, opioid tone and, 159
 pioglitazone effects on metabolism of, in subjects on high-fructose diet, 1152-1155
 PKW mitogen effects on, 76-77
 plasma, *see* Plasma glucose
 in post-small bowel resection enteral diet, 1367
 regulation of FFA levels and oxidation of, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of UCP-1 gene in FCHL, 1397-1402
 restricted calorie intake effects on, in men and women, 429-434
 in STZ-DM, continuous monitoring of, with ECU, 799-803
 in young children of NIDDM parents, 1001
 see also [^3H]Deoxyglucose; 2-[^3H]Deoxyglucose; 3-Fluoro-3-deoxy-D-glucose; Glucose system, modeling of; Glucose tolerance; GLUT4; Hyperglycemia; Hypoglycemia
 Glucose, cortisol, ACTH
 effects of recurrent hypoglycemia on cortisol response to ACTH, 1254
 stress and relationship of ACTH and cortisol to glucose and insulin and, in middle-aged men, 1440-1449
 Glucose, G effects on
 glutamine and, 716, 717, 719
 HGP activation and deactivation in conscious subjects, 135-142 in nondiabetics, 8, 9
 Glucose, leptin effects on
 on adipocyte glucose metabolism, 1360-1365
 on systemic glucose utilization in conscious subjects, 1274-1280
 Glucose in exercise
 aerobic exercise and weight loss effects on BP, glucose metabolism, and Lps in obese middle-aged hypertensive men, 1075-1082
 glucose and AA effects on ureogenesis before and during exercise, 1303-1307
 glucose effectiveness in endurance exercise measured with IVGTT, 190-194, 874-877
 liver and muscle glucose disposal, 44-49
 muscle glucose uptake and conversion to glycogen following exercise, 409-414
 oxidation of, 779, 780
 Glucose fluxes, modeling of, 1020-1026
 in non-steady-state, 1024-1026
 in steady-state, 1020-1024
 Glucose in hyperinsulinemia
 in acute hyperinsulinemia with losartan-treated hypertension, 293
 in hyperinsulinemic obese premenopausal women, 14, 15
 and in insulin resistance, 832, 834, 835
 Glucose intolerance, *see* Glucose tolerance
 Glucose in NIDDM
 acipimox effects on dyslipidemia and, 250-256
 blood, *see* Blood glucose in NIDDM
 dietary protein restriction altering metabolism of, but not protein metabolism, 1145-1151

Glucose in NIDDM (*Continued*)
 effects of, on platelet 12-LOX activity, 259
 effects of Ca and, on pancreatic islet Ca^{2+} -ATPase, 185-189
 effects of stimulation with glucose and GLP-1 on insulin release in NIDDM, 1042-1047
 GSH effects on metabolism of, 993-997
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 increased HGP production and decreased hepatic glucose uptake in prediabetic stage of NIDDM, 908-914
 in older subjects, Pro-Z effects on metabolism of zinc, insulin and, 39-43
 plasma, *see* Plasma glucose in NIDDM
 serum fasting, perindopril effects on, 1202
 tHcy, microalbuminuria and, 916
 in young IDDM adults, IGF-I effects on, 34

Glucose in obesity
 aerobic exercise and weight loss effects on BP, glucose metabolism, and Lps in obese middle-aged hypertensive men, 1075-1082
 effects of weight loss with meat-based or plant-based diet on, 1310
 plasma, *see* Plasma glucose in obesity
 stress effects on, 1385, 1387

Glucose-6-phosphatase (G6Pase), activity of, in hypothalamus of obese subjects, 627-629

Glucose-1-phosphate, RBC redox potential and synthesis of, 1425

Glucose-6-phosphate (G6P), hydrolysis of, in hypothalamus of obese subjects, 627-629

Glucose signaling, model of, 1027-1033

Glucose system, modeling of, 1020-1026
 of glucose fluxes, *see* Glucose fluxes, modeling of
 of glucose and insulin signaling, 1027-1033
 minimal models, 490-492, 875
 as prototype, 1010-1011

Glucose tolerance
 effects of stearic and oleic acid diets on S_i and, in healthy women, 529-534
 verapamil and captopril effects on insulin action and, in insulin resistance, 982-987
see also Impaired glucose tolerance; Intravenous glucose tolerance test; Oral glucose tolerance test

GLUT4
 insulin-stimulated recruitment of, to skeletal muscle cell surface, dexamethasone effects on, 3-6
 NIDDM effects on translocation of, 58

Glutamine (Gln)
 in active celiac disease, whole-body protein metabolism assessed by kinetics of, 1429-1433
 and differential recovery of $^{13}\text{CO}_2$ from infused [2- ^{13}C] versus [1- ^{13}C] acetate, 549-554
 in exercise, glucose and AA infusion effects on, 1306
 in familial HALP and HBLP, 1164
 G effects on, *see* Glutamine, G effects on
 plasma, *see* Plasma glutamine
 in post-small bowel resection enteral diet, 1368
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227

Glutamine (Gln), G effects on
 on gluconeogenesis of hepatic and renal glutamine, 1227-1232
 on glutamine uptake and release, 713-723

γ (gamma) Glutamyl transferase (GGT)
 endotoxin effects on, 682
 in LT recipients, 201

Glutathione (GSH)
 in CHD, 276
 and glucose metabolism in NIDDM, 993-997
 in retina of STZ-DM subjects, 269-272

Glutathione peroxidase (GSH-Px) in Keshan disease, vitamin E and selenium effects on, 416

Gluten-free diet in celiac disease, 1430

Glycated Hb (hemoglobin)
 in NIDDM, *see* Glycated Hb in NIDDM
 in young children of NIDDM parents, 1000

Glycated Hb (hemoglobin) in NIDDM
 acipimox effects on, 253
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

Glycation end products, *see* Advanced glycation end products in DM

Glyceraldehyde-3-phosphate dehydrogenase (GA3PDH)
 adipocyte, dexamethasone effects on, 1455-1461

CHD and activity of, 657-662

Glyceride-glycerol, glucose contribution to synthesis of, with HP, CHO-free diet, 1217-1221

Glycerol
 in offspring of protein-malnourished subjects, 1452
see also Plasma glycerol

Glycerol phosphate (glycerol-P), hydrolysis of, in hypothalamus of obese subjects, 627-629

Glycine (Gly)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 in post-small bowel resection enteral diet, 1367, 1368
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
see also Hexanoylglycine; Isobutyrylglycine; Isovalerylglycine; D,L-Propargylglycine

Glycogen
 effects of alcohol-related diols on, 1183-1184
 muscle, *see* Muscle glycogen
 perindopril effects on, in NIDDM with hypertension, 1202

Glycolysis
 CHD and, 657-662
 GLcN effects on, 451-452

Glycoprotein(s) (GP), serum, incorporation of dietary specific sugars into, 1501-1502

Glycoprotein IIIa (GP IIIa) gene, smoking and, and TG-rich Lps, 1040-1041

Glycosylation, dietary specific sugars for serum protein enzymatic, 1499-1503

GnRH, *see* Gonadotropin-releasing hormone

Gonadotropin, human chorionic, T response to, in recessive Robinow syndrome, 1337-1343

Gonadotropin-releasing hormone (GnRH)
 Chansu effects on, 1213, 1214
 in recessive Robinow syndrome, 1337-1343

Gout, serum $1,25(\text{OH})_2\text{D}_3$ in, 336-338

GP (glycoprotein), serum, incorporation of dietary specific sugars into, 1501-1502

G6P (glucose-6-phosphate), hydrolysis of, in hypothalamus of obese subjects, 627-629

G6Pase (glucose-6-phosphatase), activity of, in hypothalamus of obese subjects, 627-629

GP IIIa (glycoprotein IIIa) gene, smoking and, and TG-rich Lps, 1040-1041

Graves' disease, Na^+,K^+ ATPase activity in RBCs of women on levothyroxine therapy following total thyroidectomy for, 1194-1198

Growth and development
 breast milk and formula influence on hepatic HMG-CoA reductase and C7H mRNA but not on LDL receptor mRNA during, 20-26 of CRF children, excessive dietary protein and suboptimal caloric intake effects on, before and during GH administration, 264-268

Growth and development (*Continued*)
 renal, following unilateral nephrectomy, effects of immunosuppression on, 817-823

Growth factor (GF)
 epidermal, effects of, on leptin release in adipocytes, 1457-1458
 plasma immunoreactive vascular endothelial, smoking relation to concentration of, 27-30

Growth hormone (GH)
 hyperglucagonemia effects on, 499
 IGF-II, -III, IGFBP-1, -2, and -3 and bioactivity of, in prepubertal obese children, 1490-1493
 leptin and, *see* Leptin, GH and
 naloxone effects on response of, to melatonin and pyridostigmine in men, 814-818
 in PAM, 1265
 troglitazone effects on hepatic and peripheral insulin resistance induced by excess, 783-787
see also Growth hormone, cortisol and; Growth hormone, IGF-I and; Growth hormone, therapy with; Growth hormone-binding protein; Growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3; Growth hormone-releasing hormone; Growth hormone-releasing hormone receptor

Growth hormone (GH), cortisol and
 and cortisol response to ACTH, 1254
 GH therapy suppressing cortisol production in men, 1376-1378

Growth hormone (GH), IGF-I and
 GH bioactivity and IGF-I in prepubertal obese children, 1490-1493
 in GH deficiency, 1516
 GH response to clonidine and serum IGF-I in recessive Robinow syndrome, 1337-1343
 GH therapy effects on, 1377
 in IDDM, *see* Growth hormone, IGF-I and, in IDDM
 prednisolone and GH effects on IGF-I, 84-85
 in women, GH relationship to HDL-C and apo A-I independently of IGF-I and insulin, 339-344

Growth hormone (GH), IGF-I and, in IDDM
 IGF-I effects on insulin requirements due to GH pulsatility in young adults, 31-38
 low-dose IGF-I effects on GH in young IDDM adults, 1481-1489

Growth hormone (GH), therapy with
 cortisol production suppressed by, in men, 1376-1378
 effects of sex, fasting and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519
 prednisolone and GH effects on EE, 83-88

Growth hormone-binding protein (GHPB) in CRF children, 265

Growth hormone/insulin-like growth factor-I/insulin-like growth factor-binding protein 3 (GH/IGF-I/IGFBP3) axis in prepubertal children with β -thalassemia and/or CSS, 541-548

Growth hormone-releasing hormone (GHRH), serum insulin but not leptin in association with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without weight loss, 1127-1133

Growth hormone-releasing hormone (GHRH) receptor, inhibition of signal transduction by splice variant of, expressed in pituitary adenoma, 804-808

GSA (guanidinosuccinic acid), nephrectomy effects on, 358, 359

GSH, *see* Glutathione

GSH-Px (glutathione peroxidase) in Keshan disease, vitamin E and selenium effects on, 416

Guanidino compounds, nephrectomy effects on, 358-359

γ (gamma) Guanidinobutyric acid (GBA), nephrectomy effects on, 358, 359

β (beta) Guanidinopropionic acid, nephrectomy effects on, 358, 359

Guanidinosuccinic acid (GSA), nephrectomy effects on, 358, 359

7H, *see* Cholesterol 7 α -hydroxylase mRNA

HALP, *see* Hyperalphalipoproteinemia

Handgrip test, effects of parasympathetic dysfunction and hyperinsulinemia on hemodynamic response to, in NIDDM, 934-939

Hb (hemoglobin)
 endotoxin effects on, 682
 in falciparum malaria, 219
 glycated, *see* Glycated Hb
 Hct and, related to insulin resistance and compensatory hyperinsulinemia in healthy non-obese subjects, 831-835
 in prepubertal children with β -thalassemia and/or CSS, 543

HbA₁ (hemoglobin A₁)
 and cortisol response to ACTH, 1253
 in NIDDM, *see* HbA₁ in NIDDM

HbA₁ (hemoglobin A₁) in NIDDM
 effects of dietary protein restriction on, 1147
 insulin versus sulfonylurea therapy of NIDDM and, 640

HbA_{1c} (hemoglobin A_{1c})
 in DM, blood and urine AGE products and, 1349; *see also* HbA_{1c} in IDDM; HbA_{1c} in NIDDM
 in hyperinsulinemia, plasma HcY concentrations and, 687
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624

HbA_{1c} (hemoglobin A_{1c}) in IDDM
 CFA and, 504
 following whole pancreas-kidney transplantation in IDDM, 1328
 and insulin secretion and mode of therapy associated with leptin and AT, 1394
 urinary ET-1 and, 1409, 1410

HbA_{1c} (hemoglobin A_{1c}) in NIDDM
 CFA and, 504
 CHD and, 1259, 1260
 in elderly subjects, Pro-Z effects on, 40
 GSH effects on, 994
 hemodynamic response to handgrip test and, 935, 936
 insulin Lispro versus regular insulin effects on lipid metabolism and, 372
 and insulin secretion and mode of therapy associated with leptin and AT, 1394

LDL receptors, lipid metabolism and, 1071
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624

platelet 12-LOX activity and, 258

serum PON activity and, 599

SPA relationship to NIDDM complications and, 703

tHcy, microalbuminuria and, 916

urinary and serum TM and, 363

HBLP (hyperbetaalipoproteinemia), familial, apo A-I and apo B synthesis in, 1160-1166

HC (hydrocortisone), *see* Cortisol

HCG (human chorionic gonadotropin), T response to, in recessive Robinow syndrome, 1337-1343

HCl (hydrochloric acid), effects of, on renal and hepatic N metabolism, 163-167

Hct, *see* Hematocrit

HcY (homocysteine), *see* Plasma homocysteine

HDL, *see* High-density lipoprotein

HDL-C, *see* High-density lipoprotein-cholesterol

Head and neck squamous cell carcinoma (HNSCC) cell lines, cytochrome P450-mediated RA oxidation by retinoids in, 955-958

Healthy subjects, *see* Normal subjects

Heart
 exercise effects on weight of, 191
 in NIDDM with hypertension, long-term effects of perindopril on, 1199-1204
see also Chronic heart failure; Coronary heart disease; Heart rate

Heart rate (HR)
 effects of lipolysis inhibition on, 1465
 and exercise, β -adrenoceptor blockade effects on, 440
 in Graves' disease, 1195
 in NIDDM during handgrip test and at rest, 935, 936
 in obesity, very-low-calorie diet effects on, 593

Height
 and BMD in prepubertal children with CSS, 541-548
 of CRF children, 265
 of elderly subjects, 196, 314
 of exercising subjects, 378, 379, 440
 of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 of obese women, and effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin, compared, 1309
 of OC users, 281
 of premenopausal IDDM subjects, 213
 race and, of adolescent males, HDL-C and TG levels and, 516
see also Height of NIDDM subjects; Height of postmenopausal women

Height of NIDDM subjects
 and effects of dietary protein restriction, 1147
 premenopausal and postmenopausal, 213

Height of postmenopausal women
 exercising, and AT as risk factor for CHD, 113
 with IDDM and/or NIDDM, 213

Hematocrit (Hct)
 endotoxin effects on, 682
 Hb and, related to insulin resistance and compensatory hyperinsulinemia in healthy non-obese subjects, 831-835
 in hypoglycemia, 1472
 in LT recipients, 201

Hemodynamics
 E effects on, 246, 247
 hemodynamic response to isometric exercise in NIDDM, effects of parasympathetic dysfunction and hyperinsulinemia on, 934-939
 IL-6 effects on, 1291
see also Blood flow; Blood pressure; Heart rate

Hemoglobin, *see* Hb

Heparin
 effects of, on coronary artery SMC migration, 1065-1069
see also Postheparin lipids; Postheparin lipoprotein lipase

Hepatic amino acids (AAs)
 burn injury and transport of, 608-616
 in exercise, glucose and AA infusion effects on, 1306

Hepatic cholesterol (C)
 abundant C7H mRNA effects on, 391-395
 effects of vitamin C and dietary fat regulation of apo-containing Lps on, 883-891

Hepatic failure following LT, serum IGFs and IGFBPs in, 200-206

Hepatic glucose
 disposal of, during exercise, 44-49
 effects of positive and negative gradients of portal venous, and on uptake of, following glucose infusion in splanchnic bed of conscious subjects, 1295-1302
see also Hepatic glucose production

Hepatic glucose production (HGP)
 in exercise, glucose and AA infusion effects on, 1304-1305
 G activation and deactivation of, in conscious subjects, 135-142
 hepatic glucose uptake and increased, in prediabetic stage of NIDDM, 908-914

Hepatic glutamine (Gln), glucagon effects on gluconeogenesis of, in normal subjects, 1227-1232

Hepatic glycogen, effects of FFA elevation on, 1122-1123

Hepatic HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase
 BM 15.766 effects on, 880, 881
 effects of vitamin C and dietary fat regulation of apo-containing Lps on, 886
see also Hepatic HMG-CoA reductase mRNA

Hepatic HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase mRNA (messenger ribonucleic acid)
 breast milk and formula influence on C7H mRNA and, but not on LDL receptor mRNA during development, 20-26
 sex hormone effects of on, 393

Hepatic 11 β -hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA (messenger ribonucleic acid) in pubertal hypothyroid male subjects, T₄ and T effects on activity and, 474-478

Hepatic insulin, model of extraction of, 1026-1027

Hepatic insulin resistance induced by GH excess, troglitazone effects on, 783-787

Hepatic lipase (HL) activity
 cardioprotective profile in HALP associated with increased levels of HDL₂ and decreased, 965-973
 ERT effects on, of, 676-677
 GH levels in women correlated with, 340-342

Hepatic lipids, hypercholesterolemia-inducing diet effects on, 304

Hepatic N (nitrogen), HCl effects on metabolism of, 163-167

Hepatic triacylglycerol (TAG), effects of vitamin C and dietary fat regulation of apo-containing Lps on, 886

Hepatic urea production in exercise, glucose and AA effects on, 1304

Hepatocytes
 insulin effects on abundance of apobec-1 mRNA in, 869-873
 tamoxifen effects on C synthesis in, 1504-1513

HepG2 cells, tamoxifen effects on C synthesis in, 1504-1513

Hereditary galactosemia due to GALT deficiency, 1423-1428

Heterozygous familial hypercholesterolemia, *see* Apheresis, LDL, in FH

Heterozygous homocystinuria, 207-211

Hexanoylglycine in ethylmalonic encephalopathy, 837

Hexosamine, UDP-linked, GLcN effects on, 451

Hexose, UDP-linked, GLcN effects on, 451

HF, *see entries beginning with terms:* High-fat

HGP, *see* Hepatic glucose production

High-cholesterol, high-fat diet, extrahepatic sterol 27-hydroxylase activity and, 731-738

High-density lipoprotein (HDL; α -lipoprotein)
 BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 in hyperinsulinemia, plasma HcY concentrations and, 687
 in IDDM, urinary ET-1 and, 1409
 lipolysis stimulation in hypertriglyceridemia and production of small particles of, 234-242
 plasma, *see* Plasma high-density lipoprotein
 in postmenopausal women, 437, 438, 470
 and serum uric acid levels in non-obese premenopausal women, 437, 438
 in young children of NIDDM parents, 999
see also High-density lipoprotein in obesity; High-density lipoprotein-cholesterol; High-density lipoprotein₂; High-density lipoprotein₃; Hyperalphalipoproteinemia; Lipoprotein(a)

High-density lipoprotein (HDL; α -lipoprotein) in obesity
 effects of weight loss with meat-based or plant-based diet on, in obese women, 1310
 serum, in hyperinsulinemic and insulinopenic NIDDM, 1318

High-density lipoprotein-cholesterol (HDL-C)
 in abdominal obesity, 1189, 1190
see also High-density lipoprotein-cholesterol in CHD
 effects of stearic and oleic acid diets on, 532

High-density lipoprotein-cholesterol (HDL-C) (*Continued*)

- exercise and, *see* High-density lipoprotein-cholesterol, exercise effects on
- in familial HALP and HBLP, 1162, 1163
- and family history of NIDDM, 523, 525
- in FCH, *see* High-density lipoprotein-cholesterol in FCH
- HCHF diet effects on, 733
- HRT effects on, 1224, 1225
- in hypercholesterolemia, *see* High-density lipoprotein-cholesterol in hypercholesterolemia
- in hypertriglyceridemia, gemfibrozil effects on, 236
- in insulin resistance, *see* High-density lipoprotein-cholesterol in insulin resistance
- in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
- NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
- OC effects on, 281
- plasma, *see* Plasma high-density lipoprotein-cholesterol
- race and, *see* High-density lipoprotein-cholesterol, race, sex and relationship of GH to apo A-I and, in women, independently of IGF-I and insulin, 339-344
- serum, *see* Serum high-density lipoprotein-cholesterol
- sex hormones effects on, 392
- short-term tall oil phytosterol administration effects on, 753-754
- in very old syndrome X subjects, 536, 537
- see also* High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (HDL-C), exercise effects on low-fat, high-fiber diet effects on, 386, 387
- menopausal status and, 378, 379
- in middle-aged obese hypertensive men, 1079
- in postmenopausal women, CHD and, 1119
- High-density lipoprotein-cholesterol (HDL-C), race, sex and in adolescent males, TG level and, 514-521
- in children, 360, 760
- of nondiabetics, relationship between insulin resistance and, 1176, 1177
- High-density lipoprotein-cholesterol (HDL-C) in CHD
- Lp(a) level and, 183
- in NIDDM, 1259, 1260
- plasma homocysteine and, 276
- in postmenopausal women, 1119
- and role of TNF α in TG and glucose metabolism, 114
- High-density lipoprotein-cholesterol (HDL-C) in FCH
- and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
- in nondiabetic FCH, 509, 510
- High-density lipoprotein-cholesterol (HDL-C) in hypercholesterolemia
- fat-modified diet effects on, 745
- LDL apheresis and, 865, 1060
- in polygenic hypercholesterolemia, 98
- in primary hypercholesterolemia, 562
- High-density lipoprotein-cholesterol (HDL-C) in insulin resistance
- body composition and, 402, 404, 406
- and in hyperinsulinemia, Hb, Hct and, 832, 834
- SHBG, race and, in insulin-resistant women, 72
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM
- ACE gene polymorphism in, *see* High-density lipoprotein-cholesterol in NIDDM, ACE gene polymorphism in
- acipimox effects on, 252
- in elderly subjects, Pro-Z effects on, 42
- hemodynamic response to handgrip test and, 935, 936
- serum, insulin secretion, therapy mode and, 1394
- serum PON activity and, 599
- and SPA relationship to NIDDM complications, 703
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM, ACE gene polymorphism in
- in CHD, 1259, 1260
- I/D polymorphism in NIDDM and nondiabetics with metabolic syndrome, 624
- High-density lipoprotein₁, *see* Lipoprotein(a)
- High-density lipoprotein₂ (HDL₂)
- cardioprotective profile in HALP associated with increased levels of, and decreased HL activity, 965-973
- in NIDDM, effects of insulin versus sulfonylurea on, 641
- plasma, *see* Plasma high-density lipoprotein₂
- serum, menopausal status and exercise effect on, 378, 379
- see also* High-density lipoprotein₂-cholesterol
- High-density lipoprotein₂-cholesterol (HDL₂-C)
- CHD and, 276, 1119
- in familial HALP and HBLP, 1162
- in middle-aged obese hypertensive men, 1079
- High-density lipoprotein₃ (HDL₃)
- in NIDDM, effects of insulin versus sulfonylurea on, 641
- plasma, *see* Plasma high-density lipoprotein₃
- serum, menopausal status and exercise effect on, 378, 379
- see also* High-density lipoprotein₃-cholesterol
- High-density lipoprotein₃-cholesterol (HDL₃-C)
- CHD and, 276, 1119
- in familial HALP and HBLP, 1162
- High-fat (HF) diet
- effects of high-sucrose and, on body composition, 1354-1359
- race and effects of LF versus, on S, and serum leptin in women, 1520-1524
- see also* High-fat diet-induced diabetes mellitus and obesity
- High-fat (HF) diet-induced diabetes mellitus (DM) and obesity
- high-monounsaturated fat diet-induced NIDDM and obesity, 724-730
- reversal of, 1089-1096
- High-fat, high-cholesterol diet, extrahepatic sterol 27-hydroxylase activity and, 731-738
- High-fat, mineral-imbalanced diet, dietary Cr effects on insulin resistance induced by, 396-400
- High-fiber, low-fat diet, effects of exercise and, in subjects with multiple CV disease risk factors, 384-390
- High-fructose diet, pioglitazone effects on glucose metabolism and muscle and liver insulin uptake with, 1152-1155
- High-protein, carbohydrate-free diet, glucose contribution to synthesis of FAs and glyceride-glycerol with, 1217-1221
- High-sucrose diet, effects of HF diet and, on body composition, 1354-1359
- Histidine (His)
- endotoxin effects on, 683, 684
- in familial HALP and HBLP, 1164
- reduced energy intake effects on, in obese children, 1438
- in trauma, 226, 227
- Histopathological changes due to nephrectomy, 355-361
- HK (hypokinesia), daily Mg supplementation effects on Mg deficiency during prolonged, 903-907
- HL, *see* Hepatic lipase activity
- HMG-CoA (hydroxymethylglutaryl coenzyme A) reductase
- lovastatin as inhibitor of, for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565
- see also* Brain HMG-CoA reductase; Hepatic HMG-CoA reductase
- HNSCC (head and neck squamous cell carcinoma) cell lines, cytochrome P450-mediated RA oxidation by retinoids in, 955-958
- Homeostasis of neonatal glucose, 1239-1244
- Homoarginine, nephrectomy effects on, 358-359
- Homocysteine, *see* Plasma homocysteine
- Homocyst(e)ine (tHcy), fasting and postmethionine, correlated with

microalbuminuria and vascular damage in NIDDM and, 915-921

Homocystinuria, CBS deficiency in, 207-211

Homozygous familial hypercholesterolemia, *see* Apheresis, LDL, in FH

Hormone replacement therapy, *see* Combined hormone replacement therapy; Estrogen replacement therapy in postmenopausal women

Hot glucose minimal model, 490

HP228 (peptide), effects of, on diabetic neuropathy, 650-656

HPA (hypothalamic-pituitary-adrenal) axis in PCOS, 143-148

HR, *see* Heart rate

HRT (hormone replacement therapy), *see* Combined hormone replacement therapy; Estrogen replacement therapy in postmenopausal women

11 β -HSD1 (11 β -hydroxysteroid dehydrogenase 1) mRNA (messenger ribonucleic acid), hepatic, in pubertal hypothyroid male subjects, T₄ and T effects on activity of, 474-478

Human chorionic gonadotropin (HCG), T response to, in recessive Robinow syndrome, 1337-1343

Hydrochloric acid (HCl), effects of, on renal and hepatic N metabolism, 163-167

Hydrocortisone, *see* Cortisol

Hydrolysis, G6P and glycerol-P, in hypothalamus of obese subjects, 627-629

β -Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate

β (beta)-Hydroxybutyrate (BOHB)

- and ketosis resistance in offspring of protein-malnourished subjects, 1450-1454
- in PAM, 1265
- plasma, *see* Plasma β -hydroxybutyrate
- restricted caloric intake effects on, 430, 431
- see also* β -Hydroxybutyrate in IDDM; β -Hydroxybutyrate in NIDDM

β (beta)-Hydroxybutyrate (BOHB) in IDDM

- IGF-I effects on, in young IDDM adults, 34
- plasma, and insulin secretion and therapy mode associated with leptin and AT, 1394

β (beta)-Hydroxybutyrate (BOHB) in NIDDM

- blood and fasting, acipimox effects on, 253
- plasma, and insulin secretion and therapy mode associated with leptin and AT, 1394

7 α -Hydroxylase, *see* Cholesterol 7 α -hydroxylase mRNA

27-Hydroxylase, extrahepatic sterol, HCHF diet and activity of, 731-738

Hydroxylation, Phe, relationship between plasma AAA concentrations and, 669-674

Hydroxymethylglutaryl coenzyme A reductase, *see* HMG-CoA reductase

17-Hydroxyprogesterone in PCOS, opioid tone and, 159

11 β (beta)-Hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA (messenger ribonucleic acid), hepatic, T and T₄ effects on activity and, in pubertal hypothyroid male subjects, 474-478

25-Hydroxyvitamin D (25-OHD)

- in gout, 337
- levels of vitamin K and, in osteopenic older men, 195-199

Hyperalphalipoproteinemia (HALP)

- cardioprotective profile in, associated with increased levels of HDL₂ and decreased HL activity, 965-973
- familial, apo A-I and apo B synthesis in, 1160-1166

Hyperbetalipoproteinemia (HBLP), familial, apo A-I and apo B synthesis in, 1160-1166

Hypercholesterolemia

- apo E phenotype and, *see* Apolipoprotein E phenotype in hypercholesterolemia
- effects of diet inducing, on expression of RA, T₃, and glucocorticoid receptors, 301-308
- ERT effects on antibodies against oxidized LDLs in postmenopausal women with CHD and, 675-680

Hypercholesterolemia (*Continued*)

- familial, *see* Apheresis, LDL, in FH
- fat-modified diet effects on concentrations of serum phytosterols and serum C precursors in, 744-750
- and hypocholesterolemic effects of Cholazol H, 959-964
- polygenic, apo E genotype and cholesterogenesis in, 97-100
- primary, *see* Primary hypercholesterolemia

Hyperglucagonemia, dietary leucine kinetics and, 497-502

Hyperglycemia

- BMI and, associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in obese Jamaican women, 617-621
- chronic, effects of, on arterial LDL metabolism and atherosclerosis, in STZ-DM, 947-954
- effects of, on satiety, 321-324
- at IDDM onset, 1206

Hyperglycemic factor, *see* Glucagon

Hyperinsulinemia

- acute, *see* Acute hyperinsulinemia
- effects of, on satiety, 321-324
- insulin resistance and, *see* Hyperinsulinemia, insulin resistance and in NIDDM, *see* Non-insulin-dependent diabetes mellitus with hyperinsulinemia
- sex hormones and, in obese premenopausal women, 13-19; *see also* Testosterone in hyperinsulinemia

Hyperinsulinemia, insulin resistance and

- compensatory hyperinsulinemia in healthy non-obese subjects, Hb and Hct related to, 831-835
- in PCOS, opioid tone and, 158-162

Hyperlipidemia

- of preeclampsia, LDLs and VCAM-1 in, 1281-1288
- see also* Familial combined hyperlipidemia; Hyperalphalipoproteinemia; Hyperbetalipoproteinemia; Hypercholesterolemia; Hypertriglyceridemia

Hyperprolactinemia, bone loss due to estrogen deficiency and, 425-428

Hypertension

- borderline, stress and relationship of ACTH and cortisol to insulin and glucose in middle-aged men with, 1440-1449
- CAD, ACE genotype and, 622-624
- CHD and, *see* Hypertension, CHD and
- ET-1 in acute hyperinsulinemia and, treated with losartan, 292-296
- in hypercholesterolemia, *see* Hypertension in hypercholesterolemia in IDDM, CFA relationship to gender, microangiopathy, neuropathy and, 503-507
- with NIDDM, *see* Hypertension, NIDDM and
- obese middle-aged men with, effects of aerobic exercise and weight loss on glucose metabolism, Lps and, 1075-1082

S_i and, 493-496

Hypertension, CHD and

- Lp(a) level and, 183
- in NIDDM, ACE gene polymorphism and, 1259
- and role of TNF α in TG and glucose metabolism, 114

Hypertension, NIDDM and

- ACE gene polymorphism and, 1259, 120
- CFA relationship to gender, microangiopathy, neuropathy and, 503-507
- and long-term effects of perindopril on heart and metabolic parameters in, 1199-1204

Hypertension in hypercholesterolemia

- in primary hypercholesterolemia, 1099
- severe heterozygous FH, 864

Hyperthyroidism

- ³¹P MRS measuring metabolic efficiency of skeletal muscle in, 769-776
- total plasma Hcy in, 89-93

Hypertriglyceridemia

- fructose-induced, NO-1886 effects on, 149-153

Hypertriglyceridemia (*Continued*)
 GA3PDH in, 659-660
 production of small HDL particles in, with lipolysis stimulation, 234-242

Hyperuricemia, CHD and, 657-662

Hypocholesterolemic effects of Cholazol H, 959-964

Hypoglycemia
 muscle damage induced by, 1471-1476
 PKW mitogen effects on, 78
 recurrent, effects of, on cortisol response to ACTH in normal subjects, 1252-1259
 sex and adrenal catecholamine response to, 121-124

Hypokinesia (HK), daily Mg supplementation effects on Mg deficiency during prolonged, 903-907

Hypothalamic-pituitary-adrenal (HPA) axis in PCOS, 143-148

Hypothalamic-pituitary-testicular function, effects of methanol extract of Chansu on, 1211-1216

Hypothalamus
 activity of glucose-6-phosphatase in, in obesity, 627-629
 neonatal insulin treatment effects on, 857-858

Hypothyroidism
 hormonal regulation of 18S RNA, *Lep* mRNA, and leptin release in adipocytes in, 1455-1461
 total plasma HcY in, 89-93
see also Thyroxine in hypothyroidism

Hypoxanthine, *see* Plasma hypoxanthine; Urinary excretion, hypoxanthine

Hypoxia, retina IGF-I mRNA, IGF-IR mRNA, and IGFBP-2 and -3 mRNA in, 1331-1336

IAT, *see* Intraabdominal adipose tissue

ICAM-1 (intercellular adhesion molecules-1), endothelial cell, linoleic acid and TNF α effects on, 566-572

ICV (intracerebroventricular) leptin, effects of, on S_v and systemic glucose utilization in conscious subjects, 1274-1280

ICV (intracerebroventricular) methylatropine, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173

I/D (insertion/deletion) polymorphism of ACE gene, metabolic syndrome and electrocardiographic CAD in Pima Indians associated with, 622-626

IDDM, *see* Insulin-dependent diabetes mellitus

IDL, *see* Intermediate-density lipoprotein

IDL-C, *see* Intermediate-density lipoprotein-cholesterol

IGF, *see* Insulin-like growth factor(s)

IGFBPs, *see* Insulin-like growth factor-binding protein(s)

IGT, *see* Impaired glucose tolerance

IL, *see* Interleukin-6; Interleukin-8

Ile, *see* Isoleucine

IM (intramuscular) corticotropin 1-24 (ACTH 1-24), plasma cortisol response to, in healthy men, 1419-1422

Immune parameters at IDDM onset, 1205-1210

Immunoapheresis, *see* Apheresis, LDL, in FH

Immunoreactive vascular endothelial growth factor (IR-VEGF), plasma, smoking relation to concentration of, 27-30

Immunosuppression
 effects of, on renal and serum IGF-I, IGFBPs, and renal growth following unilateral nephrectomy, 817-823
 following whole pancreas-kidney transplantation in IDDM, 1326

Impaired glucose tolerance (IGT)
 insulin kinetics and action and muscle morphology in lean or slightly overweight subjects with, 848-854

Japanese subjects with, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 456-460
 in nondiabetic South Indians, CHD and, 230-233

Implantable central venous access devices in children with metabolic diseases, 900-902

Implementation of glucose minimal models with SAAM II, 490-492

Indomethacin
 effects of, on glucose production in falciparum malaria, 217-222
 preadipocyte differentiation and, 463

Inflammatory mediators
 of endothelial cells, linoleic acid and TNF α effects on, 566-572
see also Cytokines

Injury, *see* Trauma and injury

Inorganic phosphate (orthophosphate)
 blood, xylitol effects on, 741
 bucladesine sodium effects on, 1006-1007
 plasma, *see* Plasma inorganic phosphate

Input-output modeling, 1018-1019

Insertion/deletion (I/D) polymorphism of ACE gene, metabolic syndrome and electrocardiographic CAD in Pima Indians associated with, 622-626

Insulin
 arterial, *see* Arterial insulin
 breast milk and/or formula effects on, during development, 22
 bucladesine sodium effects on, 1006-1007
 E release induced by, 243-249
 effects of, on abundance of apobec-1 mRNA in hepatocytes, 869-873
 effects of, on 18S RNA content of adipocytes in hypothyroidic subjects, 1456-1458
 effects of GlcN and, on O-GlcNAc levels in muscle proteins, 449-455
 ET-1 inhibition of glucose uptake in adipocytes stimulated by, 1468-1471
 fasting, *see* Fasting insulin
 in GH deficiency, 1516
 GLUT4 recruitment to skeletal muscle cell surface stimulated by, dexamethasone effects on, 3-6
 glutamine uptake and release and, 716
 and HRT effects on plasma lipids and Lps, 1224
 kinetics and action of, and muscle morphology in lean or slightly overweight IGT subjects, 848-854
Lep mRNA and, *see*: *Lep* mRNA, insulin and, in STZ-DM long-term alcohol intake effects on, at puberty, 1269-1273
 in nondiabetic South Indians, 230-233
 in PAM, 1265
 in PCOS, 159, 988-992
 pioglitazone effects on liver and muscle uptake of, in subjects on high-fructose diet, 1152-1155
 PKW mitogen effects on, 76-77
 plasma, *see* Plasma insulin
 in recurrent hypoglycemia, 1254
 regulation of adipocyte LPL activity by, via Wortmannin- and rapamycin-sensitive pathways, 555-559
 restricted caloric intake effects on, 429-434
 serum, *see* Serum insulin
 syndrome X-like alterations due to neonatal treatment with, 855-862
 tetrahydrobiopterin synthesis-dependent vasodilation induced by, 1037-1039
 and TNF α in CHD, 116
 in young children of NIDDM parents, 1001
see also Hyperinsulinemia; Insulin, stress and; Insulin-dependent diabetes mellitus; Insulin receptor isoform mRNA; Insulin release and secretion; Insulin resistance; Insulin system, modeling of; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and entries beginning with terms: Insulin-like

Insulin, stress and
in obesity, 1385
stress and relationship of ACTH and cortisol to glucose and, in middle-aged men, 1440-1449

Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
insulin secretion and therapy mode association with serum leptin and AT in, 1391-1396
with and without microangiopathy, *see* Microangiopathy. IDDM with onset of, metabolic and immune parameters at, 1205-1210
plasma leptin in pregnant women with, 840-843
premenopausal and postmenopausal women with, DXA measuring body composition and AT distribution in, 212-216
regular insulin versus insulin Lispro effects on lipid metabolism in, 371-376
urinary ET-1 excretion in adolescents with, 1408-1412
whole pancreas-kidney transplantation for, proinsulin levels after, 1325-1330
young adults with, *see* Young adults with IDDM

Insulin-like growth factor(s) (IGF)
serum, in hepatic failure following LT, 200-206
see also entries beginning with terms: Insulin-like growth factor

Insulin-like growth factor-I (IGF-I)
abdominal obesity and, 1189, 1190
in children, 265, 310
GH and, *see* Growth hormone, IGF-I and
GH/IGF-I/IGFBP3 axis in prepubertal children with β -thalassemia and/or CSS, 541-548
in IDDM, *see* Insulin-like growth factor-I in young IDDM adults
mRNA of, in retina, hypoxia and, 1331-1336
pathway components of colon and small intestine, effects of dietary protein and TNF α on, in protein-depleted subjects, 345-350
plasma, diet and, 1107
renal, effects of immunosuppression on, following unilateral nephrectomy, and RMR in healthy adults, 1135, 1136
serum, *see* Serum insulin-like growth factor-I

Insulin-like growth factor-I (IGF-I) in young IDDM adults
effects of, on insulin requirements due to GH pulsatility in, 31-38
effects of low-dose, on GH, S_i, and glucagon levels, 1481-1489

Insulin-like growth factor-I receptor (IGF-IR) mRNA (messenger ribonucleic acid) in retina, hypoxia and, 1331-1336

Insulin-like growth factor-II (IGF-II), and GH bioactivity in prepubertal obese children, 1490-1493

Insulin-like growth factor-III (IGF-III), and GH bioactivity in prepubertal obese children, 1490-1493

Insulin-like growth factor-binding protein(s) (IGFBPs)
renal, effects of immunosuppression on, following unilateral nephrectomy, 817-823
see also Serum insulin-like growth factor-binding proteins and specific insulin-like growth factor-binding proteins

Insulin-like growth factor-binding protein 1 (IGFBP-1), GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493

Insulin-like growth factor-binding protein 2 (IGFBP-2)
GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493
mRNA of, in retina, hypoxia and, 1331-1336

Insulin-like growth factor-binding protein 3 (IGFBP-3)
in CRF children, 265
dietary protein and TNF α effects on, in protein-depleted subjects, 346, 347
mRNA of, in retina, hypoxia and, 1331-1336
in prepubertal children, *see* Insulin-like growth factor-binding protein 3 in prepubertal children

Insulin-like growth factor-binding protein 3 (IGFBP-3) in prepubertal children
GH bioactivity, IGF-I, IGF-II and, in prepubertal obese children, 1490-1493
GH/IGF-I/IGFBP3 axis in prepubertal children with β -thalassemia and/or CSS, 541-548

Insulin-like growth factor-binding protein 4 (IGFBP-4), dietary protein and TNF effects on mRNA of, in protein-depleted subjects, 346, 347

Insulin Lispro, effects of regular insulin versus, on lipid metabolism in IDDM, 371-376

Insulin receptor (IR) isoform mRNA (messenger ribonucleic acid), liver and skeletal muscle, in NIDDM, 129-132

Insulin release and secretion
in IDDM, association of therapy mode and, with AT and serum leptin in, 1391-1396
modeling of, 1026
in NIDDM, *see* Insulin release and secretion in NIDDM
in obesity, vagus nerve control of, 1167-1173

Insulin release and secretion in NIDDM
association of therapy mode and, with AT and serum leptin in, 1391-1396
effects of stimulation with glucose and GLP-1 on, 1042-1047

Insulin resistance, 396-408
acute, due to alcohol-related diols, 1180-1186
body composition and, related to aging, CV disease risk factors and, 401-408
due to high-fat, mineral-imbalanced diet, dietary Cr effects on, 396-400
hyperinsulinemia and, *see* Hyperinsulinemia, insulin resistance and I/D polymorphism of ACE gene and, 623
leptin response to fasting in obesity with, 125-128
in nondiabetic FCH subjects, minimal model in study of, 509-513
in PCOS, 158-162, 940-946
race and, *see* Insulin resistance, race and
troglitazone effects on, *see* Troglitazone effects on insulin resistance
Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects with, 456-460
verapamil and captopril effects on glucose tolerance and insulin-action in, 982-987
in young children of NIDDM parents, 1000
see also Insulin sensitivity

Insulin resistance, race and
and relationship between Lps and, in nondiabetics, 1174-1179
SHBG and, in insulin-resistant women, 70-74

Insulin sensitivity (S_i)
body composition and, *see* Insulin sensitivity, body composition and effects of stearic and oleic acid diets on glucose tolerance and, in women, 529-534
hypertension and, 493-496
in IGT, insulin kinetics, muscle morphology and, 851
insulin action, fibrinolysis and, in nondiabetics and NIDDM with obesity, 1372-1375
leptin and, *see* Insulin sensitivity, leptin and
in young IDDM adults, low-dose IGF-I effects on, 1481-1489
see also Insulin resistance; Women, S_i in

Insulin sensitivity (S_i), body composition and
aging-related insulin resistance and, 402, 404, 406
relationship of plasma leptin to sex, puberty, EE and, in children, 309-312

Insulin sensitivity (S_i), leptin and
ICV leptin effects on, in conscious subjects, 1274-1280
race and effects of HF versus LF diets on serum leptin and insulin sensitivity in women, 1520-1524

Insulin signaling, model of, 1027-1033

Insulin system, modeling of, 1026-1035
 of glucose and insulin signaling, 1027-1033
 of insulin fluxes, 1026-1027

Insulinopenic non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), hyperinsulinemic and, in obese subjects, Lp alterations in, 1315-1324

Intercellular adhesion molecules-1 (ICAM-1), linoleic acid and TNF α effects on endothelial cell, 566-572

Interleukin-6 (IL-6), acute and delayed effects of single-dose, on thyroid function in healthy subjects, 1289-1293

Interleukin-8 (IL-8), linoleic acid and TNF α effects on endothelial cell, 566-572

Intermediate-density lipoprotein (IDL)
 fasting, in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-373
 HRT effects on, 1224
see also Intermediate-density lipoprotein-cholesterol

Intermediate-density lipoprotein-cholesterol (IDL-C)
 in familial HALP and HBLP, 1162
 insulin versus sulfonylurea therapy of NIDDM effects on, 641

Intestinal adaptation after small bowel resection, enteral OKG effects on, 1366-1371

Intestinal peptide, vasoactive, NO in PRL secretion stimulated by, in men, 897-899

Intraabdominal adipose tissue (IAT)
 insulin resistance and, 402, 404, 406
 and RMR in healthy adults, 1135, 1136

Intracerebroventricular (ICV) leptin, effects of, on S_i and systemic glucose utilization in conscious subjects, 1274-1280

Intracerebroventricular (ICV) methylatropine, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173

Intramuscular (IM) corticotropin 1-24 (ACTH 1-24), plasma cortisol response to, in healthy men, 1419-1422

Intravascular enzymes related to lipid transport, effects of menopausal status and exercise on, 377-383

Intravenous glucose tolerance test (IVGTT)
 in fructose-induced hypertriglyceridemia, 149-153
 in glucose and insulin signaling modeling, 1028-1031
 measuring glucose effectiveness in endurance-trained subjects, 190-194, 874-877
 worsening of, in healthy subjects independently of obesity, 313-320

IR (insulin receptor) isoform mRNA (messenger ribonucleic acid), liver and skeletal muscle, in NIDDM, 129-132

59Iron (⁵⁹Fe), vanadate and uptake of, in adipocytes, 630-636

IR-VEGF (immunoreactive vascular endothelial growth factor), plasma, smoking relation to concentration of, 27-30

Ischemia, retinal, followed by recirculation, effects of, on retinal GSH levels in STZ-DM, 269-272

Isobutyrylglycine in ethylmalonic encephalopathy, 837

Isoleucine (Ile)
 abnormal metabolism of, in ethylmalonic encephalopathy, 836-839
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227

Isomerase, protein disulfide, activity of, during fasting and refeeding, protein contents and, 1083-1088

Isometric exercise, effects of parasympathetic dysfunction and hyperinsulinemia in NIDDM on hemodynamic response to, 934-939

Isovalerylglycine in ethylmalonic encephalopathy, 837

IVGTT, *see* Intravenous glucose tolerance test

Jamaican women, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621

Japanese subjects
 G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene as risk factor for CAD in Japanese men, 177-181
 with NIDDM, *see* Japanese subjects with NIDDM
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects

Japanese subjects with NIDDM
 IGT, and insulin resistance, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 456-460
 platelet 12-LOX in, 257-263

K (potassium)
 dietary, *see* Dietary K
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in hypoglycemia, 1472
 plasma, effects of lipolysis inhibition on, 1465
 serum, in Graves' disease, 1195

Keshan disease (KD), effects of selenium and vitamin E on beta cell alterations induced by, 415-419

Ketimine, cystathione, in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238

Ketoconazole, RA catabolism inhibited by, 956

α (alpha)-Ketoglutarate, enteral ornithine, effects of, on intestinal adaptation after small bowel resection, 1366-1371

α (alpha)-Keto- δ -guanidinovaleic acid (α -keto- δ -GVA), plasma and urine, nephrectomy effects on, 358-359

Ketones
 effects of restricted caloric intake on, in men and women, 429-434
see also Ketones in IDDM and NIDDM, leptin and *and specific ketones; for example: β -Hydroxybutyrate*

Ketones in IDDM and NIDDM, leptin and plasma total, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 serum leptin correlation with, 1392

Ketonuria at IDDM onset, 1206

6-Keto-prostaglandin F_{1 α} (PGF_{1 α}), and SPA relationship to NIDDM complications, 703

Ketosis resistance in offspring of protein-malnourished subjects, 1450-1454

Kidney
 activity and content of PDI in, during fasting and refeeding, 1084-1085
 of D,L-propargylglycine-treated subjects, cystathione, cystathione ketamine, NAC-cyste, and PHTZDC in, 1233-1238
 proinsulin levels after whole pancreas-kidney transplantation, 1325-1330
see also entries beginning with term: Renal and element: Neph-

Kinase
 mitogen-activated protein, NIDDM effects on, 56
 serum creatine, in hypoglycemia, 1471-1476
see also Phosphokinase

Kinetic homogeneity in compartmental modeling, defined, 1012

Kinetics
 E, 245-246
 glucose, in NIDDM, effects of dietary protein restriction on, on, 1148
 glutamine, in active celiac disease, whole-body protein metabolism assessed by, 1429-1433
 of hepatic AA transport activation in burn injury, 611
 insulin, and muscle morphology in lean or slightly overweight IGT subjects, 848-854

leucine, *see* Kinetics, leucine
 palmitate, OC effects on, 282

Phe and tyrosine, 670-671
see also Tracer kinetics

Kinetics, leucine
 in active celiac disease, whole-body protein metabolism assessed by, 1429-1433
 dietary leucine, hyperglucagonemia and kinetics of, 497-502
 dietary protein restriction effects on, in NIDDM, 1147
 hyperglucagonemia and, 497-502
 Kuwaiti children, obese and non-obese, serum lipids and BP associated with fasting insulin levels in, 420-424

Lactate
 breast milk and/or formula effects on, during development, 22 in PAM, 1265
 PKW mitogen effects on, 76-77
 plasma, *see* Plasma lactate
 Tolrestat and levels of, 1426

Lactate dehydrogenase (LDH)
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in Keshan disease, vitamin E and selenium effects on, 416, 417
 in LT recipients, 201
 serum, in hypoglycemia, 1471-1476

Lactic acid
 glucagon effects on concentrations of, 696, 697
 xylitol effects on, 741, 742

Laminin, serum, in IDDM with and without microangiopathy, levels and molecular size of, 63-69

Late pregnancy, physiological FPG reduction in, 1142-1444

Lathosterol, relationship of, to apo E phenotype in hypercholesterol emia, 747

Lauric acid in diet regulating apo B-containing Lps, 884

LCAC (long-chain acyl coenzyme A), effects of FFA elevation on, 1122-1123

LCAT, *see* Lecithin:cholesterol acyltransferase

LCPUFAs (long-chain polyunsaturated fatty acids), skeletal muscle membrane, in young children, factors affecting, 106-112

LDH, *see* Lactate dehydrogenase

LDL, *see* Low-density lipoprotein

LDL-C, *see* Low-density lipoprotein-cholesterol

Lean body mass, *see* Fat-free mass

Lean subjects, *see* Non-obese subjects

Learning, abnormal cholesterol synthesis and retarded, 878-882

Lecithin:cholesterol acyltransferase (LCAT)
 GH levels correlated with, 340-342
 HRT effects on, 1224
 menopausal status and exercise effects on, 378, 379
 plasma, effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888
 and short-term estrogen-progestin replacement therapy in postmenopausal women, 297-300

Lep gene (*ob* gene)
 effects of enterohepatic circulation manipulation and bile acid composition on regulation of, 285-291
 expression of, *see*: Lep mRNA

Lep mRNA (messenger ribonucleic acid)
 effects of enterohepatic circulation manipulation and bile acid composition on, 285-291
 effects of fasting, sex, and GH therapy on serum leptin and, in GH-deficient and healthy adults, 1514-1519
 hormonal regulation of, in adipocytes of hypothyroidic subjects, 1455-1461
see also: Lep mRNA, insulin and, in STZ-DM

Lep mRNA (messenger ribonucleic acid), insulin and, in STZ-DM
 food intake and insulin-dependent increase of, 603-607
 in insulin-treated and untreated STZ-DM and in nondiabetics, 594-591

Leptin
 expression of receptor isoforms of, in AT, 844-847; *see also* Adipose tissue
 response of, to fasting by obese insulin-resistant subjects, 125-128; *see also* Obesity
see also Adipocytes, leptin and; Glucose, leptin effects on; Lep gene; Leptin, GH and; Plasma leptin; Serum leptin

Leptin, GH and
 effects of fasting, sex, and GH therapy on Lep mRNA in GH-deficient and healthy adults, 1514-1519
 GH and prednisolone effects on EE and leptin levels, 83-88
 GH status, leptin levels, and RMR in normal subjects, 1134-1139
 in spontaneous and GHRH-stimulated GH secretion, serum insulin but not leptin associated with, in normal subjects with and without weight loss, 1127-1133

Leucine (Leu)
 endotoxin and metabolism of, in liver, 681-685
 in familial HALP and HBLP, 1164
 and G effects on glutamine uptake and release, 717, 719, 720
 kinetics of, *see* Kinetics, leucine
 plasma, *see* Plasma leucine
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227
¹³C]Leucine (Leu), GC/MS of, 708-709

Levothyroxine therapy following total thyroidectomy for Graves' disease, Na⁺,K⁺ ATPase activity in RBCs of women on, 1194-1198

Leydig cell tumors, cachexia associated with, NO-1886 effects on, 101-105

LF, *see entries beginning with terms*: Low-fat

LH, *see* Luteinizing hormone

O-Linked N-acetyl-glucosamine (*O*-GlcNAc), insulin and GLcN effects on level of, in muscle proteins, 449-455

Linoleate, effects of, on pancreatic islets following reoxygenation injury, 810-811

Linoleic acid
 in diet regulating apo B-containing Lps, 884
 effects of, on endothelial cell inflammatory mediators, 566-572
 effects of, on pancreatic islets following reoxygenation injury, 810
 in fat-modified diet for hypercholesterolemia, 745, 748

Lipase, *see* Hepatic lipase activity; Lipoprotein lipase activity

Lipids
 fasting, *see* Fasting lipids
 hepatic, effects of hypercholesterolemia-inducing diet on, 304
 in IDDM, effects of regular insulin versus insulin Lispro on metabolism of, 371-376
 in insulin-resistant women, SHBG, race and, 72
 LDL receptors and metabolism of, in NIDDM with obesity, 1070-1074
 muscle, effects of elevated FFAs on synthesis of, 1121-1126
 oxidation of, during exercise, 779, 780
 plasma, *see* Plasma lipids
 in post-small bowel resection enteral diet, 1367
 PP, *see* Postprandial lipids
 serum, *see* Serum lipids
see also Hyperlipidemia; Phospholipids *entries with element*: Lip- and specific lipids

Lipolysis
 adipocyte, and adrenoceptor binding in obese postmenopausal women, AT distribution and, 467-473
 effects of inhibition of, on β_1 -adrenoceptor-mediated thermogenesis in men, 1462-1467
 stimulation of, in hypertriglyceridemia, production of small HDL particles and, 234-242

Lipoperoxide in STZ-DM, gliclazide effects on, 978

Lipopolysaccharide (LPS), gliclazide effects serum TNF α activity enhanced by, in STZ-DM, 978-979

Lipoprotein (Lp)
 aerobic exercise and weight loss effects on glucose metabolism, BP and, in obese hypertensive middle-aged men, 1075-1082
 apo E phenotype and response of, to lovastatin or gemfibrozil for primary hypercholesterolemia, 560-565
 apo B-containing, regulation of, by vitamin C level and dietary fat saturation, 883-891
 in NIDDM, *see* Lipoprotein in NIDDM
 plasma, *see* Plasma lipoprotein
 race and relationship between insulin resistance and, in 1174-1179
 TG-rich, smoking, GPIIIa gene and, 1040-1041
see also High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein A-I; Lipoprotein A-I:A-II; Lipoprotein lipase activity; Low-density lipoprotein and specific apolipoproteins

Lipoprotein (Lp) in NIDDM
 alterations of, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1315-1324
 insulin versus sulfonylurea effects on, 641

Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in CHD, Lp(a) level and, 182-184, 276
 in insulin resistance, *see* Lipoprotein(a) in insulin resistance
 LDL apheresis and, *see* Lipoprotein(a) in FH, LDL apheresis and in NIDDM, acipimox effects on, 252
 plasma, niacin versus Niaspan effects on, in primary hypercholesterolemia, 1100
 serum, menopausal status and exercise effects on, 378, 379
 weight loss with meat-based or plant-based diet effects on, 1311

Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in FH, LDL apheresis and
 Lp(a) reduction with, 1058-1064
 in severe FH, 865

Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in insulin resistance
 body composition, 402, 404, 406
 effects of stearic and oleic acid diets on, 532
 SHBG, race and, in insulin-resistant women, 72

Lipoprotein A-I (LpA-I)
 plasma, in HALP, 968-970
 serum, race and distribution of, in children, 757-763

Lipoprotein A-I:A-II (LpA-I:A-II)
 plasma, in HALP, 968-970
 serum, race and distribution of, in children, 757-763

Lipoprotein lipase (LPL) activity
 activator of, *see* NO-1886
 in adipocytes, *see* Lipoprotein lipase activity in adipocytes
 ERT effects on, 676-677
 GH levels in women correlated with, 340-342
 in HALP, 969
 menopausal status and exercise effect on, 378, 379
 postheparin plasma, in IDDM, effects of insulin Lispro versus regular insulin on, 373

Lipoprotein lipase (LPL) activity in adipocytes
 AT distribution and, 469
 insulin regulation via Wortmannin-and rapamycin-sensitive pathways and, 555-559

Lipoxygenase (LOX), LOX pathway of arachidonic acid metabolites in preadipocyte differentiation regulation, 461-466

12-Lipoxygenase (LOX), platelet, in Japanese NIDDM subjects, 257-263

Lispro, effects of regular insulin versus, on lipid metabolism in IDDM, 371-376

Liver
 activity and content of PDI in, during fasting and refeeding, 1084-1085
 endotoxin and leucine metabolism in, 681-685
 3-FDG uptake by, enhanced by exercise, 44-49
 in NIDDM, IR isoform mRNA in, 129-132
 pioglitazone effects on insulin uptake by, in subjects on high-fructose diet, 1152-1155
 of D,L-propargylglycine-treated subjects, cystathione, cystathione ketamine, NAc-cyste, and PHTZDC in, 1233-1238
see also Liver transplantation; Organ weight, liver and entries beginning with term: Enterohepatic and element: Hepat-

Liver transplantation (LT), hepatic failure following, serum IGFs and IGFBPs in, 200-206

Long-chain acyl coenzyme A (LCAC), effects of FFA elevation on, 1122-1123

Long-chain polyunsaturated fatty acids (LCPUFAs), skeletal muscle membrane, in young children, 106-112

Long-term effects
 of alcohol intake on food intake, BW, plasma leptin, corticosterone, and insulin levels at puberty, 1269-1273
 of LDL apheresis on plasma Lps and CHD in native vessels and coronary bypass in severe heterozygous FH, 863-868
 of perindopril on metabolic parameters and heart in NIDDM with hypertension, 1199-1204

Losartan
 ET-1 in acute hyperinsulinemia and hypertension treated with, 292-296
 OT and AVP responses to, in men, 893-896

Lovastatin for primary hypercholesterolemia, apo E phenotype and Lp response to, 560-565

Low-density lipoprotein (LDL; β -lipoprotein)
 arterial, chronic hyperglycemia effects on atherosclerosis and metabolism of, in STZ-DM, 947-954
 BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
 in IDDM, *see* Low-density lipoprotein in IDDM
 in men with abdominal obesity, 1189, 1197
 in obese women, *see* Low-density lipoprotein in obese women
 in postmenopausal women, *see* Low-density lipoprotein in postmenopausal women
 race and, of nondiabetics, relationship between insulin resistance and, 1176, 1177
 serum, in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 and serum uric acid levels in non-obese premenopausal women, 437, 438
 VCAM-1 and, in hyperlipidemia of preeclampsia, 1281-1288
see also Apheresis, LDL, in FH; Apolipoprotein B, LDL; Hyperbeta-proteinemia; Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor(s); Very-low-density lipoprotein

Low-density lipoprotein (LDL; β -lipoprotein) in IDDM
 fasting, insulin Lispro and regular insulin effects on metabolism of, 372-373
 urinary ET-1 and, 1409

Low-density lipoprotein (LDL; β -lipoprotein) in obese women, 470
 effects of weight loss with meat-based or plant-based diet, 1310

Low-density lipoprotein (LDL; β -lipoprotein) in postmenopausal women
 hypercholesterolemic with CHD, effects of ERT on antibodies against oxidized LDLs in, 675-680
 in non-obese women, 437, 438
 in obese women, 470

Low-density lipoprotein (LDL; β -lipoprotein) receptor(s)
 function of, in lipid metabolism of NIDDM patients, obesity and, 1070-1074
see also Low-density lipoprotein receptor mRNA

Low-density lipoprotein (LDL; β -lipoprotein) receptor mRNA (messenger ribonucleic acid)
 amiodarone effects on, 1052-1057
 breast milk and formula effects on hepatic HMG-CoA and C7H mRNA but not on, during development, 20-26

Low-density lipoprotein-cholesterol (LDL-C)
 in adolescent males, racial differences in, 516
 CHD and, *see* Low-density lipoprotein-cholesterol, CHD and effects of stearic and oleic acid diets on, 532
 in familial HALP and HBLP, 1162, 1163
 in FCH, 509
 GH levels in women correlated with, 340-342
 HCHF diet effects on, 733
 in hypercholesterolemia, *see* Low-density lipoprotein-cholesterol in hypercholesterolemia
 in insulin resistance, *see* Low-density lipoprotein-cholesterol in insulin resistance
 in middle-aged obese hypertensive men, 1079
 in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
 in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 plasma, *see* Plasma low-density lipoprotein-cholesterol
 serum, *see* Serum low-density lipoprotein-cholesterol
 sex hormones effects on, 392
 short-term tall oil phytosterol administration effects on, 753-754
 in very old syndrome X subjects, 536, 537
 in young children of NIDDM parents, 999
see also Very-low-density lipoprotein-cholesterol

Low-density lipoprotein-cholesterol (LDL-C), CHD and ACE gene polymorphism with, in NIDDM, 1259, 1260
 in exercising postmenopausal women, 1119
 Lp(a) level and, 276
 as risk factor, 114
see also Very-low-density lipoprotein-cholesterol in CHD

Low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia
 fat-modified diet effects on, 745
 in FH, LDL apheresis effects on, 865, 1060
 in polygenic hypercholesterolemia, 98
 in primary hypercholesterolemia, 562

Low-density lipoprotein-cholesterol (LDL-C) in insulin resistance
 body composition and, related to aging, CV disease risk factors and, 402, 404, 406
 SHBG, race and, in insulin-resistant women, 72

Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
 CHD and, 1259, 1260
 in elderly NIDDM subjects, Pro-Z effects on, 42
 insulin versus sulfonylurea therapy effects on, 641
 metabolic syndrome, I/D polymorphism of ACE gene and, 624
 serum PON activity and, 599

Low-dose insulin-like growth factor-I (IGF-I) in young IDDM adults, effects of, on GH, S_i, and glucagon levels, 1481-1489

Low-fat (LF) diet
 race and effects of HF versus, on S_i and serum leptin in women, 1520-1524
 reversal of HF diet-induced obesity and DM with, 1089-1096

Low-fat, high-fiber diet, effects of exercise and, in subjects with multiple CV disease risk factors, 384-390

Low glycemic diet, effects of, on risk factors for CHD, in women, 1245-1251

LOX, *see* Lipoxygenase; 12-Lipoxygenase

Lp, *see* Lipoprotein

Lp(a), *see* Lipoprotein(a)

LpA-I, *see* Lipoprotein A-I

LpA-I:A-II, *see* Lipoprotein A-I:A-II

LPL, *see* Lipoprotein lipase activity

LPS (lipopolysaccharide), gliclazide effects on serum TNF α activity enhanced by, in STZ-DM, 978-979

LT (liver transplantation), hepatic failure following, serum IGFs and IGFBPs in, 200-206

Luteinizing hormone (LH)
 Chansu effects on, 1213, 1214
 in PCOS, 159, 941
 in recessive Robinow syndrome, 1337-1343

Lymphocytes, 27-hydroxycholesterol effects on cholesterol synthesis in, 734

Lysine (Lys)
 in diet regulating small intestinal cell turnover, 1106
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 reduced energy intake effects on, in obese children, 1438
 in trauma, 226, 227

β_2 -M, *see* β_2 -Microglobulin

Magnesium, *see* Mg

Magnetic resonance spectroscopy (MRS), 31 P, metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776

Malaria, falciparum, indomethacin effects on glucose production in, 217-222

Male subjects, *see* Adolescents; Men; Sex

Malic enzyme (ME), hypercholesterolemia-inducing diet effects on, 306

Maltodextrin in obesity- and DM-inducing diet, 1090

MAPK (mitogen-activated protein kinase), NIDDM effects on, 56

Mass spectrometry/gas chromatography (MS/GC) of metabolic tracers, 706-712

ME (malic enzyme), hypercholesterolemia-inducing diet effects on, 306

Measurement equations in compartmental modeling, 1015

Meat-based diet, weight loss with plant-based diet or, by obese women, effects of, on SAC, plasma lipids, BP, and plasma leptin, compared, 1308-1314

Medroxyprogesterone (MPA), effects of, in hypercholesterolemic postmenopausal women on ERT, 677

Melatonin (MEL), naloxone effects on GH response to pyridostigmine and, in men, 814-818

Men
 adolescent, *see* Adolescents
 β_1 -adrenoceptor-mediated thermogenesis in, effects of lipolysis inhibition on, 1462-1467
 exercising, *see* Men, exercising
 GH therapy suppressing cortisol production in, 1376-1378
 hyperglucagonemia and dietary leucine kinetics in, 497-502
 Japanese, G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene as risk factor for CAD in, 177-181
 middle-aged, *see* Middle-aged men
 naloxone effects on GH response to melatonin and pyridostigmine in, 814-818

NO in VIP-stimulated PRL secretion in, 897-899

non-obese, *see* Non-obese subjects

OT and AVP responses to angiotensin II type 1 receptor antagonist in, 893-896

plasma cortisol response to IM ACTH 1-24 in, 1419-1422

restricted caloric intake effects on serum leptin, insulin, cortisol, glucose, ketones, and NEFAs in, 429-434

Men (Continued)
see also Men, exercising; Men, obese; Men, older; Normal subjects; Sex and specific conditions

Men, exercising
 middle-aged obese hypertensive, effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in, 1075-1082
see also Exercise

Men, obese
 with abdominal obesity related to anxiety and depression, endocrine and metabolic aberrations in, 1187-1193
 middle-aged hypertensive, effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in, 1075-1082
 VAT accumulation effects on uric acid metabolism in, 929-933
see also Obesity

Men, older
 osteopenic, vitamin K and 25-OHD levels in, 195-199
 relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in very old men with syndrome X, 535-540

Menaquinone-7 (MK-7), levels of vitamin K and, in osteopenic older men, 195-199

Menopausal status
 effects of exercise and, on serum lipids and activities of intravascular enzymes related to lipid transport, 377-383
see also Postmenopausal women; Premenopausal women

Messenger ribonucleic acid, *see* mRNA

Metabolic diseases and aberrations
 children with, implantable central venous access devices in, 900-902
 in men with abdominal obesity related to anxiety and depression, 1187-1193
see also specific conditions

Metabolic parameters
 long-term effects of perindopril in NIDDM with hypertension on, 1199-1204
 at onset of IDDM, 1205-1210
 relationship between fasting plasma insulin, anthropometrics and, in very old syndrome X subjects, 535-540

Metabolic rate
 in NIDDM, BW and, 1146-1147
see also Resting metabolic rate

Metabolic syndrome (syndrome X)
 electrocardiographic CAD and, in Pima Indians, associated with ACE gene polymorphism and plasma ACE levels, 622-626
 syndrome X-like alterations due to neonatal insulin treatment, 855-862
 in very old subjects, 535-540

Metabolic tracers, *see* Tracer(s)

Methanol extract of Chansu, effects of, on hypothalamic-pituitary-testicular function, 1211-1216

Methionine (Met)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 microalbuminuria and vascular damage in NIDDM correlated with postmethionine load tHcy, 915-921
 plasma, *see* Plasma methionine
 in trauma, 226, 227

DL-Methionine (Met)
 in high-monounsaturated fat diet, 725
 in obesity- and DM-inducing diet, 1090

Methyldatropine, ICV, effects of, on vagus nerve-mediated control of insulin secretion in obesity, 1169-1173

Methylenetetrahydrofolate reductase (MTHFR) gene mutation, plasma Hcy levels related to folate status and, in healthy subjects, 1413-1418

Methylguanidine (MG), nephrectomy effects on, 358-359

Methylsuccinic acid (MSA), abnormal isoleucine metabolism and elevated EMA and, in ethylmalonic encephalopathy, 836-839

Mevalonic acid (MVA), urinary excretion of, in polygenic hypercholesterolemia, 98

MG (methylguanidine), nephrectomy effects on, 358-359

Mg (magnesium)
 deficiency of, during prolonged restriction of motor activity, daily Mg supplementation effects on, 903-907
 dietary, in post-small bowel resection enteral diet, 1367
 in elderly NIDDM subjects, Pro-Z effects on, 41

Microalbuminuria, vascular damage and, in NIDDM, fasting and postmethionine tHcy correlated with, 915-921

Microangiopathy
 in NIDDM, CFA relationship to gender, hypertension, neuropathy and, 503-507
see also Microangiopathy, IDDM with

Microangiopathy, IDDM with
 CFA relationship to gender, hypertension, neuropathy and, 503-507
 and without microangiopathy, levels and molecular size of serum laminin in, 63-69

β_2 (beta₂)-Microglobulin
 in NIDDM, 363
 urinary excretion of, in newborns, 1345

Middle-aged men
 effects of aerobic exercise and weight loss on BP, glucose metabolism, and Lps in obese hypertensive, 1075-1082
 stress and relationship of ACTH and cortisol to insulin and glucose in, 1440-1449

Mild hyperprolactinemia, bone loss due to estrogen deficiency and, 426

Milk
 skim, in diet regulating small intestinal cell turnover, 1106
see also Breast milk

Minerals
 in diet regulating small intestinal cell turnover, 1106
 in HF diet, *see* Minerals in HF diet
 mix of, in regulation of apo B-containing Lps, 884
see also Bone mineral content; Bone mineral density and specific minerals

Minerals in HF diet
 high-fat, mineral imbalanced diet, dietary Cr effects on insulin resistance induced by, 396-400
 high-monounsaturated fat diet, 725

Minimal model analysis
 of FCH in nondiabetics with insulin resistance, 509-513
 of glucose, 490-492, 875

Mitogen
 PK activated by, NIDDM effects on, 56
 PKW, metabolic effects of, 75-82

MK-7 (menaquinone-7), levels of vitamin K and, in osteopenic older men, 195-199

MNCs (mononuclear cells), cortisol effects on generation of free radicals by, 788-791

MNCV (motor nerve conduction velocity) in STZ-DM, gliclazide effects on, 979

Model, systems, *see* Systems model

Molasses in diet regulating small intestinal cell turnover, 1106

Molecular size of serum laminin in IDDM with and without microangiopathy, 63-69

N-Monoacetylcystathione (NAc-cysta) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238

Mononuclear cells (MNCs), cortisol effects on generation of free radicals by, 788-791

Monophosphate, *see* cAMP

Monounsaturated fat diet, obesity and NIDDM induced by high-, 724-730

Monounsaturated fatty acids (MUFA)
 effects of exercise and, on PAI-1 activity, 385
 in skeletal muscle membrane PLs of young children, 108, 109
 in stearic and oleic acid diets, 531

Morning pulsatile corticotropin (ACTH), release of cortisol and, in PCOS, 143-148

Morphology
 of beta cells in Keshan disease, vitamin E and selenium effects on, 416-417
 insulin kinetics and muscle, in lean or slightly overweight IGT subjects, 848-854

Motor activity, daily Mg supplementation effects on Mg deficiency during prolonged restriction of, 903-907

Motor nerve conduction velocity (MNCV) in STZ-DM, gliclazide effects on, 979

MPA (medroxyprogesterone), effects of, in hypercholesterolemic post-menopausal women on ERT, 677

mRNA (messenger ribonucleic acid)
 apobec-1, insulin effects on abundance of, in hepatocytes, 869-873
 C7H, *see* Cholesterol 7 α -hydroxylase mRNA
 hepatic HMG-CoA reductase, *see* Hepatic HMG-CoA reductase mRNA
 hepatic 11 β -HSD1, in pubertal hypothyroid male subjects, T₄ and T effects on, 474-478
 IGF-I, IGF-IR, IGFBP-2 and -3, in retina, hypoxia and, 1331-1336
 IGFBP-4, effects of dietary protein and TNF on, in protein-depleted subjects, 346, 347

LDL receptor, *see* Low-density lipoprotein receptor mRNA

Lep, *see: Lep mRNA*
 leptin receptor isoform, in AT, 844-847
 in NIDDM, liver and skeletal muscle IR isoform in, 129-132

PPAR γ , in SAT and VAT, 1494-1498
 of RA, glucocorticoid, and T₃ receptors, hypercholesterolemia-inducing diet effects on, 301-308
 splice variant of pituitary adenoma GHRH receptor, inhibiting signal transduction, 804-808

MRS (magnetic resonance spectroscopy), ^{31}P , metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776

MSA (methylsuccinic acid), abnormal isoleucine metabolism and elevated EMA and, in ethylmalonic encephalopathy, 836-839

MS/GC (mass spectrometry/gas chromatography) of metabolic tracers, 706-712

MTHFR (methylenetetrahydrofolate reductase) gene mutation, plasma Hcy levels related to folate status and, in healthy subjects, 1413-1418

MTS (tetrazolium salt; 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfonylphenyl]-2H-tetrazolium, inner salt), metabolic activation of beta cells and, 824-830

Mucosal colonocyte brush-border enzymes, rectosigmoid, SCFA effects on, 133-134

MUFAs, *see* Monounsaturated fatty acids

Multicompartment model
 in apo E metabolism study, 922-928
 of LDL apo B kinetics, 487-488

Multiple cardiovascular (CV) disease risk factors, effects of low-fat, high-fiber diet and exercise in subjects with, 384-390

Multiple tracer dilution technique in modeling of regional glucose fluxes in steady-state, 1021-1022

Muscle
 exercise and glucose disposal by, 44-49
 FFA elevation effects on lipids in, 1121-1126
 hypoglycemia-induced damage to, 1471-1476
 insulin kinetics and action and morphology of, in lean or slightly overweight IGT subjects, 848-854

Muscle (Continued)
 pioglitazone effects on insulin uptake by, in subjects on high-fructose diet, 1152-1155
 trauma effects on AAs in, 226, 227
see also Muscle glycogen; Skeletal muscle; Smooth muscle cells

Muscle glycogen
 FFA elevation effects on synthesis of, 1121-1126
 muscle glucose conversion to, following exercise, 409-414

Mutation
 G⁹⁹⁴ → T missense, of PAF acetylhydrolase gene, as risk factor for CAD in Japanese men, 177-181

MTHFR gene, plasma Hcy levels related to folate status and, in healthy subjects, 1413-1418
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene; Trp 64 Arg polymorphism of β_3 -adrenoceptor gene

MVA (mevalonic acid), urinary excretion of, in polygenic hypercholesterolemia, 98

Myristic acid in regulation of apo B-containing Lps, 884
 [9,10- $^3\text{H}]$ Myristic acid in ethylmalonic encephalopathy, 837

N (nitrogen)
 excretion of, by injured subjects, spermidine effects on, 224
 hepatic and renal, HCl effects on metabolism of, 163-167
 urea, *see* Urea nitrogen

Na (sodium)
 bucladesine sodium effects on, 1006-1007
 in elderly NIDDM subjects, Pro-Z effects on, 42
 in hypoglycemia, 1472
 in post-small bowel resection enteral diet, 1367
 serum, in Graves' disease, 1195
 very-low-calorie diet effects on balance of, in obesity, 593
see also Na⁺, K⁺ ATPase and entries beginning with term: Natriuretic Na⁺, K⁺ ATPase (sodium/potassium adenosine triphosphatase), activity of, in RBCs of women on levothyroxine therapy following total thyroidectomy for Graves' disease, 1194-1198

NAc-cysta (N-monoacetyl cystathione) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238

NaCl (salt) in obesity- and DM-inducing diet, 1090

NADH-cytochrome C reductase in ethylmalonic encephalopathy, 837

NAG, *see* N-Acetyl- β -glucosaminidase

NaHCO₃ (sodium bicarbonate) in obesity- and DM-inducing diet, 1090

Naloxone, effects of, on GH response to melatonin and pyridostigmine in men, 814-818

Native vessels, long-term effects of LDL apheresis on plasma Lps and CHD in coronary bypass and, in severe heterozygous FH, 863-868

Natriuretic factor, atrial, very-low-calorie diet effects on, in obesity, 592-597

Natriuretic peptide, plasma brain, very-low-calorie diet effects on, in obesity, 592-597

NE, *see* Norepinephrine

NEFAs (nonesterified fatty acids), *see* Free fatty acids

Negative portal venous and hepatic glucose gradients, effects of, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302

Neonatal glucose homeostasis, 1239-1244

Neonatal insulin treatment, syndrome X-like alterations due to, 855-862

Nephrectomy
 biochemical changes due to, 355-361
 unilateral, effects of immunosuppression on renal and serum IGF-I, IGFBPs, and renal growth following, 817-823

Nephropathy
 diabetic, SPA relationship to, 702

Nephropathy (*Continued*)
 with IDDM and NIDDM, and insulin secretion and therapy mode associated with leptin and AT, 1394

Nervous system, autonomic, GH and prednisolone effects on, 84-85

Neural tissue, DOPA synthesis in, effects of tyrosine-deficient TPN on, 168-176

Neuropathy, *see* Diabetic neuropathy

Newborns
 of protein-malnourished subjects, ketosis resistance in, 1450-1454
 urinary aquaporin-2 excretion and renal water channel expression in, 1344-1347
see also entries with term: Neonatal

NF- κ B (nuclear factor- κ B), linoleic acid and TNF α effects on endothelial cell, 566-572

Niacin, plain niacin versus time-release, for primary hypercholesterolemia, compared, 1097-1104

Niaspan (time-release niacin), plain niacin versus, for primary hypercholesterolemia, compared, 1097-1104

Nicotine, *see* Smoking

NIDDM, *see* Non-insulin-dependent diabetes mellitus

Nighttime pulsatile corticotropin (ACTH), release of cortisol and, in PCOS, 143-148

Nitric oxide (NO) in VIP-stimulated PRL secretion in men, 897-899

Nitric oxide synthase (NOS), insulin and production of, 1037-1039

Nitrogen, *see* N

NO (nitric oxide) in VIP-stimulated PRL secretion in men, 897-899

NO-1886
 effects of, on cachexia associated with Leydig cell tumors, 101-105
 effects of, on fructose-induced hypertriglyceridemia, 149-153

Noncholesterol sterols, relationship of, to apo E phenotype, 746, 747

Nondiabetic subjects
 blood and urine AGE products fluorescence assays in, 1348-1353
 with FCH, minimal model in study of, 509-513
 G effects of PP CHO metabolism in, 7-12
 I/D polymorphism of ACE gene associated with metabolic syndrome and electrocardiographic CAD in nondiabetic Pima Indians, 622-626
 laminin in, 64, 66
 plasma HcY concentrations in, regulated by acute hyperinsulinemia, 686-689
 plasma IR-VEGF in, 28
 plasma leptin in, *see* Nondiabetic subjects, plasma leptin in
 proinsulin in, *see* Nondiabetic subjects, proinsulin in
 race and relationship between insulin resistance and Lps in, 1174-1179
 serum PON activity in, 598-602

Nondiabetic subjects, plasma leptin in, 584-591
 in pregnant subjects, 840-843

Nondiabetic subjects, proinsulin in
 following whole pancreas-kidney transplantation in, 1325-1330
 insulin and proinsulin concentrations in nondiabetic Asian Indians, 230-233

Nonesterified fatty acids, *see* Free fatty acids

Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)
 ACE gene polymorphism with CHD in, 1258-1262
 aminoguanidine effects on role of AGE products in progression of, 1477-1480
 beta-cell function in, *see* Non-insulin-dependent diabetes mellitus, beta-cell function in
 family history of, *see* Family history of NIDDM
 fibrinolysis in, *see* Fibrinolysis in NIDDM
 glucose in, *see* Glucose in NIDDM
 high-monounsaturated fat diet-induced obesity and, 724-730

Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) (*Continued*)
 hyperinsulinemia and, *see* Non-insulin-dependent diabetes mellitus with hyperinsulinemia
 hypertension with, *see* Hypertension, NIDDM and insulin secretion in, *see* Insulin release and secretion in NIDDM
 insulin signaling in adipocytes in, 54-62
 Japanese subjects with, *see* Japanese subjects with NIDDM
 liver and skeletal muscle IR isoform mRNA in, 129-132
 microalbuminuria and vascular damage in, fasting and postmethionine tHcy correlated with, 915-921
 models of, *see* Non-insulin-dependent diabetes mellitus, model(s) of with obesity, *see* Obesity, NIDDM with plasma IR-VEGF in, 28
 premenopausal and postmenopausal women with, DXA measuring body composition and AT in, 212-216
 Pro-Z effects on zinc insulin metabolism in older subjects with, 39-43
 serum PON activity relationship to complications of, 598-602
 SPA relationship to complications of, 699-705
 urinary and serum TM in, as marker for vascular endothelial injury, 362-365

Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), beta-cell function in
 family history of NIDDM and, 522-528
 GLcN and beta-cell dysfunction in, 573-577

Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), model(s) of
 hyperinsulinemic and insulinopenic obese NIDDM as, 1315-1324
 STZ-DM as, 663-668

Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) with hyperinsulinemia
 acute hyperinsulinemia and regulation of plasma HcY concentrations, 686-689
 hyperinsulinemic and insulinopenic obese NIDDM subjects as models for, 1315-1324
 insulinopenic, with obesity, Lp alterations in, 1315-1324
 parasympathetic dysfunction and hyperinsulinemia effects on hemodynamic response to isometric exercise in, 934-939

Non-obese subjects
 glucose-6-phosphatase activity in hypothalamus of, 627-629
 Hb and Hct related to compensatory hyperinsulinemia and insulin resistance in, 831-835
 with IGT, insulin kinetics and muscle morphology in, 848-854
 Kuwaiti children, serum lipids and BP associated with fasting insulin levels in, 420-424
 LDL receptors in lipid metabolism of, 1070-1074
 with metabolic syndrome and electrocardiographic CAD, I/D polymorphism of ACE gene and, 623
 NIDDM, platelet 12-LOX activity in, 259
 with PCOS, serum leptin in, 988-992
 premenopausal and postmenopausal, serum uric acid levels in, 435-438
 Si and hypertension in, 493-496
 stress-induced FFA release in, 1383-1390

Nonparametric methods of input-output modeling, 1019

Non-steady-state, glucose flux modeling in, 1024-1026

Norepinephrine (NE; noradrenaline)
 in acute hyperinsulinemia with losartan-treated hypertension, 293 and cortisol response to ACTH, 1254
 in obesity, *see* Norepinephrine in obesity
 plasma, *see* Plasma norepinephrine
 sex and response of, to hypoglycemia, 121-124

Norepinephrine (NE; noradrenaline) in obesity
 stress effects on, 1387
 very-low-calorie diet effects on urinary excretion of, 594

Normal pregnancy, first trimester of, physiological reduction of FPG in, 1140-1144

Normal subjects

- acute and delayed single-dose IL-6 effects on thyroid function in, 1289-1293
- apo E metabolism in, 922-928
- beta-cell function in, 522-528
- Ca and glucose effects on pancreatic islet Ca^{2+} -ATPase in, 185-189
- cortisol in, *see* Normal subjects, cortisol in
- dietary protein restriction effects, on glucose and protein metabolism in, 1145-1151
- dietary specific sugars for serum protein enzymatic glycosylation in, 1499-1503
- effects of fasting, sex, and GH therapy on serum leptin and *Lep* mRNA in, 1514-1519
- G in, *see* Normal subjects, G in
- GH in, *see* Normal subjects, GH and leptin in
- HcY in, *see* Normal subjects, HcY in
- hyperinsulinemia in, *see* Normal subjects, hyperinsulinemia in
- insulin-induced release of epinephrine in, 243-249
- LDL receptor function in, 1070-1074
- leptin in, *see* Normal subjects, leptin in
- leucine and glutamine kinetics in, 1429-1433
- lipids in, *see* Normal subjects, lipids in
- minimal model study of insulin resistance in, 508-513
- mutations in, *see* Normal subjects, mutation(s) in
- older, *see* Normal subjects, older
- PAM in, 1263-1268
- Ph hydroxylation and plasma AAAs in, 669-674
- plasma IR VEGF in, smoking and, 27-30
- platelet 12-LOX activity in, 257-263
- role of glucose and glutamine in differential recovery of $^{13}\text{CO}_2$ from infused $[2-^{13}\text{C}]$ acetate versus $[1-^{13}\text{C}]$ acetate in, 549-554
- serum 1,25(OH) $_2$ D $_3$ in, 336-338
- serum PON in, 598-602
- serum and urinary TM in, 363-365
- short-chain FA effects on rectosigmoid mucosal colonocyte brush-border enzymes in, 133-134
- skeletal muscle energetics in, 769-776
- SPA in, 699-705
- TNF α role in TG and glucose metabolism disturbances in, 112-118
- uric acid metabolism in, 929-933
- worsening IVGTT in, independently of degree of obesity, 313-320
- xylitol-induced increase in plasma and urinary excretion of uridine and purines in, 739-743
- zinc supplementation effects on glucose disposal in, 792-798
- see also* Adolescents; Children; Men; Women

Normal subjects, cortisol in

- cortisol effects on free radical generation by MNCs, 788-791
- nighttime and morning release of pulsatile ACTH and cortisol, 143-148
- recurrent hypoglycemia effects on cortisol response to ACTH, 1252-1259
- sex differences in cortisol production, 974-976

Normal subjects, G in

- G effects on glutamine uptake and release, 713-723
- G effects on plasma uridine, 695-698
- G effects on renal and hepatic glutamine gluconeogenesis, 1227-1232
- hyperglucagonemia and dietary leucine kinetics in, 497-502

Normal subjects, GH and leptin in

- GH and prednisolone effects on EE and leptin levels in, 83-88
- GH status, leptin levels, and RMR in, 1134-1139
- serum insulin but not leptin associated with spontaneous or GHRH-stimulated GH secretion in, with and without weight loss, 1127-1133

Normal subjects, HcY in

- plasma HcY related to folate status and MTHFR gene mutation, 1413-1418
- total HcY, 915-921
- total plasma HcY, 273-280

Normal subjects, hyperinsulinemia in

- Hct and Hb related to insulin resistance and compensatory hyperinsulinemia, 831-835
- hyperglycemia and hyperinsulinemia effects on satiety, 321-324
- short-term hyperinsulinemia effects on T production in, 119-120

Normal subjects, leptin in

- race and effects of high-fat versus low-fat diet on S_1 and leptin levels, 1520-1524
- see also* Normal subjects, GH and leptin in

Normal subjects, lipids in

- regular insulin versus Lispro on plasma lipid metabolism in, 371-376
- tall oil phytosterol effects on plasma lipids in, 751-756

Normal subjects, mutation(s) in

- $G^{994} \rightarrow T$ missense mutation of PAF acetylhydrolase gene in, as risk factor for CAD, 177-181
- Trp 64 Arg mutation of β_3 -adrenoceptor gene, 456-460

Normal subjects, older

- fasting plasma insulin, anthropometrics, and metabolic parameters in very old subjects, 535-540
- relationship of aging, insulin resistance, and AT to risk factors for CV disease in, 401-408
- see also* Men, older; Women, older

Normal albuminuria, IDDM with, serum laminin levels in, 64-65

Normoponderal subjects, *see* Non-obese subjects

Normotensive middle-aged men, stress and relationship of ACTH and cortisol with insulin and glucose in, 1440-1449

NOS (nitric oxide synthase), insulin and production of, 1037-1039

Nuclear factor- κ B (NF- κ B), linoleic acid and TNF α effects on endothelial cell, 566-572

Numerical module of SAAM II, 485-486

O_2 (oxygen) consumption, exercise and

- β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448
- diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
- see also* $\dot{V}\text{O}_{2\text{max}}$

Oats and oat bran in diet regulating small intestinal cell turnover, 1106

ob gene, *see*: *Lep* gene

Obesity

- BP in, *see* Blood pressure in obesity
- effects of, on insulin and proinsulin in nondiabetic Asian Indians, 230-233
- effects of high-sucrose and/or HF diets on, 1354-1359
- glucose in, *see* Glucose in obesity
- high-fat diet-induced DM and, *see* High-fat diet-induced diabetes mellitus and obesity
- hypertension and S $_1$ in, 493-496
- hypothalamic G6Pase in, 627-629
- insulin kinetics and muscle morphology in IGT subjects with slight, 848-854
- with insulin resistance, leptin response to fasting in, 125-128; *see also* Leptin
- Japanese subjects with moderate, Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 1528-1530
- metabolic syndrome, electrocardiographic CAD, I/D polymorphism of ACE gene and, 623

Obesity (Continued)

- in NIDDM, *see* Obesity, NIDDM with stress-induced FFA release in, 1383-1390
- vagus nerve control of insulin secretion in, 1167-1173
- worsening of IVGTT in healthy subjects independently of, 313-320
- see also* Adipose tissue; Children, obese; Men, obese; Uric acid in obesity; Women, obese

Obesity, NIDDM with

- in high-monounsaturated fat diet-induced NIDDM, 724-730
- hyperinsulinemic and insulinopenic NIDDM, Lp alterations in, 1315-1324
- LDL receptors, lipid metabolism and, 1070-1074
- S_i, insulin action, and fibrinolysis in, 1372-1375

OCs (oral contraceptives), effects of, on FFA metabolism, 280-284

Offspring, *see* Newborns

O-GlcNAc (O-linked N-acetyl-glucosamine), insulin and GLcN effects on level of, in muscle proteins, 449-455

OGTT, *see* Oral glucose tolerance test

1,25(OH)₂D₃, *see* 1,25-Dihydroxyvitamin D₃

25-OHD, *see* 25-Hydroxyvitamin D

Oil

- coconut, in obesity- and DM-inducing diet, 1090
- olive, in high-monounsaturated fat diet, 725
- short-term administration of tall oil phytosterol, effects of, on plasma lipids, 751-756
- see also specific types of oils and fatty acids*

OKG (ornithine α -ketoglutarate), enteral, effects of, on intestinal adaptation after small bowel resection, 1366-1371

Older subjects

- NIDDM, Pro-Z effects on zinc, glucose, and insulin metabolism in, 39-43
- see also* Aging; Men, older; Very old subjects; Women, older

Oleic acid

- in diet regulating apo B-containing Lps, 884
- effects of diet with stearic acid and, on glucose tolerance and S_i in healthy women, 529-534
- in fat-modified diet for hypercholesterolemia, 745
- in high-monounsaturated fat diet, 724-730

Olive oil in high-monounsaturated fat diet, 725

Opioid tone in hyperinsulinemia and insulin resistance in PCOS, 158-162

Optimal experimental design in compartmental modeling, 1018, 1028

Oral contraceptives (OCs), effects of, on FFA metabolism, 280-284

Oral glucose tolerance test (OGTT)

- of elderly NIDDM subjects, Pro-Z effects on, 39-43
- of insulin-resistant women, 70-74
- of obese hypertensive middle-aged men, 1077
- of PCOS subjects, 158-162
- of subjects with family history of NIDDM, 523, 525

Organ weight

- heart, 191
- kidney, 164, 819, 822
- liver, *see* Organ weight, liver
- thyroid, 155

Organ weight, liver

- endotoxin effects on, 683
- fructose effects on, 150
- in hyperinsulinemic versus insulinopenic hyperglycemia, 1317
- oleic acid effects on, 726

Ornithine

- endotoxin effects on, 683
- in post-small bowel resection enteral diet, 1368
- in trauma, 226, 227

Ornithine α -ketoglutarate (OKG), enteral, effects of, on intestinal adaptation after small bowel resection, 1366-1371

Orotic acid, effects of Triton WR 1339 and, on biliary and serum dolichols, 644-649

Orthophosphate, *see* Inorganic phosphate

Osteocalcin, serum, in ETA receptor antagonist-induced osteopenia, 1405

Osteopenia

- in children, urinary collagen pyridinium cross-links and, 333-335
- ETA receptor antagonist inducing, 1403-1407
- in older men, vitamin K and 25-OHD levels in, 195-199

Osteoporosis in STZ-DM, xylitol effects on, 578-583

OT, *see* Oxytocin

Overweight, *see* Obesity

Oxidase, cytochrome, in ethylmalonic encephalopathy, 837

Oxidation

- cytochrome P450-mediated RA, by retinoids in HNSCC cell lines, 955-958
- of dietary specific sugars, 1499-1503
- FA, during exercise, 442
- glucose, regulation of FFA levels and, by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of UCP-1 gene in FHCL, 1397-1402
- LDL, ERT effects on, 677
- substrate, during exercise, diet selection and, 777-782

Oxidation-reduction (redox potential), elevated RBC, linked to galactonate synthesis, Tolrestat effects on, 1423-1428

Oxidized low-density lipoprotein (LDL), effects of ERT on antibodies against, in hypercholesterolemic postmenopausal women with CHD, 675-680

Oxygen, *see* O₂ consumption, exercise and

Oxytocin (OT)

- effects of, on leptin release in adipocytes, 1457-1458
- responses of AVP and, to angiotensin II type 1 receptor antagonist, in men, 893-896

P (phosphorus)

- in post-small bowel resection enteral diet, 1367
- see also* P in osteopenia

P (phosphorus) in osteopenia

- in ETA receptor antagonist-induced osteopenia, 1405
- in osteopenic elderly men, 196

³¹P MRS (³¹phosphorus magnetic resonance spectroscopy), metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776

PAF (platelet-activating factor) acetylhydrolase gene, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181

PAI (plasminogen activator inhibitor), and risk factor for CHD in exercising postmenopausal women, 1119

PAI-1, *see* Plasminogen activator inhibitor type 1

Palmitate

- effects of, on pancreatic islets following reoxygenation injury, 810-811
- OC effects on kinetics of, 282

[²H₂]Palmitate, GC/MS of, 707-709

Palmitic acid in regulation of apo B-containing Lps, 884

[9,10-³H]Palmitic acid in ethylmalonic encephalopathy, 837

PAM (postaggression metabolism) in healthy subjects, 1263-1268

Pancreas-kidney transplantation, whole, for IDDM, proinsulin levels after, 1325-1330

Pancreatic islets

- Ca²⁺-ATPase of, in NIDDM, glucose and Ca effects on, 185-189
- reoxygenation injury effects on response of, to fatty acids, 809-813
- see also* Beta cells

Parameters in compartmental modeling, 1016-1019
 a posteriori identifiability and, 1016-1018
 parametric methods in input-output modeling, 1019

Paraoxonase (PON), serum, relationship of, to NIDDM complications, 598-602

Parasympathetic dysfunction, effects of hyperinsulinemia and, on hemodynamic response to isometric exercise in NIDDM, 934-939

Parathyroid hormone (PTH)
 in CRF children, 265
 in gout, 337
 in prepubertal children with β -thalassemia and/or CSS, 543

Parenteral nutrition (PN), total, effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176

Parkinson's disease, CYP2D6 gene in, 94-96

PCOS, *see* Polycystic ovary syndrome

PDGF (platelet-derived growth factor), effects of, on coronary artery SMC migration, 1066

PDH (phosphate dehydrogenase), *see* Glyceraldehyde-3-phosphate dehydrogenase

PDI (protein disulfide isomerase), activity of, and protein contents during fasting and refeeding, 1083-1088

Penile development in recessive Robinow syndrome, 1341

Peptide(s)
 C-, *see* C-peptide
 effects of stimulation with glucose and GLP-1 on insulin release in NIDDM, 1042-1047
 HP228, effects of, on diabetic neuropathy, 650-656
 plasma brain natriuretic, very-low-calorie diet effects on, in obesity, 592-597
 vasoactive intestinal, NO in PRL secretion stimulated by, in men, 897-899
see also specific peptides

Perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238

Perindopril, long-term effects of, on metabolic parameters and heart in NIDDM with hypertension, 1199-1204

Peripheral insulin resistance induced by GH excess, troglitazone effects on, 783-787

Peroxidase (Px), GSH, in Keshan disease, vitamin E and selenium effects on, 416

Peroxisome proliferator-activated receptor γ (PPAR γ) gene, expression of, in SAT and VAT, 1494-1498

PET technique in modeling of regional glucose fluxes in steady-state, 1022-1024

PG(s) (prostaglandins), and preadipocyte differentiation, 461-466

PGF_{1 α} (6-keto-prostaglandin F_{1 α}), and SPA relationship to NIDDM complications, 703

pH
 blood, HCl effects on, 164
 in CRF children, 265
 skeletal muscle, in hyperthyroidism, 771

Phe, *see* Phenylalanine

Phenotype, apo E, *see* Apolipoprotein E phenotype in hypercholesterolemia

Phenylalanine (Phe)
 endotoxin effects on, 683, 684
 in familial HALP and HBLP, 1164
 and G effects on glutamine uptake and release, 716, 717, 719
 reduced energy intake effects on, in obese children, 1438
 relationship between hydroxylation of, and plasma AAA concentrations, 669-674
 in trauma, 226, 227

Phosphatase, *see* Alkaline phosphatase; ATPase; Glucose-6-phosphatase; Protein phosphatase-1; Protein phosphatase-2A

Phosphate
 PO₄ in prepubertal children with β -thalassemia and/or CSS, 543, 545
 serum, in gout, 337
see also cAMP; Diphosphate; Galactose-1-phosphate; Galactose-1-phosphate uridylyltransferase deficiency; Glucose-1-phosphate; Glucose-6-phosphate; Glyceraldehyde-3-phosphate dehydrogenase; Glycerol phosphate; Inorganic phosphate; Phosphate dehydrogenase; Triphosphate

Phosphate dehydrogenase, *see* Glyceraldehyde-3-phosphate dehydrogenase

Phosphokinase
 creatine, in Keshan disease, vitamin E and selenium effects on, 416, 417
 serum, in Graves' disease, 1195

Phospholipid transfer protein (PLTP) in HALP, 969

Phospholipids (PLs)
 HRT effects on, 1224
 skeletal muscle membrane, factors affecting FA composition in, 106-112
see also Phospholipids, breast milk effects on

Phospholipids (PLs), breast milk effects on
 and effects of formula during development, 23
 on skeletal muscle membrane PL FA composition, 106-112

Phosphorus, *see* P; ³¹P magnetic resonance spectroscopy

PHTZDC (perhydro-1,4-thiazepine-3,5-dicarboxylic acid) in liver and kidney of D,L-propargylglycine-treated subjects, 1233-1238

Phylloquinone, levels of vitamin K and, in osteopenic older men, 195-199

Physiological reduction of FPG in first trimester of normal pregnancy, 1140-1144

Phytosterols, *see* Plant sterol(s)

Pima Indians
 metabolic syndrome and electrocardiographic CAD in, associated with ACE gene polymorphism and plasma ACE levels, 622-626
 Trp 64 Arg polymorphism of β_2 -adrenoceptor gene and plasma leptin in, 1525-1527

Pioglitazone, effects of, on glucose metabolism and liver and muscle insulin uptake in subjects on high-fructose diet, 1152-1155

Pituitary adenoma, inhibition of signal transduction by splice variant of GHRH receptor expressed in, 804-808

Pituitary gland, *see* Hypothalamic-pituitary-adrenal axis; Hypothalamic-pituitary-testicular function; Pituitary adenoma

PK (protein kinase), mitogen-activated, NIDDM effects on, 56

PKW (pokeweed) mitogen, metabolic effects of, 75-82

PL(s), *see* Phospholipids

Plant-based diet, effects of weight loss with meat-based diet or, on SAC, plasma lipids, BP, and plasma leptin in obese women, compared, 1308-1314

Plant sterol(s) (phytosterols), 744-756
 effects of short-term administration of tall oil, on plasma lipids, 751-756
 serum, fat-modified diet effects on concentrations of serum C precursors and, in hypercholesterolemia, 744-750

Plant sterol 27-hydroxylase, extrahepatic, HCHF diet and activity of, 731-738

Plasma alanine (Ala)
 endotoxin effects on, 683
 in trauma, 226

Plasma amino acids (AAs)
 aromatic, relationship between Phe hydroxylation and concentrations of, 669-674
 endotoxin effects on, 683
see also specific amino acids

Plasma angiotensin-converting enzyme (ACE), ACE gene polymorphism and levels of, associated with metabolic syndrome and electrocardiographic CAD in Pima Indians, 622-626

Plasma apolipoprotein A-I (apo A-I)

- ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- in HALP, 968, 969
- HRT effects on, 1224
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma apolipoprotein A-I/B (apo A-I/B), HRT effects on, 1224

Plasma apolipoprotein A-II (apo A-II) in HALP, 968, 969

Plasma apolipoprotein B (apo B)

- breast milk and/or formula effects on, during development, 22
- effects of vitamin C and dietary fat regulation of apo-containing Lps on, 887-888
- in HALP, 968, 969
- HRT effects on, 1224
- in hypercholesterolemia, *see* Plasma apolipoprotein B in hypercholesterolemia

Plasma apolipoprotein B (apo B) in hypercholesterolemia

- ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma apolipoprotein E (apo E) in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma arginine (Arg)

- endotoxin effects on, 683
- in trauma, 226

Plasma asparagine (Asn)

- endotoxin effects on, 683
- in trauma, 226

Plasma aspartate, endotoxin effects on, 683

Plasma brain natriuretic peptide (BNP), very-low-calorie diet effects on, in obesity, 592-597

Plasma Ca (calcium) in elderly NIDDM subjects, Pro-Z effects on, 41

Plasma cholesterol (C)

- amiodarone effects on, 1053
- breast milk and/or formula effects on, during development, 22
- endotoxin effects on, 682
- ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- HCHF diet effects on, 733
- ICV leptin effects on, 1277
- in offspring of protein-malnourished subjects, 1452
- short-term tall oil phytosterol administration effects on, 753-754
- total, *see* Total plasma cholesterol

Plasma cholesteryl ester transfer protein (CETP), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888

Plasma corticosterone, ICV leptin effects on, 1277

Plasma cortisol (hydrocortisone)

- β-adrenoceptor blockade effects on, 443
- response of, to IM ACTH 1-24 in healthy men, 1419-1422
- very-low-calorie diet effects on, in obesity, 594

Plasma C-peptide

- fibrinolysis in obese nondiabetics and in NIDDM, 1373
- G effects on, in nondiabetics, 8

Plasma creatinine

- endotoxin effects on, 682
- nephrectomy effects on, 356

Plasma cysteine in trauma, 226

Plasma endothelin-1 (ET-1), very-low-calorie diet effects on, in obesity, 592-597

Plasma epinephrine (E; adrenaline)

- GH and prednisolone effects on, 84-85

Plasma epinephrine (E; adrenaline) (*Continued*)

- OC effects on, 281-282
- exercise effects on, 411, 443

Plasma free fatty acids (FFAs; nonesterified fatty acids)

- effects of lipolysis inhibition with acipimox on, in men, 1462-1467
- ICV leptin effects on, 1277
- in NIDDM, 250-256, 910
- in offspring of protein-malnourished subjects, 1452
- postexercise levels of, 411

Plasma glucagon (G)

- fasting, in prediabetic stage of NIDDM, 910
- in offspring of protein-malnourished subjects, 1451
- Phe hydroxylation and, 670

Plasma glucose

- and dexamethasone-induced insulin resistance, 352
- effects of diet type and level of, on skeletal muscle membrane LCPUFAs in young children, 106-112
- endotoxin effects on, 682
- fasting, *see* Fasting plasma glucose
- FFA elevation effects on, 1122
- G and, *see* Plasma glucose, G and GlcN effects on, 451
- high-fat diet effects on, 1090
- in hyperglycemia, 150, 322
- in insulin resistance, 983
- lipolysis inhibition effects on, 1465
- in NIDDM, *see* Plasma glucose in NIDDM
- in obesity, *see* Plasma glucose in obesity
- OC effects on, 281-282

Plasma glucose, G and

- and effects of HGP activation and deactivation by G, 137-138
- G effects on glucose in nondiabetics, 8
- G effects on plasma uridine and, 695-696

Plasma glucose in NIDDM

- fibrinolysis in obese NIDDM subjects, 1373
- in prediabetic stage of NIDDM, 910
- see also* Fasting plasma glucose in NIDDM

Plasma glucose in obesity

- and fibrinolysis in obese NIDDM and nondiabetic subjects, 1373
- ICV methatropine effects on, 1168-1170

Plasma glutamate, endotoxin effects on, 683

Plasma glutamine (Gln)

- endotoxin effects on, 683
- in trauma, 226

Plasma glycerol

- effects of lipolysis inhibition with acipimox on, in men, 1462-1467
- ICV leptin effects on, 1277

Plasma glycine (Gly)

- endotoxin effects on, 683
- in trauma, 226

Plasma guanidino compounds, nephrectomy effects on, 358-359

Plasma high-density lipoprotein (HDL)

- breast milk and/or formula effects on, during development, 22
- in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373

Plasma high-density lipoprotein-cholesterol (HDL-C)

- and chronic hyperglycemia effects in STZ-DM, 949
- ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
- in HALP, 968
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma high-density lipoprotein₂ (HDL₂)

- in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373
- see also* Plasma high-density lipoprotein₂ in hypercholesterolemia

Plasma high-density lipoprotein₂ (HDL₂) in hypercholesterolemia
 ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
 in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma high-density lipoprotein₃ (HDL₃)
 in HALP, 968-969
 in IDDM, insulin Lispro and regular insulin effects on metabolism of, 373
see also Plasma high-density lipoprotein₃ in hypercholesterolemia

Plasma high-density lipoprotein₃ (HDL₃) in hypercholesterolemia
 ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677
 in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma high-density lipoprotein₃-cholesterol (HDL₃-C) in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma histidine (His)
 endotoxin effects on, 683
 in trauma, 226

Plasma homocysteine (HcY)
 acute hyperinsulinemia regulating concentrations of, in nondiabetic subjects but not in NIDDM, 686-689
 in healthy subjects, levels of, related to folate status and MTHFR gene mutation, 1413-1418
see also Total plasma homocysteine

Plasma β (beta)-hydroxybutyrate (BOHB)
 ICV leptin effects on, 1277
 in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394

Plasma 27-hydroxycholesterol, protein level and, 733-734

Plasma hypoxanthine
 bucladesine sodium effects on concentrations of, 1005-1008
 glucagon effects on, 696
 xylitol effects on concentrations of, 739-743

Plasma immunoreactive vascular endothelial growth factor (IR-VEGF), smoking relation to concentration of, 27-30

Plasma inorganic phosphate
 glucagon effects on concentrations of, 696, 697
 xylitol effects on, 742

Plasma insulin
 β -adrenoceptor blockade effects on, 443
 and dexamethasone-induced insulin resistance, 352
 effects of lipolysis inhibition on, 1465
 effects of weight loss with meat-based or plant-based diet on, 1311
 in exercise, *see* Plasma insulin in exercise
 fasting, *see* Fasting plasma insulin
 FFA elevation effects on, 1122
 and fibrinolysis in obese nondiabetics, 1373
 G and, in nondiabetics, 8
 high-fat diet effects on, 1090
 hyperglucagonemia effects on, 499
 in hyperinsulinemia, 322
 ICV leptin effects on, 1277
 in NIDDM *see* Plasma insulin in NIDDM
 NO-1886 effects on, in hypertriglyceridemia, 150
 in offspring of protein-malnourished subjects, 1451
 Phe hydroxylation and, 670
 in STZ-DM, plasma leptin, *Lep* mRNA and, 604-606

Plasma insulin in exercise
 arterial, glucose and AA infusion effects on, 1305, 1306
 and liver 3-FDG uptake, 46
 muscle glucose uptake and conversion to glycogen and, 411

Plasma insulin in NIDDM
 fibrinolysis and, 1373

Plasma insulin in NIDDM (Continued)
 in prediabetic stage of NIDDM, 910
see also Fasting plasma insulin in NIDDM

Plasma insulin-like growth factor-I (IGF-I), diet and concentrations of, 1107

Plasma intermediate-density lipoprotein-cholesterol (IDL-C), ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677

Plasma isoleucine (Ile)
 endotoxin effects on, 683
 in trauma, 226

Plasma K (potassium), effects of lipolysis inhibition on, 1465

Plasma ketones, total, in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394

Plasma lactate
 effects of lipolysis inhibition on, 1465
 in ethylmalonic encephalopathy, 837
 fasting, in prediabetic stage of NIDDM, 910
 ICV leptin effects on, 1277
 postexercise levels of, 411

Plasma lactic acid, xylitol effects on, 741

Plasma lecithin:cholesterol acyltransferase (LCAT), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 888

Plasma leptin
 Trp 64^{Arg} polymorphism of β_3 -adrenoceptor gene and, in Pima Indians, 1525-1527
see also Plasma leptin in STZ-DM, insulin and; Puberty, plasma leptin and; Women, plasma leptin in

Plasma leptin in STZ-DM, insulin and
 food intake and insulin-dependent increase in *Lep* mRNA and, 603-607
 in insulin-treated and untreated STZ-DM and in nondiabetics, 584-591

Plasma leucine (Leu)
 effects of dietary protein restriction in NIDDM on, 1147
 endotoxin effects on, 683
 in trauma, 226

Plasma lipids
 combined HRT effects on, 1222-1226
 effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 887-888

ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 676-677
 gemfibrozil effects on, 236
 in obese women, effects of weight loss with meat-based or plant-based diet on SAC, BP, plasma leptin and, 1308-1314
 short-term tall oil phytosterol administration effects on, 751-756
see also specific lipids

Plasma lipoprotein (Lp)
 combined HRT effects on, 1222-1226
 plasma 27-hydroxycholesterol, sterol 27-hydroxylase and, 734
 in severe heterozygous FH, long-term effects of LDL apheresis on CHD and, in native vessels and coronary bypass, 863-868
 short-term tall oil phytosterol administration effects on, 753-754

Plasma lipoprotein(a) [Lp(a)] in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma lipoprotein A-I (LpA-I) in HALP, 968-970

Plasma lipoprotein A-I:A-II (LpA-I:A-II) in HALP, 968-970

Plasma low-density lipoprotein-cholesterol (LDL-C)
 in HALP, 968

HRT effects on, 1224
 in hypercholesterolemia, *see* Plasma low-density lipoprotein-cholesterol in hypercholesterolemia

Plasma low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia (*Continued*)

Plasma low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia

- in hypercholesterolemic postmenopausal women with CHD, effects of ERT on, 677
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma lysine (Lys)

- endotoxin effects on, 683
- in trauma, 226

Plasma methionine (Met)

- endotoxin effects on, 683
- in trauma, 226

Plasma Mg (magnesium)

- in elderly NIDDM subjects, Pro-Z effects on, 41
- Mg supplementation effects on, 905-906

Plasma norepinephrine (NE; noradrenaline)

- GH and prednisolone effects on, 84-85
- OC effects on, 281-282
- postexercise levels of, 411, 443

Plasma ornithine

- endotoxin effects on, 683
- in trauma, 226

Plasma phenylalanine (Phe)

- endotoxin effects on, 683
- in trauma, 226

Plasma plasminogen activator inhibitor type 1 (PAI-1)

- effects of low-fat, high-fiber diet and exercise on, in subjects with multiple CV disease risk factors, 384-390
- in very old syndrome X subjects, 535-540

Plasma postheparin lipoprotein lipase (LPL) in IDDM, effects of insulin Lispro versus regular insulin on activity of, 373

Plasma proline (Pro) in trauma, 226

Plasma pyruvate

- in ethylmalonic encephalopathy, 837
- fasting, in prediabetic stage of NIDDM, 910

Plasma pyruvic acid, xylitol effects on, 741

Plasma renin activity (PRA), perindopril effects on, in NIDDM with hypertension, 1202

Plasma serine (Ser)

- endotoxin effects on, 683
- in trauma, 226

Plasma taurine

- endotoxin effects on, 683
- in trauma, 226

Plasma threonine (Thr)

- endotoxin effects on, 683
- in trauma, 226

Plasma triacylglycerol (TAG), effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 887

Plasma triglycerides (TGs)

- breast milk and/or formula effects on, during development, 22
- chronic hyperglycemia effects on, in STZ-DM, 949
- endotoxin effects on, 682
- fasting, *see* Fasting plasma triglycerides
- FFA elevation effects on, 1122
- HRT effects on, 1224
- in hypercholesterolemia, *see* Plasma triglycerides in hypercholesterolemia
- ICV leptin effects on, 1277
- in NIDDM, *see* Plasma triglycerides in NIDDM
- NO-1886 effects on, in hypertriglyceridemia, 151
- in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624

Plasma triglycerides (TGs) (*Continued*)

- in offspring of protein-malnourished subjects, 1452
- short-term tall oil phytosterol administration effects on, 753-754

Plasma triglycerides (TGs) in hypercholesterolemia

- in hypercholesterolemic postmenopausal women with CHD, ERT effects on, 677
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100

Plasma triglycerides (TGs) in NIDDM

- fasting plasma, in prediabetic stage of NIDDM, 910
- with metabolic syndrome, I/D polymorphism of ACE gene and, 624

Plasma tryptophan (Trp), endotoxin effects on, 683

Plasma tyrosine (Tyr)

- endotoxin effects on, 683
- Phe hydroxylation and, 670, 671
- in trauma, 226

Plasma urea

- endotoxin effects on, 682
- in exercise, glucose and AA effects on, 1304
- nephrectomy effects on, 356

Plasma urea nitrogen, very-low-calorie diet effects on, in obesity, 593

Plasma uric acid

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696

Plasma uridine

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on concentrations of, 695-698
- xylitol effects on concentrations of, 739-743

Plasma valine (Val)

- endotoxin effects on, 683
- in trauma, 226

Plasma very-low-density lipoprotein (VLDL)

- in IDDM, insulin Lispro and regular insulin effects on metabolism of, 374
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- in STZ-DM, chronic hyperglycemia effects on, 949

Plasma very-low-density lipoprotein-cholesterol (VLDL-C), ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677

Plasma volume, very-low-calorie diet effects on, in obesity, 593-594

Plasma xanthine

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696
- xylitol effects on concentrations of, 739-743

Plasma zinc (Zn) in cirrhosis, effects of zinc supplementation on glucose disposal in, 794

Plasminogen activator, *see* Plasminogen activator inhibitor; Plasminogen activator inhibitor type 1; Tissue plasminogen activator

Plasminogen activator inhibitor (PAI), and risk factor for CHD in exercising postmenopausal women, 1119

Plasminogen activator inhibitor type 1 (PAI-1)

- in NIDDM, 624, 641
- in nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- see also* Plasma plasminogen activator inhibitor type 1

Plasminogen activator inhibitor type 1 (PAI-1) antigen, fibrinolysis in obese nondiabetics and in NIDDM, 1373, 1374

Platelet(s), endotoxin effects on, 682

Platelet-activating factor (PAF) acetylhydrolase gene, G⁹⁹⁴ → T missense mutation in, as risk factor for CAD in Japanese men, 177-181

Platelet aggregation, spontaneous, relationship of NIDDM complications to, 699-705

Platelet-derived growth factor (PDGF), effects of, on coronary artery SMC migration, 1066

Platelet 12-lipoxygenase (LOX) in Japanese NIDDM subjects, 257-263

PLTP (phospholipid transfer protein) in HALP, 969

PN (parenteral nutrition), total, effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176

Pokeweed (PKW) mitogen, metabolic effects of, 75-82

Polycystic ovary syndrome (PCOS)

- insulin resistance, *see* Polycystic ovary syndrome with insulin resistance
- morning and nighttime pulsatile ACTH and cortisol release in, 143-148
- serum leptin in obese women with, correlated with BW and AT distribution but not with androgen and insulin levels, 988-992

Polycystic ovary syndrome (PCOS) with insulin resistance in fibroblasts of PCOS subjects, 940-946

- and hyperinsulinemia, opioid tone in, 158-162

Polygenic hypercholesterolemia, apo E genotype and cholesterogenesis in, 97-100

Polymorphism

- ACE gene, *see* Angiotensin-converting enzyme gene polymorphism
- apo E, and Lp response to lovastatin or gemfibrozil for hypercholesterolemia, 563
- PON, serum PON activity in NIDDM and, 598-602
- see also* Trp 64 Arg polymorphism of β_3 -adrenoceptor gene

Polyunsaturated fatty acids (PUFAs)

- effects of exercise and, on PAI-1, 385
- skeletal muscle membrane long-chain, in young children, 106-112
- in stearic and oleic acid diets, 531
- n-3 and n-6 Polyunsaturated fatty acids (PUFAs), skeletal muscle membrane PL content of, in young children, 108, 109

PON (paraoxonase), serum, relationship of, to NIDDM complications, 598-602

Portal venous and hepatic glucose gradients, effects of positive and negative, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302

Positive portal venous and hepatic glucose gradients, effects of, on hepatic glucose uptake following glucose infusion in splanchnic bed of conscious subjects, 1295-1302

Postaggression metabolism (PAM) in healthy subjects, 1263-1268

Postexercise O₂ (oxygen) consumption, excess, β -adrenoceptor blockade effects on TG/FA cycling and, 439-448

Postheparin lipids, gemfibrozil effects on, 236-238

Postheparin lipoprotein lipase (LPL), plasma, in IDDM, effects of insulin Lispro versus regular insulin on activity of, 373

Postmenopausal women

- non-obese, serum uric acid levels in, 435-438
- see also* Adipose tissue distribution in postmenopausal women; Estrogen replacement therapy in postmenopausal women

Postmethionine load homocyst(e)ine (tHcy), correlation between microalbuminuria and vascular damage in NIDDM and, 915-921

Postprandial (PP) blood glucose in IDDM and NIDDM, CFA and, 504

Postprandial (PP) carbohydrates (CHO), G effects of metabolism of, in nondiabetics, 7-12

Postprandial (PP) glycemia in NIDDM subjects, hemodynamic response to handgrip test and, 935, 936

Postprandial (PP) insulin in NIDDM subjects, hemodynamic response to handgrip test and, 935, 936

Postprandial (PP) lipids

- gemfibrozil effects on, 236, 238
- in IDDM, insulin Lispro versus regular insulin effects on, 374

Potassium, *see* K

PP, *see entries beginning with term: Postprandial*

PP-1 (protein phosphatase-1), NIDDM effects on, 56

PP-2A (protein phosphatase-2A), NIDDM effects on, 56

PPAR γ (peroxisome proliferator-activated receptor γ) gene, expression of, in SAT and VAT, 1494-1498

PRA (plasma renin activity), perindopril effects on, in NIDDM with hypertension, 1202

Preadipocytes

- differentiation of, arachidonic acid metabolites of COX and LOX pathways in regulation of, 461-466
- see also* Adipocytes

Prediabetic stage of NIDDM, increased HGP production and decreased hepatic glucose uptake in, 908-914

Prednisolone

- effects of CsA and, on renal and serum IGF-I, IGFbps, and renal growth following unilateral nephrectomy, 817-823
- effects of GH and, on EE and leptin levels, 83-88

Preeclampsia, LDL and VCAM-1 in hyperlipidemia of, 1281-1288

Pregnancy

- nondiabetic and IDDM, plasma leptin in, 840-843
- normal, physiological reduction of FPG in first trimester of, 1140-1144
- preeclamptic, LDL and VCAM-1 in hyperlipidemia of, 1281-1288

Premenopausal women

- IDDM or NIDDM, DXA measuring body composition and AT in, 212-216
- non-obese, serum uric acid levels in, 435-438
- obese hyperinsulinemic, sex hormones in, 13-19

Prepubertal children

- obese, *see* Prepubertal children, obese
- plasma leptin in, 309-312
- with β -thalassemia and/or CSS, BMD in, 541-548
- see also* Young children

Prepubertal children, obese

- GH bioactivity, IGF-I, IGF-II, IGFbp-1, -2, and -3 in, 1490-1493
- Kuwaiti, association of fasting insulin with serum lipids and BP in, 420-424

Preterm infants, urinary collagen pyridinium cross-links in osteopenic, 333-335

Primary hypercholesterolemia

- apo E phenotype and Lp response to lovastatin or gemfibrozil for, 560-565
- time-release niacin versus plain niacin for, compared, 1097-1104

PRL (prolactin), NO in VIP-stimulated secretion of, in men, 897-899

Progesterone in CETP regulation in female transgenic subjects, 1048-1051

Proinsulin

- in IDDM after whole pancreas-kidney transplantation, 1325-1330
- in NIDDM, 640, 1001
- in nondiabetics, *see* Nondiabetics, proinsulin in
- see also* Des-31,32 proinsulin; Des-32,33 proinsulin; Fasting proinsulin

Prolactin (PRL), NO in VIP-stimulated secretion of, in men, 897-899

Proline (Pro)

- in familial HALP and HBLP, 1164
- in post-small bowel resection enteral diet, 1368
- reduced energy intake effects on, in obese children, 1438
- in trauma, 226, 227

Promoter variant A-3826G of UCP-1 gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402

Prone position, DEXA assessment of body composition in supine and, 1379-1382

D,L-Propargylglycine, cystathione, cystathione ketamine, NAc-cyste, and PHTZDC in liver and kidney of subjects treated with, 1233-1238

Prostaglandins (PGs), and preadipocyte differentiation, 461-466

Prostate powder (Pro-Z), effects of, on zinc, glucose, and insulin metabolism in older NIDDM subjects, 39-43

Protein
HRT effects on, 1224
LDL receptor, amiodarone effects on expression of, 1052-1057
serum, dietary specific sugars for enzymatic glycosylation of, 1499-1503
skeletal muscle, insulin and GlcNAc effects on *O*-GlcNAc level in, 449-455
see also Dietary protein; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Lipoprotein; Total protein; Transfer protein; Whole-body protein and specific proteins

Protein disulfide isomerase (PDI), protein contents and activity of, during fasting and refeeding, 1083-1088

Protein 1 gene, promoter variant A-3826G of uncoupling, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402

Protein phosphatase-1 (PP-1), NIDDM effects on, 56

Protein phosphatase-2A (PP-2A), NIDDM effects on, 56

Prothrombin
in cirrhosis, effects of zinc supplementation on, 793
in LT recipients, 201

Pro-Z (prostate powder), effects of, on zinc, glucose, and insulin metabolism in older NIDDM subjects, 39-43

Psychosocial stress, *see* Stress

PTH, *see* Parathyroid hormone

PTLP (phospholipid transfer protein) in HALP, 969

Puberty
testicular size and function during, in recessive Robinow syndrome, 1342
see also Adolescents; Prepubertal children; Puberty, plasma leptin and

Puberty, plasma leptin and
long-term alcohol intake effects on plasma leptin at puberty, 1269-1273
relationship of plasma leptin level to sex, body composition, S_i, EE, and pubertal status, 309-312

PUFAs, *see* Polyunsaturated fatty acids

Pulsatile corticotropin (ACTH) and cortisol, nighttime and morning release of, in PCOS, 143-148

Pulse rate, *see* Heart rate

Purines
effects of energy intake and, on small intestinal cell proliferation, differentiation, and apoptosis, 1105-1111
see also Plasma hypoxanthine; Plasma uridine; Plasma xanthine; Uric acid; Urinary excretion, hypoxanthine; Urinary excretion, uridine; Urinary excretion, xanthine

Putrescine in post-small bowel resection enteral diet, 1368

Px (peroxidase), GSH, in Keshan disease, vitamin E and selenium effects on, 416

Pyridinium cross-links, collagen, in osteopenic preterm infants, urinary excretion of, 333-335

Pyridostigmine
effects of, on TSH response to TRH in endogenous depression and subclinical thyrotoxicosis, 50-53
naloxone effects on GH response to melatonin and, in men, 814-818

Pyruvate
in PAM, 1265
see also Plasma pyruvate
Tolrestat effects on levels on, 1426

Pyruvate carboxylase in ethylmalonic encephalopathy, 837

Pyruvate dehydrogenase in ethylmalonic encephalopathy, 837

Pyruvic acid
glucagon effects on concentrations of, 696, 697
xylitol effects on, 741, 742

RA, *see* All-trans-retinoic acid; All-trans-retinoic acid receptors

Race and ethnicity
Asian Indian subjects, *see* Asian Indians
and distribution of serum LpA-I and LpA-I:A-II in children, 757-763
and effects of HF versus LF diets on S_i and serum leptin in women, 1520-1524

HDL-C and *see* High-density lipoprotein-cholesterol, race, sex and insulin resistance and, *see* Insulin resistance, race and Jamaican women, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621

Japanese subjects, *see* Japanese subjects

Pima Indians, *see* Pima Indians
serum lipids and BP associated with fasting insulin levels in obese and non-obese Kuwaiti children, 420-424
of young children of NIDDM parents, 998-1004

Rapamycin-sensitive pathways, insulin regulation of LPL activity in adipocytes via, 555-559

RBCs, *see* Red blood cell(s)

Recessive Robinow syndrome, endocrine functions with, 1337-1343

Recirculation, effects of ischemia followed by, on GSH level in retina of STZ-DM subjects, 269-272

Recombinant human growth hormone, *see* Growth hormone

Recombinant human insulin-like growth factor-I, *see* Insulin-like growth factor-I

Rectosigmoid mucosal colonocyte brush-border enzymes, SCFA effects on, 133-134

Recurrent hypoglycemia, effects of, on cortisol response to ACTH in normal subjects, 1252-1259

Red blood cell(s) (RBCs)
elevated redox potential of, linked to galactonate synthesis, Tolrestat effects on, 1423-1428
of women on levothyroxine therapy following total thyroidectomy for Graves' disease, Na⁺,K⁺ ATPase activity in, 1194-1198
see also Red blood cell count; Red blood cell folate

Red blood cell (RBC) count, endotoxin effects on, 682

Red blood cell (RBC) folate, MTHFR gene mutation and, 1415, 1417

Redox potential, elevated RBC, linked to galactonate synthesis, Tolrestat effects on, 1423-1428

Reductase, *see* Cytochrome C reductase; HMG-CoA reductase; Methylenetetrahydrofolate reductase gene mutation; NADH-cytochrome C reductase

Refeeding, activity of PDI during fasting and, protein contents and, 1083-1088

Regional adipose tissue distribution, *see* Adipose tissue distribution

Regional blood flow in exercise, glucose and AA infusion effects on, 1305, 1306

Regional glucose fluxes in steady-state, modeling of, 1021-1022

Renal blood flow, glucagon effects on, 1228

Renal failure
biochemical changes due to nephrectomy for, 355-361
children with chronic, excessive dietary protein and suboptimal caloric intake effects on growth of, before and during GH therapy, 264-268

Renal glutamine, glucagon effects on gluconeogenesis of, in normal subjects, 1227-1232

Renal growth following unilateral nephrectomy, effects of immunosuppression on, 817-823

Renal insulin-like growth factor (IGF-I), effects of immunosuppression on, following unilateral nephrectomy, 817-823

Renal insulin-like growth factor-binding proteins (IGFBPs), effects of immunosuppression on, following unilateral nephrectomy, 817-823

Renal N (nitrogen), HCl effects on metabolism of, 163-167

Renal transplantation, whole pancreas and, for IDDM, proinsulin levels after, 1325-1330

Renal water channel, urinary aquaporin-2 excretion and expression of, in newborns, 1344-1347

Renin-aldosterone system, very-low-calorie diet effects on, in obesity, 593-594

Renin in IDDM, urinary ET-1 and, 1409, 1410

Reoxygenation injury, effects of, on pancreatic islet response to FAs, 809-813

Reproductive function, neonatal insulin treatment effects on, 857

Resection, small bowel, enteral OGK effects on intestinal adaptation after, 1366-1371

Respiratory gas exchange, NO-1886 effects on, in hypertriglyceridemia, 151

Resting metabolic rate (RMR)

- in healthy adults, GH status, leptin levels and, 1134-1139
- in NIDDM, effects of dietary protein restriction and, 1147

Resting O₂ (oxygen) uptake, β -adrenoceptor blockade effects on, 444-445

Resting skeletal muscle, metabolic efficiency of, in hyperthyroidism measured with ³¹P MRS, 771, 773

Retarded learning, abnormal cholesterol synthesis and, 878-882

Retina

- GSH levels in, in STZ-DM, effects of ischemia followed by recirculation on, 269-272
- IGF-I mRNA, IGF-IR mRNA, and IGFBP-2 and -3 mRNA in, under hypoxic conditions, 1331-1336

Retinoic acid, *see All-trans-retinoic acid; All-trans-retinoic acid receptors*

Retinoids, cytochrome P450-mediated RA oxidation by, in HNSCC cell lines, 955-958

Retinol (vitamin A), response to sucrose and deficiency in, 1-2

Retinopathy, *see Diabetic retinopathy*

Reversal of high-fat diet-induced obesity and DM, 1089-1096

rhGH (recombinant human growth hormone), *see Growth hormone*

rhIGF-I (recombinant human insulin-like growth factor-I), *see Insulin-like growth factor-I*

Ribonucleic acid, *see mRNA*

Risk factors for CHD

- metabolic disturbances of glucose and TG predisposing to CHD, TNF α role in, 113-118
- in NIDDM, 1260

see also Risk factors for CHD in women

Risk factors for CHD in women

- low glycemic diet effects on, 1245-1251
- in postmenopausal exercising women, AT as, 1112-1120

Risk factors for CV disease

- and aging relationship to insulin resistance and body composition, 401-408
- for CAD in Japanese men, G⁹⁹⁴ → T missense mutation in PAF acetylhydrolase gene as, 177-181
- multiple, effects of low-fat, high-fiber diet and exercise in subjects with, 384-390
- in NIDDM, effects of insulin versus sulfonylurea therapy on, 637-643

see also Risk factors for CHD

RMR, *see Resting metabolic rate*

RNA (ribonucleic acid), *see mRNA*

Robinow syndrome, recessive, endocrine functions with, 1337-1343

S, *see Sucrose*

S, *see Insulin sensitivity*

18S RNA (ribonucleic acid), hormonal regulation of *Lep* mRNA, leptin release and, in adipocytes of hypothyroidic subjects, 1455-1461

SAAM (Simulation, Analysis, and Modeling) II software, 484-492

SAC (systemic arterial compliance), weight loss with meat-based or plant-based diet effects on BP, plasma leptin, and plasma lipids in women, compared, 1308-1314

Safety of niacin and Niaspan, 1101-1102

SAT, *see Subcutaneous adipose tissue*

Satiety, hyperglycemia and hyperinsulinemia effects on, 321-324

Saturated fatty acids (SFAs)

- effects of exercise and, on PAI-1 activity, 385
- in skeletal muscle membrane PLs of young children, 108, 109
- in stearic and oleic acid diets, 531

SBP (systolic blood pressure), *see Blood pressure*

SCC (squamous cell carcinoma) cell lines, head and neck, cytochrome P450-mediated RA oxidation by retinoids in, 955-958

SCFAs (short-chain fatty acids), effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134

SCI (spinal cord injury), acute, serum lipids following, 367-370

Sedentary subjects, glucose effectiveness in, measured with IVGTT, 874-877

Selenium, effects of vitamin E and, on Keshan disease-induced beta-cell alterations, 415-419

Semistarvation of obese subjects, effects of, on vasoactive and volume regulatory hormones, and BP in, 592-597

Serine (Ser)

- endotoxin effects on, 683, 684
- in familial HALP and HBLP, 1164
- reduced energy intake effects on, in obese children, 1438
- in trauma, 226, 227

Serum alanine aminotransferase (SGPT)

- in hypoglycemia, 1471-1476
- niacin and Niaspan effects on, 1101

Serum alkaline phosphatase (ALP) in CRF children, 265

Serum apolipoprotein(s) (apo)

- in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- see also specific apolipoproteins*

Serum apolipoprotein A-I (apo A-I), menopausal status and exercise effects on, 378, 379

Serum apolipoprotein B (apo B)

- in hyperlipidemia of preeclampsia, 1284
- menopausal status and exercise effects on, 378, 379

Serum aspartate aminotransferase (SGOT)

- in hypoglycemia, 1471-1476
- niacin and Niaspan effects on, 1101

Serum Ca (calcium)

- in ETA receptor antagonist-induced osteopenia, 1405
- in gout, 337

Serum cholesterol (C)

- CHD, Lp(a) levels and, 183
- in hypercholesterolemia, fat-modified diet effects on concentrations of serum phytosterols and precursors of, 744-750
- nicotine effects on, 155, 156
- in obese NIDDM subjects, LDL receptors and metabolism of, 1071
- see also* Serum high-density lipoprotein-cholesterol; Serum low-density lipoprotein-cholesterol; Total serum cholesterol

Serum cobalamin in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91

Serum C-peptide (connecting peptide)

- in IDDM, fasting, and insulin secretion and mode of therapy associated with leptin and AT, 1394

see also Serum C-peptide in NIDDM

Serum C-peptide (connecting peptide) in NIDDM

- acipimox effects on, 253
- fasting, and insulin secretion and mode of therapy associated with leptin and AT, 1394

Serum creatine kinase (CK) in hypoglycemia, 1471-1476

Serum creatinine
 in DM, blood and urine AGE products and, 1349
 in gout, 337
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
 in IDDM, *see* Serum creatinine in IDDM
 VAT accumulation effects on, in obese men, 930

Serum creatinine in IDDM
 and proinsulin levels following whole pancreas-kidney transplantation, 1326, 1328
 urinary ET-1 and, 1409, 1410

Serum cytokines, level of, in burn injury, 612

Serum 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃] in gout, 336-338

Serum dolichols, effects of Triton WR 1339 and orotic acid on, 644-649

Serum folate in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91

Serum free fatty acids (FFAs)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 in hyperlipidemia of preeclampsia, 1284

Serum glucose, fasting, perindopril effects on, in NIDDM with hypertension, 1202

Serum glutamate pyruvate transaminase, *see* Alanine aminotransferase

Serum glutamic-oxaloacetic transaminase, *see* Aspartate aminotransferase

Serum glycoprotein(s) (GPs), incorporation of dietary specific sugars into, 1501-1502

Serum high-density lipoprotein (HDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318

Serum high-density lipoprotein-cholesterol (HDL-C)
 following acute SCI, 367-370
 in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 menopausal status and exercise effects on, 378, 379
 VAT accumulation effects on, in obese men, 930

Serum high-density lipoprotein₂ (HDL₂), menopausal status and exercise effects on, 378, 379

Serum high-density lipoprotein₃ (HDL₃), menopausal status and exercise effects on, 378, 379

Serum insulin
 fasting, perindopril effects on, in NIDDM with hypertension, 1202
 in GH deficiency, 1517
 but not leptin in association with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without weight loss, 1127-1133
 in STZ-DM, gliclazide effects on, 978, 979

Serum insulin-like growth factor(s) (IGF) in hepatic failure following LT, 200-206

Serum insulin-like growth factor-I (IGF-I)
 GH response to clonidine and, in recessive Robinow syndrome, 1337-1343
 immunosuppression effects on, following unilateral nephrectomy, 817-823

Serum insulin-like growth factor-binding proteins (IGFBPs)
 in hepatic failure following LT, 200-206
 immunosuppression effects on, following unilateral nephrectomy, 817-823

Serum K (potassium) in Graves' disease, 1195

Serum lactate dehydrogenase (LDH) in hypoglycemia, 1471-1476

Serum laminin in IDDM with and without microangiopathy, levels and molecular size of, 63-69

Serum leptin
 effects of fasting, sex, and GH therapy on, in GH-deficient and healthy adults, 1514-1519
 insulin secretion and therapy mode association with AT and, in IDDM and NIDDM, 1391-1396

Serum leptin (*Continued*)
 restricted caloric intake effects on, 429-434
 in women, *see* Women, serum leptin in

Serum lipids
 BP and, associated with fasting insulin levels in obese and non-obese Kuwaiti children, 420-424
 following acute SCI, 367-370
 hypercholesterolemia-inducing diet effects on, 304
 in IDDM, leptin correlation with, 1392
 menopausal status and exercise effects on intravascular enzymes related to transport of, 377-383
 in NIDDM, *see* Serum lipids in NIDDM
 and Trp 64 Arg mutation of β_1 -adrenoceptor gene, 457-458
see also specific lipids

Serum lipids in NIDDM
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 leptin correlation with, 1392

Serum lipoprotein (Lp)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
see also specific serum lipoproteins

Serum lipoprotein(a) [Lp(a)], menopausal status and exercise effects on, 378, 379

Serum lipoprotein A-I (LpA-I), race and distribution of, in children, 757-763

Serum lipoprotein A-I:A-II (LpA-I:A-II), race and distribution of, in children, 757-763

Serum low-density lipoprotein (LDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318

Serum low-density lipoprotein-cholesterol (LDL-C)
 following acute SCI, 367-370
 in hyperlipidemia of preeclampsia, 1284
 menopausal status and exercise effect on, 378, 379

Serum Na (sodium) in Graves' disease, 1195

Serum osteocalcin in ETA receptor antagonist-induced osteopenia, 1405

Serum P (phosphorus) in ETA receptor antagonist-induced osteopenia, 1405

Serum paraoxonase (PON), relationship of, to NIDDM complications, 598-602

Serum phosphate in gout, 337

Serum phosphokinase in Graves' disease, 1195

Serum phytosterols (plant sterols), fat-modified diet effects on concentrations of serum C precursors and, in hypercholesterolemia, 744-750

Serum protein, enzymatic glycosylation of, dietary specific sugars for, 1499-1503

Serum thrombomodulin (TM) in NIDDM, as marker for vascular endothelial injury, 362-365

Serum thyroxine (T₄)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91

Serum triglycerides (TGs)
 in hyperlipidemia of preeclampsia, 1284
 in IDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394
 menopausal status and exercise effects on, 378, 379
 in NIDDM, *see* Serum triglycerides in NIDDM
 VAT accumulation effects, in obese men, 930, 931

Serum triglycerides (TGs) in NIDDM
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
 and insulin secretion and mode of therapy associated with leptin and AT, 1394

Serum triiodothyronine (T₃)
 in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

Serum triiodothyronine (T_3) (*Continued*)
 in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
 Serum tumor necrosis factor α (TNF α), gliclazide effects on LPS-induced enhanced activity of, in STZ-DM, 978-979
 Serum urea, HCl effects on, 164
 Serum uric acid
 in gout, 337
 in non-obese premenopausal and postmenopausal women, 435-438
 VAT accumulation effects on, in obese men, 930
 Serum very-low-density lipoprotein (VLDL) in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
 Severe familial hypercholesterolemia, *see* Atherosclerosis, LDL, in FH
 Severe hyperprolactinemia, bone loss due to estrogen deficiency and, 426
 Sex
 and adrenal catecholamine response to hypoglycemia, 121-124
 body composition, *see* Sex, body composition and of celiac disease patients, 1430
 of CHD subjects, plasma total HcY and, 274
 of cirrhotic subjects, 793
 and cortisol, *see* Sex, cortisol and and dietary specific sugars for serum protein enzymatic glycosylation, 1500
 of DM subjects, blood and urine AGE products and, 1349; *see also* Sex of IDDM subjects; Sex of NIDDM subjects
 effects of fasting, GH therapy and, on serum leptin and *Lep* mRNA in GH-deficient and healthy adults, 1514-1519
 of endogenous depression subjects, 51
 of familial HALP and HBLP subjects, 1162
 and family history of NIDDM, 523
 fasting insulin levels, BP, serum lipids and, 422
 and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398
 of HALP subjects, 968
 of hypercholesterolemic subjects, *see* Sex of hypercholesterolemic subjects
 of hyperthyroidic and hypothyroidic subjects, 90, 91
 of hypertriglyceridemic subjects, 236
 of IGT subjects, insulin kinetics, muscle morphology and, 850
 of nondiabetics with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 of obese subjects, *see* Sex of obese subjects
 race and, *see* Sex, race and and RMR, 1135
 of Robinow syndrome patients, 1341
 of subjects with multiple CV disease risk factors, diet and exercise effects on, 386, 387
 Trp 64 Arg polymorphism of β_3 -adrenoceptor gene, plasma leptin and, 1526
 of young children of NIDDM parents, 999
see also Men; Women
 Sex, body composition and insulin resistance and, 402, 404, 406
 relationship of plasma leptin in children to puberty, S, EE, and body composition, 309-312
 Sex, cortisol and cortisol response to ACTH, 1253
 and differences in cortisol production, 974-976
 Sex, race and distribution of serum LpA-I and LpA-I:A-II, 758-761
 of nondiabetics, relationship between Lps and insulin resistance and, 1176, 1177
see also High-density lipoprotein-cholesterol, race, sex and

Sex hormone(s)
 effects of, on C7H mRNA, 391-395
 hyperinsulinemia and, in obese premenopausal women, 13-19
 race and, in adolescent males, HDL-C and TG level and, 514-521
see also Sex steroids and specific sex hormones
 Sex hormone-binding globulin (SHBG) in women in hyperinsulinemic obese premenopausal women, 13-19
 insulin resistance, race and, 70-74
 with PCOS, 159, 990

Sex of hypercholesterolemic subjects
 efficacy of plain niacin versus Niaspan and, 1099
 fat-modified diet effects on serum cholesterol and plant sterol concentrations and, 745
 with FH, LDL apheresis and, 1059
 polygenic hypercholesterolemic subjects, 98
 primary hypercholesterolemic subjects, 561
 with severe heterozygous FH and, 864, 866

Sex of IDDM subjects
 CFA relationship to microangiopathy, neuropathy and, 503-507
 and proinsulin levels following whole pancreas-kidney transplantation, 1326
 and urinary ET-1 excretion, 1409

Sex of NIDDM subjects
 acipimox effects and, 251
 CFA relationship to hypertension, microangiopathy, neuropathy and, 503-507
 and GSH effects on glucose metabolism in NIDDM, 994
 hemodynamic response to handgrip test and, 935, 936
 with metabolic syndrome, I/D polymorphism of ACE gene and, 624
 and mode of therapy associated with leptin and AT, 1394, 1395
 obese, S, insulin action, fibrinolysis and, 1372-1375
 platelet 12-LOX activity and, 259, 260
 serum PON activity and, 599
 SPA relationship to NIDDM complications and, 701-703
 Trp 64 Arg mutation of β_3 -adrenoceptor gene and, 457

Sex of obese subjects
 of healthy elderly subjects, IVGTT and, 314, 315, 317
 with NIDDM, S, insulin action, fibrinolysis and, 1372-1375
 prepubertal, GH bioactivity and, 1491

Sex steroids
 regulating CETP in female transgenic subjects, 1048-1051
see also specific sex steroids
 SFAs, *see* Saturated fatty acids
 SGOT, *see* Serum aspartate aminotransferase
 SGPT, *see* Serum alanine aminotransferase
 SHBG, *see* Sex hormone-binding globulin in women
 Short-chain fatty acids (SCFAs), effects of, on rectosigmoid mucosal colonocyte brush-border enzymes, 133-134
 Short stature, constitutional, BMD in prepubertal children with, 541-548
 Short-term estrogen-progestin replacement therapy in postmenopausal women, LCAT during, 297-300
 Short-term hyperinsulinemia, effects of, on T production in healthy men, 119-120
 Short-term tall oil phytosterol administration, effects of, on plasma lipids, 751-756
 Side effects, *see* Adverse effects
 Signal transduction, inhibition of, by splice variant of GHRH receptor expressed in pituitary adenoma, 804-808
 Simulation, Analysis, and Modeling (SAAM) II software, 484-492
 Simulation studies, 478-492
 of LDL apo B metabolism following apheresis, 478-483
 with SAAM II software, 484-492
see also Systems model

Single-dose interleukin-6 (IL-6), acute and delayed effects of, on thyroid function in healthy subjects, 1289-1293

Sitosterol, relationship of, to apo E phenotype in hypercholesterolemia, 747

16:0, *see* Palmitic acid; [9,10-³H]Palmitic acid

Skeletal muscle

- in hyperthyroidism, ³¹P MRS measuring metabolic efficiency of, 769-776
- in NIDDM, IR isoform mRNA in, 129-132
- verapamil and captopril effects in, 982-987
- see also* Skeletal muscle cell surface; Skeletal muscle membrane phospholipids; Skeletal muscle proteins

Skeletal muscle cell surface, insulin-stimulated GLUT4 recruitment to, dexamethasone effects on, 3-6

Skeletal muscle membrane phospholipids (PLs), factors affecting FA composition in, in young children, 106-112

Skeletal muscle proteins, insulin and GLcN effects on *O*-GlcNAc level in, 449-455

Skim milk in diet regulating small intestinal cell turnover, 1106

Small intestine (small bowel)

- effects of energy intake and purines on cell proliferation, cell differentiation, and apoptosis in, 1105-1111
- enteral OKG effects on intestinal adaptation after resection of, 1366-1371
- of protein-depleted subjects, effects of dietary protein and TNF on IGF-I pathway components in, 345-350

SMCs (smooth muscle cells), coronary artery, heparin effects on migration of, 1065-1069

Smoking

- CHD and, *see* Smoking, CHD and effects of, on thyroid function, 154-157
- ERT efficacy and, 677-678
- and hyperinsulinemia, plasma HcY concentrations and, 687
- maternal, and FPG reduction in pregnancy, 1141
- by non-obese postmenopausal women, serum uric acid levels and, 437
- by premenopausal women, 16, 437
- and primary hypercholesterolemia, 1099
- relationship of, to plasma IR-VEGF concentration, 27-30
- TG-rich Lps, GPIIa gene and, 1040-1041

Smoking, CHD and

- Lp(a) level and, 183
- in NIDDM, ACE gene polymorphism and, 1259, 1260
- plasma homocysteine and, 274
- and role of TNF α in TG and glucose metabolism, 114

Smooth muscle cells (SMCs), coronary artery, heparin effects on migration of, 1065-1069

Sodium, *see* Na

Sodium bicarbonate (NaHCO₃) in obesity- and DM-inducing diet, 1090

Somatoliberin in PAM, 1264

South Asians, *see* Asian Indians

Soybean oil

- in diet regulating small intestinal cell turnover, 1106
- in obesity- and DM-inducing diet, 1090

SPA (spontaneous platelet aggregation), relationship of NIDDM complications to, 699-705

Spectrometry, gas chromatography and mass, of metabolic tracers, 706-712

Spectroscopy, ³¹P MRS, metabolic efficiency of skeletal muscle in hyperthyroidism measured with, 769-776

Spermidine, effects of, on protein utilization in trauma and injury, 223-229

Spinal cord injury (SCI), acute, serum lipids following, 367-370

Splanchnic bed of conscious subjects, effects of positive and negative portal venous and hepatic glucose gradients on hepatic glucose uptake following glucose infusion in, 1295-1302

Splice variant of GHRH receptor expressed in pituitary adenoma, signal transduction inhibited by, 804-808

Spontaneous platelet aggregation (SPA), relationship of NIDDM complications to, 699-705

Squalene, relationship of, to apo E phenotype in hypercholesterolemia, 747

Squamous cell carcinoma (SCC) cell lines, head and neck, cytochrome P450-mediated RA oxidation by retinoids in, 955-958

Starvation, effects of semistarvation on vasoactive and volume regulatory hormones, and BP in obese subjects, 592-597

Steady-state, modeling of glucose fluxes in, 1020-1024

Stearic acid

- effects of oleic acid and, on glucose tolerance and S_i in healthy women, 529-534
- in regulation of apo B-containing Lps, 884

Steroids, *see specific steroids; for example: Sex steroids*

Sterol(s), *see* Plant sterol(s); Plant sterol 27-hydroxylase and specific sterols

Strenuous (endurance) exercise, IVGTT measuring, glucose effectiveness in, 190-194, 874-877

Streptozotocin-induced diabetes mellitus (STZ-DM)

- chronic hyperglycemia effects on arterial LDL metabolism and atherosclerosis in, 947-954
- continuous glucose monitoring with ECU in, 799-803
- diabetic neuropathy in, inhibited by gliclazide irrespective of blood glucose levels, 977-981
- as model of NIDDM pathology, 663-668
- plasma leptin, *see* Plasma leptin in STZ-DM, insulin and retinal GSH levels in, 269-272
- xylitol supplementation effects on osteoporosis in, 578-583

Stress

- FFA release induced by, in obesity, 1383-1390
- and relationship of ACTH and cortisol with insulin and glucose in middle-aged men, 1440-1449

Structural modeling, defined, 1009

STZ-DM, *see* Streptozotocin-induced diabetes mellitus

Subclinical thyrotoxicosis, pyridostigmine effects on TSH response to TRH in, 50-53

Subcutaneous adipose tissue (SAT)

- effects of HF versus LF diets on S_i and serum leptin and, in women, race and, 1521
- insulin resistance and, 402, 404, 406
- in obesity, *see* Subcutaneous adipose tissue in obesity and RMR in healthy adults, 1135

Subcutaneous adipose tissue (SAT) in obesity

- in obese women with PCOS, serum leptin in, 989, 990
- PPAR γ gene expression in, 1494-1498

Substrates

- oxidation of, during exercise, diet selection and, 777-782
- see also specific substrates*

Sucrose (S)

- effects of high-sucrose and HF diets on body composition, 1354-1359
- in high-monounsaturated fat diet, 725
- in obesity- and DM-inducing diet, 1090
- vitamin A deficiency and response to, 1-2

Sugars

- dietary specific, for serum protein enzymatic glycosylation, 1499-1503
- see also specific sugars*

Sulfonylurea, effects of NIDDM therapy with insulin versus, on cardiovascular risk factors and fibrinolysis, 637-643

Supine position, DEXA assessment of body composition in prone and, 1379-1382

Supplementation
daily Mg, effects of, on Mg deficiency during prolonged restriction of motor activity, 903-907

spermidine, in trauma, effects of, on protein, 223-229

xylitol, effects of, on osteoporosis in STZ-DM, 578-583

zinc, effects of, on glucose disposal in cirrhosis, 792-798

Sympathetic effects of insulin, 247

Syndrome X, *see* Metabolic syndrome

Synthase
citrate, in ethylmalonic encephalopathy, 837

cystathione- β -, deficiency of, in homocystinuria, 207-211

nitric oxide, insulin and production of, 1037-1039

Systemic arterial compliance (SAC), BP, plasma leptin, and plasma lipids in women, effects of weight loss with meat-based or plant-based diet on, compared, 1308-1314

Systemic glucose, ICV leptin effects on utilization of, in conscious subjects, 1274-1280

Systems model, 1009-1035
input-output modeling, 1018-1019
validation of, 1019
see also Compartmental modeling; Glucose system, modeling of; Insulin system, modeling of; Minimal model analysis; Simulation studies

Systolic blood pressure, *see* Blood pressure

T, *see* Testosterone

T₃, *see* Triiodothyronine

T₄, *see* Thyroxine

T cells, PKW mitogen stimulating, 79

TAG, *see* Triacylglycerol

Tall oil phytosterols, effects of short-term administration of, on plasma lipids, 751-756

Tamoxifen, effects of, on C synthesis in HepG2 cells and hepatocytes, 1504-1513

Tanner stage of breast development with recessive Robinow syndrome, 1341, 1342

TAT, *see* Tyrosine aminotransferase

Taurine
plasma, *see* Plasma taurine
in trauma, 226, 227

TC, *see* Total cholesterol

Testicular function
hypothalamic-pituitary-, effects of methanol extract of Chansu on, 1211-1216

size and, during puberty in recessive Robinow syndrome, 1342

Testosterone (T)
Chansu effects on secretion of, 1213-1214

effects of T₄ and, on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroidic male subjects, 474-478

in men with abdominal obesity, 1189, 1190

in osteopenic elderly men, 196

in PCOS, 159, 941

and plasma leptin in children, 310

response of, to HCG in recessive Robinow syndrome, 1337-1343
see also Testosterone in hyperinsulinemia

Testosterone (T) in hyperinsulinemia
in obese premenopausal women, 13-19

short-term hyperinsulinemia effects on T production in healthy men, 119-120

Tetrahydrobiopterin (BH₄), insulin-induced vasodilation dependent on synthesis of, 1037-1039

Tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt; MTS), metabolic activation of beta cells and, 824-830

TGs, *see* Triglycerides

β (beta)-Thalassemia, BMD in prepubertal children with, 541-548

tHcy [homocyst(e)ine], fasting and postmethionine, correlated with microalbuminuria and vascular damage in NIDDM and, 915-921

Thermogenesis
 β -adrenoceptor-mediated, in men, effects of lipolysis inhibition on, 1462-1467
see also entries beginning with term: Energy and element: Calcium

Threonine (Thr)
endotoxin effects on, 683, 684

in familial HALP and HBLP, 1164

reduced energy intake effects on, in obese children, 1438

in trauma, 226, 227

Thrombomodulin (TM), serum and urinary, in NIDDM, as marker for vascular endothelial injury, 362-365

Thromboxane B₂ (TXB₂), and SPA relationship to NIDDM complications, 703

Thyroid function
acute and delayed effects of single-dose IL-6 on, in healthy subjects, 1289-1293

GH and prednisolone effects on, 85, 86

in Graves' disease, 1196

nicotine effects on, 154-157
see also Hyperthyroidism; Hypothyroidism

Thyroid hormones
effects of, on PDI, 1085
see also Thyroxine; Triiodothyronine

Thyroidectomy, total, for Graves' disease, Na⁺,K⁺ ATPase activity in RBCs of women on levothyroxine therapy following, 1194-1198

Thyrotoxicosis, subclinical, pyridostigmine effects on TSH response to TRH in, 50-53

Thyrotropin (TSH; thyroid-stimulating hormone)
amiodarone effects on, 1053

GH and prednisolone effects on, 86

nicotine effects on, 155, 156

in prepubertal children with β -thalassemia and/or CSS, 543

pyridostigmine effects on response of, to TRH in endogenous depression and subclinical thyrotoxicosis, 50-53

Thyrotropin-releasing hormone (TRH), pyridostigmine effects on TSH response to, in endogenous depression and subclinical thyrotoxicosis, 50-53

Thyroxine (T₄)
amiodarone effects on, 1053

breast milk and/or formula effects on, during development, 22

GH and prednisolone effects on, 86

in Graves' disease, 1196

in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

nicotine effects on, 155, 156

and RMR in healthy adults, 1135

serum, *see* Serum thyroxine
see also Thyroxine in hypothyroidism

Thyroxine (T₄) in hypothyroidism
effects of T and, on hepatic 11 β -HSD1 mRNA and activity in pubertal hypothyroid male subjects, 474-478

serum, plasma Hcy and, 90, 91

Time-release niacin (Niaspan), plain niacin versus, for primary hypercholesterolemia, compared, 1097-1104

Tissue-plasminogen activator (t-PA)
in exercising postmenopausal women, CHD and, 1119
see also Tissue-plasminogen activator in NIDDM, fibrinolysis in

Tissue-plasminogen activator (t-PA) in NIDDM, fibrinolysis in insulin versus sulfonylurea therapy effects on, 641 and in obese nondiabetics, 1373, 1374

TM (thrombomodulin), serum and urinary, in NIDDM, as marker for vascular endothelial injury, 362-365

TNF, *see* Tumor necrosis factor; Tumor necrosis factor α

Tobacco, *see* Smoking

α Tocopherol, *see* Vitamin E

Tolerance to niacin and Niaspan, 1101

Tolrestat, effects of on elevated RBC redox potential linked to galactone synthesis of, 1423-1428

Total amino acids (AAs)

- endotoxin effects on, 684
- in exercise, glucose and AA infusion effects on, 1306

Total bilirubin

- in elderly NIDDM subjects, Pro-Z effects on, 42
- in LT recipients, 201

Total cholesterol (TC)

- BP and, associated with fasting insulin levels, 421, 422
- breast milk and/or formula effects on, during development, 22, 23
- in FCH, *see* Total cholesterol in FCH
- GH levels in women correlated with, 341, 342
- in Graves' disease, 1195
- in hypercholesterolemia, *see* Total cholesterol in hypercholesterolemia
- in insulin resistance, *see* Total cholesterol in insulin resistance
- LDL apheresis effects on, 865
- menopausal status and exercise effect on, 378, 379
- in NIDDM, *see* Total cholesterol in NIDDM
- in nondiabetics, *see* Total cholesterol in nondiabetics
- sex hormones effects on, 392
- short-term tall oil phytosterol administration effects on, 753-754
- stearic and oleic acid effects on, 532
- and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
- in very old syndrome X subjects, 536
- in young children of NIDDM parents, 999
- see also* Total plasma cholesterol; Total serum cholesterol

Total cholesterol (TC) in FCH

- FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene and, 1398-1400
- in nondiabetic FCH, 509, 510

Total cholesterol (TC) in hypercholesterolemia

- fat-modified diet effects on, 745
- in polygenic hypercholesterolemia, 98
- in primary hypercholesterolemia, 562

Total cholesterol (TC) in insulin resistance

- body composition and, related to aging, CV disease risk factors and, 402, 404, 406
- SHBG, race and, in insulin-resistant women, 72

Total cholesterol (TC) in NIDDM

- CHD and, 1119, 1260
- insulin versus sulfonylurea therapy effects on, 641
- in familial HALP and HBLP, 1162, 1163
- fibrinolysis and, in obese subjects, 1373
- hemodynamic response to handgrip test and, 935, 936
- high-monounsaturated fat diet effects on, 726
- with metabolic syndrome, I/D polymorphism of ACE gene and, 624
- plasma, effects of weight loss with meat-based versus plant-based diet on, 1310
- serum PON activity and, 599
- and SPA relationship to NIDDM complications, 703
- tHcy, microalbuminuria and, 916
- see also* Total serum cholesterol in NIDDM

Total cholesterol (TC) in nondiabetics

- with metabolic syndrome, 624
- in nondiabetic FCH, 509, 510
- in obese nondiabetics, fibrinolysis and, 1373

Total cysteine in CHD, 276

Total insulin-like growth factor-I (IGF-I), GH levels in women correlated with, 340

Total parenteral nutrition (TPN), effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176

Total plasma cholesterol (C)

- in HALP, 968
- HRT effects on, 1224
- in middle-aged obese hypertensive men, 1079
- in obese women, effects of weight loss with meat-based or plant-based diet on, 1310
- in primary hypercholesterolemia, niacin versus Niaspan effects on, 1100
- in STZ-DM, chronic hyperglycemia effects on, 949

Total plasma homocysteine (HcY)

- in CHD, 273-279
- in hyperthyroidism and hypothyroidism, 89-93

Total plasma ketones in IDDM and NIDDM, and insulin secretion and mode of therapy associated with leptin and AT, 1394

Total protein

- blood, in elderly NIDDM subjects, Pro-Z effects on, 42
- NO-1886 effects on, in Leydig cell tumor-associated cachexia, 102
- in post-small bowel resection enteral diet, 1368

Total serum cholesterol (C)

- following acute SCI, 367-370
- in hyperlipidemia of preeclampsia, 1284
- in hyperthyroidism and hypothyroidism, total plasma HcY and, 90, 91
- in IDDM, and mode of therapy associated with leptin and AT, 1394
- in NIDDM, *see* Total serum cholesterol in NIDDM
- VAT accumulation effects on, in obese men, 930, 931

Total serum cholesterol (C) in NIDDM

- acipimox effects on, 252
- and mode of therapy associated with leptin and AT, 1394

Total thyroidectomy for Graves' disease, Na^+,K^+ ATPase activity in RBCs of women on levothyroxine therapy following, 1194-1198

Total triglycerides (TGs)

- in FCH, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
- in NIDDM, effects of insulin versus sulfonylurea therapy on, 641

t-PA, *see* Tissue plasminogen activator

TPN (total parenteral nutrition), effects of tyrosine-deficient, on DOPA synthesis in neural tissue, tyrosine activities, and branched-chain aminotransferases, 168-176

Tracee model in compartmental modeling, 1012-1013

Tracer(s)

- GC/MS of, 706-712
- see also* entries beginning with term: Tracer and specific tracers

Tracer compartmental model, 1013-1014

Tracer dilution technique, multiple, in modeling of regional steady-state glucose fluxes, 1021-1022

Tracer kinetics, 478-492

- of LDL apo B metabolism following apheresis, 478-483
- studies of, with SAAM II software, 484-492

Tracer probe in systems model, 1009

Tracer-tracee compartmental model, 1014-1015

Training, *see* Exercise

Transaminases, *see* Aminotransferases

Transfer protein
phospholipid, in HALP, 969
see also Cholestryol ester transfer protein

[¹²⁵I]-Transferrin, vanadate and binding of, in adipocytes, 630-636

Transgenic subjects, female, sex steroids regulating CETP in, 1048-1051

Transplantation
liver, hepatic failure following, serum IGFs and IGFBPs in, 200-206
whole pancreas-kidney, for IDDM, proinsulin levels after, 1325-1330

Trauma and injury
acute spinal cord, serum lipids following, 367-370
hepatic AA transport in burn injury, 608-616
and PAM in healthy subjects, 1263-1268
rexygenation, effects of, on pancreatic islet response to fatty acids, 809-813
spermidine supplement effects on protein in, 223-229
vascular endothelial, urinary and serum TM in NIDDM as marker for, 362-365

TRG, *see* Troglitazone effects on insulin resistance

TRH (thyrotropin-releasing hormone), pyridostigmine effects on TSH response to, in endogenous depression and subclinical thyrotoxicosis, 50-53

Triacylglycerol (TAG)
effects of vitamin C and dietary fat regulation of apo B-containing Lps on, 886-888
in obese women, effects of weight loss with meat-based or plant-based diet on, 1310

Triglycerides (TGs)
in CHD, *see* Triglycerides in CHD
exercise and, *see* Triglycerides, exercise and
in familial HALP and HBLP, 1162
and family history of NIDDM, 523, 525
fasting, *see* Fasting triglycerides
in FCH, *see* Triglycerides in FCH
and fibrinolysis in obese nondiabetics, 1373
GH levels in women correlated with, 340-342
in Graves' disease, 1195
HDL-C levels and, in adolescent males, race and, 514-521
hepatic, breast milk and/or formula effects on, during development, 23
HRT effects on, 1224
in hypercholesterolemia, *see* Triglycerides in hypercholesterolemia in hyperinsulinemia, *see* Triglycerides in hyperinsulinemia
in IDDM, *see* Triglycerides in IDDM
in insulin resistance, *see* Triglycerides in insulin resistance
in Kuwaiti children, BP and, associated with fasting insulin levels, 421, 422
LDL apheresis effects on, 865
Lps rich in, smoking, GPIIIa gene and, 1040-1041
in NIDDM, *see* Triglycerides in NIDDM
NO-1886 effects on, in Leydig cell tumor-associated cachexia, 103
in nondiabetics, *see* Triglycerides in nondiabetics
in obese men, *see* Triglycerides in obese men
OC effects on, 281
plasma, *see* Plasma triglycerides
race and, *see* Triglycerides, race, sex and
serum, *see* Serum triglycerides
and serum uric acid levels in non-obese premenopausal women, 437, 438
sex hormones effects on, 392
total, *see* Total triglycerides
and Trp 64 Arg mutation of β_3 -adrenoceptor gene, 457-458
in very old syndrome X subjects, 536
see also Hypertriglyceridemia

Triglycerides (TGs), exercise and
 β -adrenoceptor blockade effects on EPOC and TG/FA cycling, 439-448

AT and, and CHD in postmenopausal women, 1119
diet and exercise effects on, in subjects with multiple CV disease risk factors, 386, 387
menopausal status and exercise effects on, serum TGs, 378, 379; *see also* Triglycerides in postmenopausal women

Triglycerides (TGs), race, sex and
of nondiabetics, relationship between insulin resistance and, 1176, 1177
and relation of LpA-I and LpA-I:A-II to, in children, 760

Triglycerides (TGs) in CHD
AT and, and CHD in postmenopausal women, 1119
ERT effects on plasma, in hypercholesterolemic postmenopausal women, 677
fasting, as risk factor for CHD, 1246
metabolic disturbances of glucose and, predisposing to CHD, TNF α and, 113-118
in NIDDM, 1259, 1260
total plasma Hcy and, 276

Triglycerides (TGs) in FCH
in nondiabetic FCH, 509-511
total, with FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400

Triglycerides (TGs) in hypercholesterolemia
ERT effects on, 677
fat-modified diet effects on, 745
in FH, LDL apheresis effects on, 1060
plasma, *see* Plasma triglycerides in hypercholesterolemia
in polygenic hypercholesterolemia, 98
in primary hypercholesterolemia, 562

Triglycerides (TGs) in hyperinsulinemia
insulin resistance and, 832, 834, 835
in obese premenopausal women, 687

Triglycerides (TGs) in IDDM
and CFA, 504
Lispro effects on, 372-374
urinary ET-1 and, 1409, 1410

Triglycerides (TGs) in insulin resistance
body composition and, related to aging, CV disease risk factors and, 402, 404, 406
SHBG, race and, in insulin-resistant women, 72

Triglycerides (TGs) in NIDDM
acipimox effects on, 252
CFA and, 504
CHD and, 1259, 1260
in elderly subjects, Pro-Z effects on, 42
hemodynamic response to handgrip test and, 935, 936
high-monounsaturated fat diet effects on, 726, 727
LDL receptors and metabolism of, 1071
plasma, *see* Plasma triglycerides in NIDDM
with obesity, *see* Triglycerides in obese NIDDM subjects
serum, *see* Serum triglycerides in NIDDM
serum PON activity and, 599
and SPA relationship to NIDDM complications, 703
total, effects of insulin versus sulfonylurea therapy on, 641

Triglycerides (TGs) in nondiabetics, 231
with FCH, 509-511
relationship between insulin resistance and, 1176, 1177

Triglycerides (TGs) in obese men
with abdominal obesity, 1189, 1190
middle-aged hypertensive, 1079

Triglycerides (TGs) in obese NIDDM subjects
and fibrinolysis, 1373
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317

Triglycerides (TGs) in postmenopausal women
ERT effects on plasma, in hypercholesterolemic postmenopausal women, 677
in exercising postmenopausal women, AT, CHD and, 1119
non-obese women, serum uric acid and, 437, 438
regional differences in adrenoceptor binding an AT cell lipolysis in obese women, 470

Triiodothyronine (T_3)
amiodarone effects on, 1053
breast milk and/or formula effects on, during development, 22
GH and prednisolone effects on, 86
in Graves' disease, 1196
in hyperinsulinemic and insulinopenic NIDDM with obesity, 1317
nicotine effects on, 155, 156
and RMR in healthy adults, 1135
serum, *see* Serum triiodothyronine

Triiodothyronine (T_4) receptors, effects of hypercholesterolemia-inducing diet on expression of, 301-308

Triphosphatase, *see* ATPase

Triphosphate, adenosine, skeletal muscle, in hyperthyroidism, 771, 774-775

Triton WR 1339, effects of orotic acid and, on biliary and serum dolichols, 644-649

Troglitazone (TRG; CS-045) effects on insulin resistance
on dexamethasone-induced insulin resistance, 351-354
on hepatic and peripheral insulin resistance induced by GH excess, 783-787

Trp 64 Arg mutation of β_3 -adrenoceptor gene
hyperglycemia and BMI associated with, in Jamaican women, 617-621
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects

Trp 64 Arg mutation of β_3 -adrenoceptor gene in Japanese subjects
with IGT, NIDDM, and insulin resistance, 456-460
moderately overweight, 1528-1530

Trp 64 Arg polymorphism of β_3 -adrenoceptor gene
and plasma leptin in Pima Indians, 1525-1527
and promoter variant A-3826G of UCP-1 gene in FCHL, regulation of FFA levels and glucose oxidation in, 1397-1402
see also Trp 64 Arg mutation of β_3 -adrenoceptor gene

Tryptophan
endotoxin effects on, 683, 684
reduced energy intake effects on, in obese children, 1438

TSH, *see* Thyrotropin

Tumor necrosis factor (TNF)
effects of antibodies to, on hepatic AA transport in burn injury, 612
effects of dietary protein and, on colon and small intestine IGF-I pathway components in protein-depleted subjects, 345-350

Tumor necrosis factor α (TNF α)
effects of, on inflammatory mediators of endothelial cells, 566-572
and role of TGs and glucose metabolic disturbances in predisposition to CHD, 113-118
serum, gliclazide effects on LPS-induced enhanced activity of, in STZ-DM, 978-979

TXB2 (thromboxane B2), and SPA relationship to NIDDM complications, 703

Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus

Type I receptor antagonist of angiotensin II, *see* Angiotensin II type 1 receptor antagonist

Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus

Tyrosine (Tyr)
endotoxin effects on, 683, 684

Tyrosine (Tyr) (Continued)
in familial HALP and HBLP, 1164
kinetics of, 670-671
TPN deficient in, effect of, on DOPA synthesis in neural tissue and activities of, 168-176
reduced energy intake effects on, in obese children, 1438
in trauma, 226, 227

Tyrosine aminotransferase (TAT)
and effects of tyrosine-deficient TPN on DOPA synthesis in neural tissue, 168-176
hypercholesterolemia-inducing diet effects on, 306

UCP-1 (uncoupling protein 1) gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402

UDP (uridine diphosphate)-linked hexosamine (and hexose), GLcN effects on, 451

Uncoupling protein 1 (UCP-1) gene, Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and promoter variant A-3826G of, in FCHL, regulation of FFA levels and glucose oxidation by, 1397-1402

Unilateral nephrectomy, effects of immunosuppression on renal and serum IGF-I, IGFBPs, and renal growth following, 817-823

Urate production
metabolic control of, 658
sites of, 657-658

Urea
in PAM, 1265
plasma, *see* Plasma urea
serum, HCl effects on, 164
see also [15 N] $_2$ Urea; Urea nitrogen; Ureogenesis; Urinary excretion, urea

[15 N] $_2$ Urea, GC/MS of, 708

Urea nitrogen
blood, in elderly NIDDM subjects, Pro-Z effects on, 42
plasma, very-low-calorie diet effects on, in obesity, 593

Ureogenesis, glucose and AA effects on, before and during exercise, 1303-1307

Uric acid
in CHF, anaerobic threshold and, 1156-1159
hyperuricemia and CHD, 657-662
see also Plasma uric acid; Serum uric acid; Uric acid in obesity; Urinary excretion, uric acid

Uric acid in obesity
VAT accumulation effects on metabolism of, 929-933
very-low-calorie diet effects on, 593

Uridine, *see* Plasma uridine; Urinary excretion, uridine

Uridine diphosphate (UDP)-linked hexosamine (and hexose), GLcN effects on, 451

Uridyltransferase, galactose-1-phosphate (GALT), deficiency in, hereditary galactosemia due to, 1423-1428

Urinary excretion
of AGE products in DM, fluorescence assay of, 1348-1353
aquaporin-2, and renal water channel expression in newborns, 1344-1347

Ca, hyperprolactinemia effects on, 426

of collagen pyridinium cross-links in osteopenic preterm infants, 333-335

creatinine, effects of reduced energy intake on, 1437

of dopamine, E, and NE, in obesity, very-low-calorie diet effects on, 594

ET-1, in IDDM adolescents and young adults, 1408-1412

free cortisol, in AIDS patients, 690-694

of guanidino compounds, nephrectomy effects on, 358-359

Urinary excretion (Continued)

- Mg, effects of Mg supplementation on, 905, 906
- MVA, in polygenic hypercholesterolemia, 98
- N, in injury, spermidine effects on, 224
- Na, Cl, and inorganic phosphate, bucladesine effects on, 1007
- see also Urinary excretion, albumin; Urinary excretion, hypoxanthine; Urinary excretion, uric acid; Urinary excretion, uridine; Urinary excretion, xanthine; Urinary excretion in NIDDM and entries ending with suffix: -uria

Urinary excretion, albumin

- in NIDDM, see Urinary excretion, albumin, in NIDDM
- plasma IR-VEGF and, 28
- relationship between ET-1 excretion and, in IDDM adolescents and young adults, 1408-1412
- TM and, 363
- see also Microalbuminuria; Normoalbuminuria

Urinary excretion, albumin, in NIDDM

- CHD and, 1259, 1260
- insulin versus sulfonylurea therapy and, 639
- microalbuminuria and vascular damage in NIDDM, fasting and postmethionine tHcy correlated with, 915-921

Urinary excretion, hypoxanthine

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696
- xylitol-induced increase in, 739-743

Urinary excretion, urea

- in exercise, glucose and AA effects on, 1304
- in injury, spermidine effects on, 224

Urinary excretion, uric acid

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696

Urinary excretion, uridine

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696
- xylitol-induced increase in, 739-743

Urinary excretion, xanthine

- bucladesine sodium effects on concentrations of, 1005-1008
- glucagon effects on, 696
- xylitol-induced increase in, 739-743

Urinary excretion in NIDDM

- albumin, see Urinary excretion, albumin, in NIDDM
- CV risk factors, fibrinolysis and, 639
- of glucose, zinc, Ca, and Mg in elderly NIDDM subjects, Pro-Z effects on, 41
- of TM, as potential marker for vascular endothelial injury, 362-365

VO₂

- OC effects on, 281
- see also VO_{2max}

VO_{2max}

- exercise and, see VO_{2max} in exercise
- in postmenopausal obese women, adrenoceptor binding and adipocyte lipolysis and, 469
- and RMR in healthy adults, 1135, 1136
- VO_{2max} in exercise
- β-adrenoceptor blockade effects on EPOC and, 440
- in endurance exercise, 875
- menopausal status and exercise effects on, 378, 379
- in postmenopausal women, 1113

Vagus nerve, control of insulin secretion by, in obesity, 1167-1173

Validation of systems model, 1019

Valine (Val)

- endotoxin effects on, 683, 684
- in familial HALP and HBLP, 1164

Valine (Val) (Continued)

- reduced energy intake effects on, in obese children, 1438
- in trauma, 226, 227
- Vanadate, [¹²⁵I]-transferrin binding and ⁵⁹Fe uptake in adipocytes stimulated by, 630-636

Vascular cell adhesion molecule-1 (VCAM-1), LDL and, in hyperlipidemia of preeclampsia, 1281-1288

Vascular damage, microalbuminuria and, in NIDDM, fasting and postmethionine tHcy correlated with, 915-921

Vascular endothelium, see entries beginning with term: Endothelial

Vasoactive intestinal peptide (VIP), NO in PRL secretion stimulated by, in men, 897-899

Vasoactive regulatory hormones, changes in volume regulatory hormones, BP and, in obese subjects on very-low-calorie diet, 592-597

Vasodilation, insulin-induced, dependent on synthesis of BH₄, 1037-1039

Vasopressin, see Arginine vasopressin

VCAM-1 (vascular cell adhesion molecule-1), LDL and, in hyperlipidemia of preeclampsia, 1281-1288

VEGF (vascular endothelial growth factor), plasma immunoreactive, smoking relation to concentration of, 27-30

Venous access devices, implantable central, in children with metabolic diseases, 900-902

Verapamil, effects of captopril and, on glucose tolerance and insulin action in insulin resistance, 982-987

Very-low-calorie diet, effects of, on BP, vasoactive regulatory hormones, and volume regulatory hormones in obesity, 592-597

Very-low-density lipoprotein (VLDL)

- BP and, associated with fasting insulin levels in Kuwaiti children, 421, 422
- in IDDM, insulin Lispro and regular insulin effects on metabolism of, 372-374
- plasma, see Plasma very low-density lipoprotein
- serum in hyperinsulinemic and insulinopenic NIDDM with obesity, 1318
- see also Very-low-density lipoprotein-cholesterol

Very-low-density lipoprotein-cholesterol (VLDL-C)

- in CHD, see Very-low-density lipoprotein-cholesterol in CHD
- effects of stearic and oleic acid diets on, 532
- in familial HALP and HBLP, 1162
- HCHP jet effects on, 733
- in NIDDM, effects of insulin versus sulfonylurea on, 641
- race and, of nondiabetics, relationship between insulin resistance and, 1176
- in young children of NIDDM parents, 999

Very-low-density lipoprotein-cholesterol (VLDL-C) in CHD

- Lp(a) level and, 276
- metabolic disturbances of, predisposing to CHD, 114
- plasma, ERT effects on, in hypercholesterolemic postmenopausal women with CHD, 677

Very old subjects with syndrome X, relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in, 535-540

VIP (vasoactive intestinal peptide), NO in PRL secretion stimulated by, in men, 897-899

Visceral adipose tissue (VAT)

- and effects of HF versus LF diets on S, and serum leptin in women, race and, 1521
- see also Visceral adipose tissue in obesity

Visceral adipose tissue (VAT) in obesity

- effects of accumulation of, on uric acid metabolism in obese men, 929-933
- in obese women with PCOS, serum leptin and, 989, 990
- PPAR γ gene expression in, 1494-1498

Vitamin(s)
 in diet regulating apo B-containing Lps, 884
 in diet regulating small intestinal cell turnover, 1106
 in high-monounsaturated fat diet, 725
 in obesity- and DM-inducing diet, 1090
see also specific vitamins

Vitamin A (retinol), response to sucrose and deficiency in, 1-2

Vitamin B₁₂
 in homocystinuria, 208
 in NIDDM, tHcy, microalbuminuria and, 916
see also Vitamin B₁₂, plasma HcY and

Vitamin B₁₂, plasma HcY and
 and plasma HcY related to folate status and MTHFR gene mutation in healthy subjects, 1415
 total plasma HcY and serum cobalamin level in hyperthyroidism and hypothyroidism, 90, 91

Vitamin C (ascorbic acid)
 effects of exercise and, on PAI-1 activity, 385
 regulation of apo B-containing Lps with dietary fat saturation and, 883-891

Vitamin D, *see specific vitamin D metabolites*

Vitamin E (α tocopherol)
 effects of exercise and, on PAI-1 activity, 385
 effects of selenium and, on Keshan disease-induced beta cell alterations, 415-419

Vitamin K in osteopenic older men, 195-199

VLDL, *see Very-low-density lipoprotein*

VLDL-C, *see Very-low-density lipoprotein-cholesterol*

Volume regulatory hormones, changes in vasoactive regulatory hormones, BP and, in obese subjects on very-low-calorie diet, 592-597

Waist-to-hip ratio (WHR)
 body composition, insulin resistance and, 402, 404, 406
 exercise and, *see* Waist-to-hip ratio, exercise and
 and family history of NIDDM, 523, 525
 of FCH subjects, *see* Waist-to-hip ratio of FCH subjects and HRT effects on plasma lipids and Lp, 1224
 of hyperglycemic subjects with Trp 64 Arg mutation of β_3 -adrenoceptor gene, 618-620
 of hyperinsulinemic subjects, plasma HcY concentrations and, 687
 of IGT subjects, insulin kinetics, muscle morphology and, 850
 of Kuwaiti children, 421, 422
 of men with abdominal obesity, 1189, 1190
 of NIDDM subjects, *see* Waist-to-hip ratio of NIDDM subjects of nondiabetic Asian Indians, 231
 of obese women, *see* Waist-to-hip ratio of obese women of PCOS subjects, 941
 of postmenopausal women, *see* Waist-to-hip ratio of postmenopausal women
 in pregnant women, 1141
 of premenopausal women, *see* Waist-to-hip ratio of premenopausal women
 race and, *see* Waist-to-hip ratio, race and as risk factor for CHD, 1141, 1246
 of very old syndrome X subjects, 536, 537
 of young children of NIDDM parents, 999

Waist-to-hip ratio (WHR), exercise and
 effects of menopausal status and exercise on, 386, 387
 endurance exercise effects on, 875

Waist-to-hip ratio (WHR), race and
 effects of HF versus LF diets on S, and serum leptin and, 1521
 relationship between insulin resistance and, in nondiabetics, 1176, 1177

Waist-to-hip ratio (WHR) of FCH subjects and FFA and glucose regulation by Trp 64 Arg polymorphism of β_3 -adrenoceptor gene and A-3826G promoter variant of UCP-1 gene, 1398-1400
 in nondiabetics, 509, 510

Waist-to-hip ratio (WHR) of NIDDM subjects as CV disease risk factor, 639
 DEXA measurement of, 213

Waist-to-hip ratio (WHR) of obese women effects of weight loss with meat-based or plant-based diet on, 1309, 1310
 of PCOS women, serum leptin and, 989
 postmenopausal, 469
 premenopausal, 14, 16

Waist-to-hip ratio (WHR) of postmenopausal women DEXA measurement of, 213
 obese, 469

Waist-to-hip ratio of premenopausal women DEXA measurement of, 213
 obese, 14, 16

WAT (white adipose tissue), NO-1886 effects on, in hypertriglyceridemia, 150

Water channel, renal, urinary aquaporin-2 excretion and expression of, in newborns, 1344-1347

WBC (white blood cell) count, endotoxin effects on, 682

Weight loss
 effects of aerobic exercise and, on BP, glucose metabolism, and Lps in obese hypertensive middle-aged men, 1075-1082
 serum insulin but not leptin associated with spontaneous and GHRH-stimulated GH secretion in normal subjects with and without, 1127-1133
 very-low-calorie diet and, 593
see also Weight loss, plasma leptin and

Weight loss, plasma leptin and
 effects of weight loss with meat-based or plant-based diet on SAC, plasma lipids, BP, and plasma leptin in obese women, compared, 1308-1314
 in insulin-treated and untreated STZ-DM subjects, 585

Well-mixed in compartmental modeling, defined, 1012

Wheat (and wheat bran) in diet regulating small intestinal cell turnover, 1106

White adipose tissue (WAT), NO-1886 effects on, in hypertriglyceridemia, 150

White blood cell (WBC) count, endotoxin effects on, 682

White subjects, *see* Race and ethnicity

Whole-body glucose fluxes in steady-state, modeling of, 1020-1021

Whole-body protein, 1429-1439
 metabolism of, in active celiac disease assessed by leucine and glutamine kinetics, 1429-1433
 reduced energy intake effects on utilization of, in obese children, 1434-1439

Whole pancreas-kidney transplantation for IDDM, proinsulin levels after, 1325-1330

WHR, *see* Waist-to-hip ratio

Withdrawal
 from acipimox, 254
 from Niaspan, 1101-1102

Women
 on levothyroxine therapy following total thyroidectomy for Graves' disease, RBC Na⁺,K⁺ ATPase activity in, 1194-1198
 non-obese, *see* Non-obese subjects
 relationship of GH to HDL-C and apo A-I independently of IGF-I and insulin in, 339-344
 restricted caloric intake effects on insulin, cortisol, glucose, ketones, and NEFAs in, 429-434

Women (*Continued*)
see also Lecithin:cholesterol acyltransferase; Menopausal status; Normal subjects; Pregnancy; Risk factors for CHD in women; Sex; Sex hormone-binding globulin in women; Women, exercising; Women, plasma leptin in; Women, obese; Women, older; Women, S₁ in; Women, serum leptin in and specific conditions

Women, exercising
menopausal status and exercise effects on intravascular enzymes related to lipid transport, 377-383

postmenopausal, influence of AT on risk factors for CHD in, 1112-1120
see also Exercise

Women, obese
effects of weight loss with meat-based or plant-based diet on BP, SAC, plasma leptin, and plasma lipids in, 1308-1314

hyperinsulinemic premenopausal, sex hormones in, 13-19

Jamaican, hyperglycemia and BMI associated with Trp 64 Arg mutation of β_3 -adrenoceptor gene in, 617-621

with PCOS, serum leptin in, correlated with BW and AT distribution but not with androgen and insulin levels, 988-992

postmenopausal, adrenoceptor binding and adipocyte lipolysis in, AT distribution and, 467-473
see also Obesity

Women, older
very old women with syndrome X, relationship between fasting plasma insulin, anthropometrics, and metabolic parameters in, 535-540
see also Older subjects

Women, plasma leptin in
effects of weight loss with meat-based or plant-based diet on BP, SAC, plasma lipids, and plasma leptin, 1308-1314
in pregnant nondiabetic and IDDM women, 840-843

Women, S₁ in
glucose tolerance and S₁, effects of stearic and oleic acid diets on, 529-534
race and effects of HF versus LF diets on S₁ and serum leptin, 1520-1524

Women, S₁ in (*Continued*)
at risk for CHD, effects of low glycemic diet on, 1245-1251

and serum uric acid levels in non-obese premenopausal and postmenopausal women, 437, 438

Women, serum leptin in
correlated with BW and AT distribution but not with androgen and insulin levels in obese PCOS women, 988-992

race and effects of HF versus LF diets on S₁ and serum leptin, 1520-1524

restricted calorie intake effects on, 429-434

Wortmannin-sensitive pathways, insulin regulation of LPL activity in adipocytes via, 555-559

Xanthine, *see* Plasma xanthine; Urinary excretion, xanthine

X-ray absorptiometry, *see* Dual-energy x-ray absorptiometry, assessment of body composition with

Xylitol
effects of supplementation with, on osteoporosis in STZ-DM, 578-583

plasma concentrations and urinary excretion of uridine and purine bases and, 739-743

Yeast, brewer's, in diet regulating small intestinal cell turnover, 1106

Young adults with IDDM
urinary ET-1 excretion in, 1408-1412
see also Insulin-like growth factor-I in young IDDM adults

Young children
effects of diet type and plasma glucose level on LCPUFAs in skeletal muscle membrane of, 106-112

of NIDDM parents, race and characteristics of, 998-1004
see also Prepubertal children

Zinc (Zn)
effects of supplementation with, on glucose disposal in cirrhosis, 792-798

Pro-Z effects on glucose and insulin metabolism in older NIDDM subjects, 39-43